US20200408757A1 - Methods and Compositions for Modulating TH-GM Cell Function - Google Patents
Methods and Compositions for Modulating TH-GM Cell Function Download PDFInfo
- Publication number
- US20200408757A1 US20200408757A1 US16/902,189 US202016902189A US2020408757A1 US 20200408757 A1 US20200408757 A1 US 20200408757A1 US 202016902189 A US202016902189 A US 202016902189A US 2020408757 A1 US2020408757 A1 US 2020408757A1
- Authority
- US
- United States
- Prior art keywords
- stat5
- cells
- csf
- mice
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title abstract description 11
- 230000003915 cell function Effects 0.000 title description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 283
- 210000004027 cell Anatomy 0.000 claims abstract description 253
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims abstract description 184
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims abstract description 184
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 103
- 230000001404 mediated effect Effects 0.000 claims abstract description 97
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 90
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 82
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 81
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 80
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 61
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract 4
- 239000003112 inhibitor Substances 0.000 claims description 40
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 230000037361 pathway Effects 0.000 claims description 29
- 239000002243 precursor Substances 0.000 claims description 22
- 201000006417 multiple sclerosis Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 108700011259 MicroRNAs Proteins 0.000 claims description 11
- 239000002679 microRNA Substances 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 239000004055 small Interfering RNA Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 229960003634 pimozide Drugs 0.000 claims description 3
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical group C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 3
- 229960001350 tofacitinib Drugs 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 229960004238 anakinra Drugs 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract description 53
- 238000011282 treatment Methods 0.000 abstract description 27
- 230000001105 regulatory effect Effects 0.000 abstract description 20
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 279
- 108090000623 proteins and genes Proteins 0.000 description 206
- 210000001744 T-lymphocyte Anatomy 0.000 description 188
- 241000699670 Mus sp. Species 0.000 description 178
- 230000014509 gene expression Effects 0.000 description 105
- 102100021592 Interleukin-7 Human genes 0.000 description 88
- 229940100994 interleukin-7 Drugs 0.000 description 88
- 230000006870 function Effects 0.000 description 83
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 70
- 239000003795 chemical substances by application Substances 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 59
- 102000000646 Interleukin-3 Human genes 0.000 description 52
- 229940076264 interleukin-3 Drugs 0.000 description 51
- 102000004889 Interleukin-6 Human genes 0.000 description 50
- 108090001005 Interleukin-6 Proteins 0.000 description 50
- 102100037850 Interferon gamma Human genes 0.000 description 49
- 108010074328 Interferon-gamma Proteins 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 49
- 108020003175 receptors Proteins 0.000 description 49
- 102000004127 Cytokines Human genes 0.000 description 48
- 108090000695 Cytokines Proteins 0.000 description 48
- 102000013691 Interleukin-17 Human genes 0.000 description 45
- 108050003558 Interleukin-17 Proteins 0.000 description 45
- 108020004635 Complementary DNA Proteins 0.000 description 44
- 238000010804 cDNA synthesis Methods 0.000 description 44
- 239000002299 complementary DNA Substances 0.000 description 44
- 230000000694 effects Effects 0.000 description 43
- 230000006698 induction Effects 0.000 description 42
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 229920001184 polypeptide Polymers 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 206010003246 arthritis Diseases 0.000 description 33
- 108010002350 Interleukin-2 Proteins 0.000 description 32
- 102000000588 Interleukin-2 Human genes 0.000 description 32
- 238000011161 development Methods 0.000 description 32
- 230000018109 developmental process Effects 0.000 description 32
- 238000002560 therapeutic procedure Methods 0.000 description 32
- 210000003169 central nervous system Anatomy 0.000 description 31
- 210000000440 neutrophil Anatomy 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 29
- 230000004069 differentiation Effects 0.000 description 28
- 201000010099 disease Diseases 0.000 description 28
- 230000004913 activation Effects 0.000 description 25
- 238000000684 flow cytometry Methods 0.000 description 24
- 230000002950 deficient Effects 0.000 description 23
- 210000005222 synovial tissue Anatomy 0.000 description 23
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 22
- 102100022338 Integrin alpha-M Human genes 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 102000014914 Carrier Proteins Human genes 0.000 description 19
- 210000004988 splenocyte Anatomy 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 108091008324 binding proteins Proteins 0.000 description 18
- 210000000629 knee joint Anatomy 0.000 description 18
- 230000008595 infiltration Effects 0.000 description 16
- 238000001764 infiltration Methods 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 102000017589 Chromo domains Human genes 0.000 description 13
- 108050005811 Chromo domains Proteins 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 12
- 108010065805 Interleukin-12 Proteins 0.000 description 12
- 102000013462 Interleukin-12 Human genes 0.000 description 12
- 108060004795 Methyltransferase Proteins 0.000 description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 11
- 235000018417 cysteine Nutrition 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 108010012236 Chemokines Proteins 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 10
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 10
- 208000009386 Experimental Arthritis Diseases 0.000 description 10
- 229940122344 Peptidase inhibitor Drugs 0.000 description 10
- 238000011529 RT qPCR Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108010065637 Interleukin-23 Proteins 0.000 description 9
- 102000013264 Interleukin-23 Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000003292 diminished effect Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000010212 intracellular staining Methods 0.000 description 9
- 210000000066 myeloid cell Anatomy 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 8
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 8
- 102000012547 Olfactory receptors Human genes 0.000 description 8
- 108050002069 Olfactory receptors Proteins 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 8
- 230000024245 cell differentiation Effects 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 230000003959 neuroinflammation Effects 0.000 description 8
- 230000007918 pathogenicity Effects 0.000 description 8
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- 230000008409 synovial inflammation Effects 0.000 description 8
- -1 EBI-3 Proteins 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 108091006027 G proteins Proteins 0.000 description 7
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 7
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 230000001850 reproductive effect Effects 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 6
- 102000030782 GTP binding Human genes 0.000 description 6
- 108091000058 GTP-Binding Proteins 0.000 description 6
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 6
- 102100038931 Proenkephalin-A Human genes 0.000 description 6
- 230000002917 arthritic effect Effects 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 6
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 108010074732 preproenkephalin Proteins 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000001179 synovial fluid Anatomy 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001131 transforming effect Effects 0.000 description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 6
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 6
- 102100030630 C-myc promoter-binding protein Human genes 0.000 description 5
- 102100026191 Class E basic helix-loop-helix protein 40 Human genes 0.000 description 5
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 5
- 101000584310 Homo sapiens C-myc promoter-binding protein Proteins 0.000 description 5
- 101000765038 Homo sapiens Class E basic helix-loop-helix protein 40 Proteins 0.000 description 5
- 206010023232 Joint swelling Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 108010006035 Metalloproteases Proteins 0.000 description 5
- 102000005741 Metalloproteases Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000000395 SH3 domains Human genes 0.000 description 5
- 108050008861 SH3 domains Proteins 0.000 description 5
- 108091006207 SLC-Transporter Proteins 0.000 description 5
- 102000037054 SLC-Transporter Human genes 0.000 description 5
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 5
- 206010054094 Tumour necrosis Diseases 0.000 description 5
- 230000003286 arthritogenic effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 201000004595 synovitis Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- 208000004736 B-Cell Leukemia Diseases 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 101150018129 CSF2 gene Proteins 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 4
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 108010081690 Pertussis Toxin Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 108091008778 RORγ2 Proteins 0.000 description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000013000 chemical inhibitor Substances 0.000 description 4
- 239000004927 clay Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 208000002574 reactive arthritis Diseases 0.000 description 4
- 230000021595 spermatogenesis Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010035053 B7-1 Antigen Proteins 0.000 description 3
- 102000038504 B7-1 Antigen Human genes 0.000 description 3
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000004031 Carboxy-Lyases Human genes 0.000 description 3
- 108090000489 Carboxy-Lyases Proteins 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101000644718 Homo sapiens NEDD8-conjugating enzyme UBE2F Proteins 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 102100020694 NEDD8-conjugating enzyme UBE2F Human genes 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100028965 Proteoglycan 4 Human genes 0.000 description 3
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 3
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 108090000184 Selectins Proteins 0.000 description 3
- 102000003800 Selectins Human genes 0.000 description 3
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000017290 interleukin-3 production Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000004901 leucine-rich repeat Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000031972 neutrophil apoptotic process Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 102100028810 28S ribosomal protein S5, mitochondrial Human genes 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100022406 60S ribosomal protein L10a Human genes 0.000 description 2
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000008822 Ankylosis Diseases 0.000 description 2
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 2
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 2
- 102000009039 Axonemal Dyneins Human genes 0.000 description 2
- 108010049197 Axonemal Dyneins Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108091016585 CD44 antigen Proteins 0.000 description 2
- 108010052382 CD83 antigen Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 102000011933 Cathepsin W Human genes 0.000 description 2
- 108010061112 Cathepsin W Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102100028188 Cystatin-F Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- 241000289632 Dasypodidae Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108010028143 Dioxygenases Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101800001224 Disintegrin Proteins 0.000 description 2
- 108010030483 Dynamin III Proteins 0.000 description 2
- 102100021179 Dynamin-3 Human genes 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000858488 Homo sapiens 28S ribosomal protein S5, mitochondrial Proteins 0.000 description 2
- 101000755323 Homo sapiens 60S ribosomal protein L10a Proteins 0.000 description 2
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101000577555 Homo sapiens Neuritin Proteins 0.000 description 2
- 101001084276 Homo sapiens Phosphotriesterase-related protein Proteins 0.000 description 2
- 101000872736 Homo sapiens Protein HEG homolog 1 Proteins 0.000 description 2
- 101000606545 Homo sapiens Receptor-type tyrosine-protein phosphatase F Proteins 0.000 description 2
- 101000821521 Homo sapiens Saccharopine dehydrogenase-like oxidoreductase Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 206010023198 Joint ankylosis Diseases 0.000 description 2
- 206010023203 Joint destruction Diseases 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101100182712 Mus musculus Ly6a gene Proteins 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 102100034431 Nebulette Human genes 0.000 description 2
- 101710113660 Nebulette Proteins 0.000 description 2
- 102100028749 Neuritin Human genes 0.000 description 2
- 102100035484 Neurotrypsin Human genes 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 2
- 102100021133 Nuclear protein 1 Human genes 0.000 description 2
- 101710170054 Nuclear protein 1 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000016978 Orphan receptors Human genes 0.000 description 2
- 108070000031 Orphan receptors Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102100030961 Phosphotriesterase-related protein Human genes 0.000 description 2
- 102100030264 Pleckstrin Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100034735 Protein HEG homolog 1 Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 101710127913 Proteoglycan 4 Proteins 0.000 description 2
- 108010010974 Proteolipids Proteins 0.000 description 2
- 102000016202 Proteolipids Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 102100021591 Saccharopine dehydrogenase-like oxidoreductase Human genes 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 102000009203 Sema domains Human genes 0.000 description 2
- 108050000099 Sema domains Proteins 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 102000005488 Thioesterase Human genes 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 101150116184 abi gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000024949 interleukin-17 production Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108010037733 neurotrypsin Proteins 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 108010026735 platelet protein P47 Proteins 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 108020002982 thioesterase Proteins 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 102100028734 1,4-alpha-glucan-branching enzyme Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- KVUXYQHEESDGIJ-UHFFFAOYSA-N 10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2CC(O)CCC2(C)C2C1C1CC(O)CC1(C)CC2 KVUXYQHEESDGIJ-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
- 102100022313 2-iminobutanoate/2-iminopropanoate deaminase Human genes 0.000 description 1
- 108700020465 2-iminobutanoate/2-iminopropanoate deaminase Proteins 0.000 description 1
- 102000034279 3-hydroxybutyrate dehydrogenases Human genes 0.000 description 1
- 108090000124 3-hydroxybutyrate dehydrogenases Proteins 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100040637 60S ribosomal protein L34 Human genes 0.000 description 1
- 102100030982 60S ribosomal protein L38 Human genes 0.000 description 1
- 108091007507 ADAM12 Proteins 0.000 description 1
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
- 102100030674 ADP-ribosylation factor-like protein 6-interacting protein 1 Human genes 0.000 description 1
- 102100024378 AF4/FMR2 family member 2 Human genes 0.000 description 1
- 101150056293 AJUBA gene Proteins 0.000 description 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 102100022933 ATM interactor Human genes 0.000 description 1
- 101710170219 ATM interactor Proteins 0.000 description 1
- 102100020973 ATP-binding cassette sub-family D member 3 Human genes 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 102100029631 Actin-related protein 3B Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- 102100033567 Acyl-CoA-binding domain-containing protein 7 Human genes 0.000 description 1
- 101710104471 Acyltransferase Pun1 Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102100031793 Adipolin Human genes 0.000 description 1
- 102100024396 Adrenodoxin, mitochondrial Human genes 0.000 description 1
- 101710119622 Adrenodoxin, mitochondrial Proteins 0.000 description 1
- 102000004379 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 101710171434 Aftiphilin Proteins 0.000 description 1
- 102100031815 Aftiphilin Human genes 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
- 102100031795 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Human genes 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- 101710146120 Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 101710170638 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 102100029233 Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase Human genes 0.000 description 1
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100026468 Androgen-induced gene 1 protein Human genes 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102100025672 Angiopoietin-related protein 2 Human genes 0.000 description 1
- 102100040432 Ankyrin repeat and BTB/POZ domain-containing protein 1 Human genes 0.000 description 1
- 102100034611 Ankyrin repeat domain-containing protein 12 Human genes 0.000 description 1
- 102100039173 Ankyrin repeat domain-containing protein 50 Human genes 0.000 description 1
- 101710189073 Ankyrin repeat domain-containing protein 50 Proteins 0.000 description 1
- 102100031326 Ankyrin repeat domain-containing protein 55 Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 102000004145 Annexin A1 Human genes 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102100031325 Anthrax toxin receptor 2 Human genes 0.000 description 1
- 101710125926 Anthrax toxin receptor 2 Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 101001118491 Arabidopsis thaliana Nuclear pore complex protein NUP62 Proteins 0.000 description 1
- 101100309519 Arabidopsis thaliana SAT1 gene Proteins 0.000 description 1
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 102100022108 Aspartyl/asparaginyl beta-hydroxylase Human genes 0.000 description 1
- 101710140787 Aspartyl/asparaginyl beta-hydroxylase Proteins 0.000 description 1
- 108010023546 Aspartylglucosylaminase Proteins 0.000 description 1
- 102000002785 Ataxin-10 Human genes 0.000 description 1
- 108010043914 Ataxin-10 Proteins 0.000 description 1
- 102100027935 Attractin-like protein 1 Human genes 0.000 description 1
- 108010056594 Avian Proteins Proteins 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102100037546 BEN domain-containing protein 6 Human genes 0.000 description 1
- 239000010754 BS 2869 Class F Substances 0.000 description 1
- 102100022806 BTB/POZ domain-containing protein KCTD14 Human genes 0.000 description 1
- 102000008836 BTB/POZ domains Human genes 0.000 description 1
- 108050000749 BTB/POZ domains Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026013 Beta-citrylglutamate synthase B Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100028738 CAP-Gly domain-containing linker protein 3 Human genes 0.000 description 1
- 101710198974 CAP-Gly domain-containing linker protein 3 Proteins 0.000 description 1
- 102100031173 CCN family member 4 Human genes 0.000 description 1
- 101710137353 CCN family member 4 Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100028879 COP9 signalosome complex subunit 8 Human genes 0.000 description 1
- 101100316118 Caenorhabditis elegans unc-51 gene Proteins 0.000 description 1
- 102100027557 Calcipressin-1 Human genes 0.000 description 1
- 108050008834 Calcipressin-1 Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102100023074 Calcium-activated potassium channel subunit beta-1 Human genes 0.000 description 1
- 102100036362 Calcium-binding and coiled-coil domain-containing protein 1 Human genes 0.000 description 1
- 102100029184 Calmodulin regulator protein PCP4 Human genes 0.000 description 1
- 101710097252 Calmodulin regulator protein PCP4 Proteins 0.000 description 1
- 102100032539 Calpain-3 Human genes 0.000 description 1
- 108030001375 Calpain-3 Proteins 0.000 description 1
- 102100033592 Calponin-3 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100033041 Carbonic anhydrase 13 Human genes 0.000 description 1
- 101710094324 Carbonic anhydrase 13 Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102100032407 Carboxypeptidase D Human genes 0.000 description 1
- 108090000018 Carboxypeptidase D Proteins 0.000 description 1
- 108090000007 Carboxypeptidase M Proteins 0.000 description 1
- 102100032936 Carboxypeptidase M Human genes 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 101710085984 Centrin-4 Proteins 0.000 description 1
- 102100025829 Centrosomal protein of 97 kDa Human genes 0.000 description 1
- 102100036158 Ceramide kinase Human genes 0.000 description 1
- 108010017573 Ceramide kinase Proteins 0.000 description 1
- 102100038274 Charged multivesicular body protein 4b Human genes 0.000 description 1
- 101710163821 Charged multivesicular body protein 4b Proteins 0.000 description 1
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 101000573882 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP3 Proteins 0.000 description 1
- 102100025826 Coiled-coil domain-containing protein 22 Human genes 0.000 description 1
- 102100032644 Copine-2 Human genes 0.000 description 1
- 101710125101 Copine-2 Proteins 0.000 description 1
- 102100023778 Corepressor interacting with RBPJ 1 Human genes 0.000 description 1
- 101710163439 Corepressor interacting with RBPJ 1 Proteins 0.000 description 1
- 108050007222 Coronin Proteins 0.000 description 1
- 102100039444 Cortexin-1 Human genes 0.000 description 1
- 101710082741 Cortexin-1 Proteins 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 102000034534 Cotransporters Human genes 0.000 description 1
- 101000785223 Crocosmia x crocosmiiflora Myricetin 3-O-glucosyl 1,2-rhamnoside 6'-O-caffeoyltransferase AT1 Proteins 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100029141 Cyclic nucleotide-gated cation channel beta-1 Human genes 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000004030 Cyclin G2 Human genes 0.000 description 1
- 108090000487 Cyclin G2 Proteins 0.000 description 1
- 102100035429 Cystathionine gamma-lyase Human genes 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 108010061635 Cystatin B Proteins 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102100026891 Cystatin-B Human genes 0.000 description 1
- 102100026897 Cystatin-C Human genes 0.000 description 1
- 101710169749 Cystatin-F Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 102100025843 Cytohesin-4 Human genes 0.000 description 1
- 101710160292 Cytohesin-4 Proteins 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 102100029581 DDB1- and CUL4-associated factor 17 Human genes 0.000 description 1
- 102100025267 DENN domain-containing protein 5A Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710188220 DNA-binding protein 7 Proteins 0.000 description 1
- 101100412663 Danio rerio rasgef1bb gene Proteins 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 description 1
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 1
- 102100039178 Dimethyladenosine transferase 1, mitochondrial Human genes 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 102100029858 Dipeptidase 2 Human genes 0.000 description 1
- 101710117905 Dipeptidase 2 Proteins 0.000 description 1
- 102100037923 Disco-interacting protein 2 homolog B Human genes 0.000 description 1
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 description 1
- 102100031116 Disintegrin and metalloproteinase domain-containing protein 19 Human genes 0.000 description 1
- 101710121160 Disintegrin and metalloproteinase domain-containing protein 19 Proteins 0.000 description 1
- 101800000620 Disintegrin-like Proteins 0.000 description 1
- 102100023317 DnaJ homolog subfamily C member 10 Human genes 0.000 description 1
- 102100034108 DnaJ homolog subfamily C member 12 Human genes 0.000 description 1
- 102100029638 Dual serine/threonine and tyrosine protein kinase Human genes 0.000 description 1
- 101710120965 Dual serine/threonine and tyrosine protein kinase Proteins 0.000 description 1
- 102100025734 Dual specificity protein phosphatase CDC14A Human genes 0.000 description 1
- 102100025699 Dual specificity protein phosphatase CDC14B Human genes 0.000 description 1
- 102100023112 Dual specificity tyrosine-phosphorylation-regulated kinase 4 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100023228 Dynein axonemal intermediate chain 4 Human genes 0.000 description 1
- 101710173288 Dynein axonemal intermediate chain 4 Proteins 0.000 description 1
- 102100032243 Dynein light chain Tctex-type protein 2B Human genes 0.000 description 1
- 101710145865 Dynein light chain Tctex-type protein 2B Proteins 0.000 description 1
- 102100032249 Dystonin Human genes 0.000 description 1
- 108010013976 Dystonin Proteins 0.000 description 1
- 102100035863 E3 SUMO-protein ligase ZNF451 Human genes 0.000 description 1
- 101710184191 E3 SUMO-protein ligase ZNF451 Proteins 0.000 description 1
- 102100033360 E3 ubiquitin-protein ligase DZIP3 Human genes 0.000 description 1
- 102100032710 E3 ubiquitin-protein ligase Jade-2 Human genes 0.000 description 1
- 101710134139 E3 ubiquitin-protein ligase Jade-2 Proteins 0.000 description 1
- 102100021183 E3 ubiquitin-protein ligase RNF130 Human genes 0.000 description 1
- 101710162575 E3 ubiquitin-protein ligase RNF130 Proteins 0.000 description 1
- 102100036275 E3 ubiquitin-protein ligase RNF149 Human genes 0.000 description 1
- 101710162570 E3 ubiquitin-protein ligase RNF149 Proteins 0.000 description 1
- 102100040278 E3 ubiquitin-protein ligase RNF19A Human genes 0.000 description 1
- 101710157279 E3 ubiquitin-protein ligase RNF19A Proteins 0.000 description 1
- 102100029211 E3 ubiquitin-protein ligase TTC3 Human genes 0.000 description 1
- 102100039658 E3 ubiquitin-protein ligase pellino homolog 2 Human genes 0.000 description 1
- 101710150161 E3 ubiquitin-protein ligase pellino homolog 2 Proteins 0.000 description 1
- 102000016675 EF-hand domains Human genes 0.000 description 1
- 108050006297 EF-hand domains Proteins 0.000 description 1
- 102100032443 ER degradation-enhancing alpha-mannosidase-like protein 3 Human genes 0.000 description 1
- 102100023078 Early endosome antigen 1 Human genes 0.000 description 1
- 102100027094 Echinoderm microtubule-associated protein-like 1 Human genes 0.000 description 1
- 101710203443 Echinoderm microtubule-associated protein-like 1 Proteins 0.000 description 1
- 102100035090 Elongator complex protein 4 Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100030751 Eomesodermin homolog Human genes 0.000 description 1
- 101710142207 Eomesodermin homolog Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001226424 Erato <angiosperm> Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 102100022112 F-box only protein 30 Human genes 0.000 description 1
- 102100038547 FSD1-like protein Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710088939 Ferredoxin-1 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102100037000 Fidgetin-like protein 1 Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102100031389 Formin-binding protein 1-like Human genes 0.000 description 1
- 101710098911 Formin-binding protein 1-like Proteins 0.000 description 1
- 102100028931 Formin-like protein 2 Human genes 0.000 description 1
- 102100028121 Fos-related antigen 2 Human genes 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 1
- 101710094136 GTP cyclohydrolase 1 Proteins 0.000 description 1
- 102100023745 GTP-binding protein 4 Human genes 0.000 description 1
- 101710102120 GTP-binding protein 4 Proteins 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 1
- 102100031687 Galactose mutarotase Human genes 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 1
- 101710196196 Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 102000004038 Glia Maturation Factor Human genes 0.000 description 1
- 108090000495 Glia Maturation Factor Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101710113609 Glutamic acid-rich protein Proteins 0.000 description 1
- 102100033424 Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 2 Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010073791 Glycine amidinotransferase Proteins 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102100021182 Golgi integral membrane protein 4 Human genes 0.000 description 1
- 101710140584 Golgi integral membrane protein 4 Proteins 0.000 description 1
- 101150040584 Gpr18 gene Proteins 0.000 description 1
- 102100034228 Grainyhead-like protein 1 homolog Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100039844 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 Human genes 0.000 description 1
- 108020004202 Guanylate Kinase Proteins 0.000 description 1
- 101710110797 Guanylate-binding protein 4 Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 102100028893 Hemicentin-1 Human genes 0.000 description 1
- 101710142180 Hemicentin-1 Proteins 0.000 description 1
- 102100039991 Heparan-alpha-glucosaminide N-acetyltransferase Human genes 0.000 description 1
- 108030000639 Heparan-alpha-glucosaminide N-acetyltransferases Proteins 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102100030338 Hexokinase-1 Human genes 0.000 description 1
- 101710198391 Hexokinase-1 Proteins 0.000 description 1
- 102100024228 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 101710177326 Histone deacetylase 9 Proteins 0.000 description 1
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 description 1
- 101710110793 Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001058479 Homo sapiens 1,4-alpha-glucan-branching enzyme Proteins 0.000 description 1
- 101001127039 Homo sapiens 60S ribosomal protein L38 Proteins 0.000 description 1
- 101000793552 Homo sapiens ADP-ribosylation factor-like protein 6-interacting protein 1 Proteins 0.000 description 1
- 101000833172 Homo sapiens AF4/FMR2 family member 2 Proteins 0.000 description 1
- 101000783770 Homo sapiens ATP-binding cassette sub-family D member 3 Proteins 0.000 description 1
- 101000728742 Homo sapiens Actin-related protein 3B Proteins 0.000 description 1
- 101000801606 Homo sapiens Acyl-CoA-binding domain-containing protein 7 Proteins 0.000 description 1
- 101000775461 Homo sapiens Adipolin Proteins 0.000 description 1
- 101000634075 Homo sapiens Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 101000779572 Homo sapiens Alpha-protein kinase 3 Proteins 0.000 description 1
- 101000718108 Homo sapiens Androgen-induced gene 1 protein Proteins 0.000 description 1
- 101000693081 Homo sapiens Angiopoietin-related protein 2 Proteins 0.000 description 1
- 101000964352 Homo sapiens Ankyrin repeat and BTB/POZ domain-containing protein 1 Proteins 0.000 description 1
- 101000924485 Homo sapiens Ankyrin repeat domain-containing protein 12 Proteins 0.000 description 1
- 101000796113 Homo sapiens Ankyrin repeat domain-containing protein 55 Proteins 0.000 description 1
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101000697938 Homo sapiens Attractin-like protein 1 Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000739794 Homo sapiens BEN domain-containing protein 6 Proteins 0.000 description 1
- 101000974808 Homo sapiens BTB/POZ domain-containing protein KCTD14 Proteins 0.000 description 1
- 101000575704 Homo sapiens Beta-citrylglutamate synthase B Proteins 0.000 description 1
- 101000934394 Homo sapiens C-C chemokine receptor-like 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000916502 Homo sapiens COP9 signalosome complex subunit 8 Proteins 0.000 description 1
- 101001049849 Homo sapiens Calcium-activated potassium channel subunit beta-1 Proteins 0.000 description 1
- 101000714589 Homo sapiens Calcium-binding and coiled-coil domain-containing protein 1 Proteins 0.000 description 1
- 101000945410 Homo sapiens Calponin-3 Proteins 0.000 description 1
- 101000914244 Homo sapiens Centrosomal protein of 97 kDa Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000861327 Homo sapiens Cholesterol side-chain cleavage enzyme, mitochondrial Proteins 0.000 description 1
- 101000932756 Homo sapiens Coiled-coil domain-containing protein 22 Proteins 0.000 description 1
- 101000737584 Homo sapiens Cystathionine gamma-lyase Proteins 0.000 description 1
- 101000916688 Homo sapiens Cystatin-F Proteins 0.000 description 1
- 101000917433 Homo sapiens DDB1- and CUL4-associated factor 17 Proteins 0.000 description 1
- 101000722275 Homo sapiens DENN domain-containing protein 5A Proteins 0.000 description 1
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101000889412 Homo sapiens Dimethyladenosine transferase 1, mitochondrial Proteins 0.000 description 1
- 101000805871 Homo sapiens Disco-interacting protein 2 homolog B Proteins 0.000 description 1
- 101000908042 Homo sapiens DnaJ homolog subfamily C member 10 Proteins 0.000 description 1
- 101000870234 Homo sapiens DnaJ homolog subfamily C member 12 Proteins 0.000 description 1
- 101000932600 Homo sapiens Dual specificity protein phosphatase CDC14A Proteins 0.000 description 1
- 101000932592 Homo sapiens Dual specificity protein phosphatase CDC14B Proteins 0.000 description 1
- 101001049983 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 4 Proteins 0.000 description 1
- 101000926716 Homo sapiens E3 ubiquitin-protein ligase DZIP3 Proteins 0.000 description 1
- 101000633723 Homo sapiens E3 ubiquitin-protein ligase TTC3 Proteins 0.000 description 1
- 101001016391 Homo sapiens ER degradation-enhancing alpha-mannosidase-like protein 3 Proteins 0.000 description 1
- 101000877423 Homo sapiens Elongator complex protein 4 Proteins 0.000 description 1
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 1
- 101000824117 Homo sapiens F-box only protein 30 Proteins 0.000 description 1
- 101001030528 Homo sapiens FSD1-like protein Proteins 0.000 description 1
- 101000878272 Homo sapiens Fidgetin-like protein 1 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001059384 Homo sapiens Formin-like protein 2 Proteins 0.000 description 1
- 101001059934 Homo sapiens Fos-related antigen 2 Proteins 0.000 description 1
- 101000997966 Homo sapiens Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 2 Proteins 0.000 description 1
- 101001069933 Homo sapiens Grainyhead-like protein 1 homolog Proteins 0.000 description 1
- 101000887521 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 Proteins 0.000 description 1
- 101001117261 Homo sapiens High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Proteins 0.000 description 1
- 101001045123 Homo sapiens Hyccin Proteins 0.000 description 1
- 101000599778 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 1
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 description 1
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 1
- 101001081548 Homo sapiens Islet cell autoantigen 1-like protein Proteins 0.000 description 1
- 101001056560 Homo sapiens Juxtaposed with another zinc finger protein 1 Proteins 0.000 description 1
- 101001006789 Homo sapiens Kinesin heavy chain isoform 5C Proteins 0.000 description 1
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101000956807 Homo sapiens Leukocyte tyrosine kinase receptor Proteins 0.000 description 1
- 101000780202 Homo sapiens Long-chain-fatty-acid-CoA ligase 6 Proteins 0.000 description 1
- 101001047659 Homo sapiens Lymphocyte transmembrane adapter 1 Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 description 1
- 101000988591 Homo sapiens Minor histocompatibility antigen H13 Proteins 0.000 description 1
- 101001051835 Homo sapiens Mitochondrial pyruvate carrier 1 Proteins 0.000 description 1
- 101000577033 Homo sapiens Monocarboxylate transporter 7 Proteins 0.000 description 1
- 101000957807 Homo sapiens Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Proteins 0.000 description 1
- 101000957333 Homo sapiens Muscleblind-like protein 3 Proteins 0.000 description 1
- 101000583016 Homo sapiens Myosin-IIIb Proteins 0.000 description 1
- 101000650158 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP1 Proteins 0.000 description 1
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 1
- 101000637183 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF4 Proteins 0.000 description 1
- 101000979259 Homo sapiens Neurolysin, mitochondrial Proteins 0.000 description 1
- 101001069237 Homo sapiens Neuronal membrane glycoprotein M6-b Proteins 0.000 description 1
- 101001023731 Homo sapiens Neuropilin and tolloid-like protein 1 Proteins 0.000 description 1
- 101001025772 Homo sapiens Neutral alpha-glucosidase C Proteins 0.000 description 1
- 101001118493 Homo sapiens Nuclear pore glycoprotein p62 Proteins 0.000 description 1
- 101001121168 Homo sapiens ORM1-like protein 1 Proteins 0.000 description 1
- 101001130862 Homo sapiens Oligoribonuclease, mitochondrial Proteins 0.000 description 1
- 101000594698 Homo sapiens Ornithine decarboxylase antizyme 1 Proteins 0.000 description 1
- 101000992396 Homo sapiens Oxysterol-binding protein-related protein 3 Proteins 0.000 description 1
- 101000693238 Homo sapiens PDZ domain-containing protein 2 Proteins 0.000 description 1
- 101001129621 Homo sapiens PH domain leucine-rich repeat-containing protein phosphatase 1 Proteins 0.000 description 1
- 101001123306 Homo sapiens PR domain zinc finger protein 10 Proteins 0.000 description 1
- 101000609957 Homo sapiens PTB-containing, cubilin and LRP1-interacting protein Proteins 0.000 description 1
- 101000922137 Homo sapiens Peripheral plasma membrane protein CASK Proteins 0.000 description 1
- 101000605432 Homo sapiens Phospholipid phosphatase 1 Proteins 0.000 description 1
- 101000730599 Homo sapiens Pleckstrin homology domain-containing family F member 1 Proteins 0.000 description 1
- 101001001793 Homo sapiens Pleckstrin homology domain-containing family O member 1 Proteins 0.000 description 1
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 description 1
- 101000597239 Homo sapiens Pleckstrin homology-like domain family B member 2 Proteins 0.000 description 1
- 101000974745 Homo sapiens Potassium channel subfamily K member 10 Proteins 0.000 description 1
- 101000870730 Homo sapiens Probable ATP-dependent RNA helicase DDX28 Proteins 0.000 description 1
- 101000915008 Homo sapiens Probable C-mannosyltransferase DPY19L3 Proteins 0.000 description 1
- 101000914997 Homo sapiens Probable C-mannosyltransferase DPY19L4 Proteins 0.000 description 1
- 101000976219 Homo sapiens Probable ribonuclease ZC3H12C Proteins 0.000 description 1
- 101000640842 Homo sapiens Probable sodium-coupled neutral amino acid transporter 6 Proteins 0.000 description 1
- 101000986265 Homo sapiens Protein MTSS 1 Proteins 0.000 description 1
- 101000595899 Homo sapiens Protein O-glucosyltransferase 2 Proteins 0.000 description 1
- 101000981742 Homo sapiens Protein lifeguard 1 Proteins 0.000 description 1
- 101000981717 Homo sapiens Protein lifeguard 3 Proteins 0.000 description 1
- 101001122742 Homo sapiens Protein phosphatase 1 regulatory inhibitor subunit 16B Proteins 0.000 description 1
- 101000768927 Homo sapiens Protein yippee-like 1 Proteins 0.000 description 1
- 101000769165 Homo sapiens Protein yippee-like 2 Proteins 0.000 description 1
- 101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 description 1
- 101000823193 Homo sapiens RUN domain-containing protein 1 Proteins 0.000 description 1
- 101001106821 Homo sapiens Rab11 family-interacting protein 1 Proteins 0.000 description 1
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 101001079084 Homo sapiens Ras-related protein Rab-18 Proteins 0.000 description 1
- 101001106090 Homo sapiens Receptor expression-enhancing protein 5 Proteins 0.000 description 1
- 101000700402 Homo sapiens Regulatory solute carrier protein family 1 member 1 Proteins 0.000 description 1
- 101000637411 Homo sapiens Rho guanine nucleotide exchange factor TIAM2 Proteins 0.000 description 1
- 101000681263 Homo sapiens Ribosome-recycling factor, mitochondrial Proteins 0.000 description 1
- 101000707215 Homo sapiens SH2 domain-containing protein 2A Proteins 0.000 description 1
- 101000825289 Homo sapiens SPRY domain-containing SOCS box protein 1 Proteins 0.000 description 1
- 101000702542 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 Proteins 0.000 description 1
- 101000650811 Homo sapiens Semaphorin-3D Proteins 0.000 description 1
- 101000739671 Homo sapiens Semaphorin-6D Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000783377 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform Proteins 0.000 description 1
- 101000783373 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Proteins 0.000 description 1
- 101000803165 Homo sapiens Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform Proteins 0.000 description 1
- 101000799180 Homo sapiens Short transient receptor potential channel 4-associated protein Proteins 0.000 description 1
- 101001123847 Homo sapiens Sialidase-3 Proteins 0.000 description 1
- 101000685690 Homo sapiens Sialin Proteins 0.000 description 1
- 101000702479 Homo sapiens Sodium/hydrogen exchanger 1 Proteins 0.000 description 1
- 101000821918 Homo sapiens Solute carrier family 15 member 3 Proteins 0.000 description 1
- 101000868917 Homo sapiens Spermatogenesis-defective protein 39 homolog Proteins 0.000 description 1
- 101000615384 Homo sapiens Stromal membrane-associated protein 2 Proteins 0.000 description 1
- 101000587717 Homo sapiens Sulfide:quinone oxidoreductase, mitochondrial Proteins 0.000 description 1
- 101000625330 Homo sapiens T-cell acute lymphocytic leukemia protein 2 Proteins 0.000 description 1
- 101000595554 Homo sapiens TIR domain-containing adapter molecule 2 Proteins 0.000 description 1
- 101001063514 Homo sapiens Telomerase-binding protein EST1A Proteins 0.000 description 1
- 101000648265 Homo sapiens Thymocyte selection-associated high mobility group box protein TOX Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000764634 Homo sapiens Transmembrane gamma-carboxyglutamic acid protein 4 Proteins 0.000 description 1
- 101000851431 Homo sapiens Transmembrane protein 70, mitochondrial Proteins 0.000 description 1
- 101000835646 Homo sapiens Tubulin beta-2B chain Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000807524 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 22 Proteins 0.000 description 1
- 101000643895 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 6 Proteins 0.000 description 1
- 101000644653 Homo sapiens Ubiquitin-conjugating enzyme E2 E2 Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 101000641296 Homo sapiens Vacuolar protein sorting-associated protein 37A Proteins 0.000 description 1
- 101000804736 Homo sapiens Vacuolar protein sorting-associated protein 54 Proteins 0.000 description 1
- 101000743544 Homo sapiens Vomeronasal type-1 receptor 2 Proteins 0.000 description 1
- 101000743543 Homo sapiens Vomeronasal type-1 receptor 3 Proteins 0.000 description 1
- 101000650148 Homo sapiens WD repeat domain phosphoinositide-interacting protein 1 Proteins 0.000 description 1
- 101000708573 Homo sapiens Y+L amino acid transporter 2 Proteins 0.000 description 1
- 101000785728 Homo sapiens Zinc finger FYVE domain-containing protein 1 Proteins 0.000 description 1
- 101000759565 Homo sapiens Zinc finger and BTB domain-containing protein 1 Proteins 0.000 description 1
- 101000818605 Homo sapiens Zinc finger and BTB domain-containing protein 32 Proteins 0.000 description 1
- 101000641227 Homo sapiens von Willebrand factor A domain-containing protein 5A Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100022652 Hyccin Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 101150081223 IGFBP4 gene Proteins 0.000 description 1
- 102000039995 Ikaros C2H2-type zinc-finger protein family Human genes 0.000 description 1
- 108091069197 Ikaros C2H2-type zinc-finger protein family Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100033336 Integrin beta-8 Human genes 0.000 description 1
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 description 1
- 101710157897 Interferon regulatory factor 5 Proteins 0.000 description 1
- 102100030130 Interferon regulatory factor 6 Human genes 0.000 description 1
- 101710157822 Interferon regulatory factor 6 Proteins 0.000 description 1
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
- 102000012473 Interleukin-1 receptor-associated kinase 1-binding protein 1 Human genes 0.000 description 1
- 108050002038 Interleukin-1 receptor-associated kinase 1-binding protein 1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
- 102100035015 Interleukin-17 receptor D Human genes 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 102100027664 Islet cell autoantigen 1-like protein Human genes 0.000 description 1
- 108010065958 Isopentenyl-diphosphate Delta-isomerase Proteins 0.000 description 1
- 102100027665 Isopentenyl-diphosphate Delta-isomerase 1 Human genes 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 108010019421 Janus Kinase 3 Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 102100023956 Junction-mediating and -regulatory protein Human genes 0.000 description 1
- 101710172842 Junction-mediating and -regulatory protein Proteins 0.000 description 1
- 102100025727 Juxtaposed with another zinc finger protein 1 Human genes 0.000 description 1
- 101150094197 KLRD1 gene Proteins 0.000 description 1
- 102100027928 Kinesin heavy chain isoform 5C Human genes 0.000 description 1
- 102100027798 Krueppel-like factor 10 Human genes 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 108010017123 Kruppel-Like Transcription Factors Proteins 0.000 description 1
- 102000004434 Kruppel-Like Transcription Factors Human genes 0.000 description 1
- 108010041081 Kv Channel-Interacting Proteins Proteins 0.000 description 1
- 102100021173 Kv channel-interacting protein 2 Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 1
- 102100026910 Leucine zipper protein 4 Human genes 0.000 description 1
- 101710192805 Leucine zipper protein 4 Proteins 0.000 description 1
- 101710201625 Leucine-rich protein Proteins 0.000 description 1
- 102100038420 Leukocyte tyrosine kinase receptor Human genes 0.000 description 1
- 102100032755 Leupaxin Human genes 0.000 description 1
- 101710156018 Leupaxin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102100031961 Liprin-beta-1 Human genes 0.000 description 1
- 108050001513 Liprin-beta-1 Proteins 0.000 description 1
- 102100034337 Long-chain-fatty-acid-CoA ligase 6 Human genes 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 101710118198 Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- BKZOUCVNTCLNFF-UHFFFAOYSA-N Lonomycin Natural products COC1C(C)C(C2(C)OC(CC2)C2(C)OC3(OC(C(C)C(OC)C3)C(C)C3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)C)CC2)OC1C1OC(C)(O)C(C)C(OC)C1C BKZOUCVNTCLNFF-UHFFFAOYSA-N 0.000 description 1
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 description 1
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 description 1
- 102100024034 Lymphocyte transmembrane adapter 1 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 108010041980 MAP-kinase-activated kinase 3 Proteins 0.000 description 1
- 102000042257 MAPRE family Human genes 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 102100022211 MTRF1L release factor glutamine methyltransferase Human genes 0.000 description 1
- 101710122561 MTRF1L release factor glutamine methyltransferase Proteins 0.000 description 1
- 102100024573 Macrophage-capping protein Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710159527 Maturation protein A Proteins 0.000 description 1
- 101710091157 Maturation protein A2 Proteins 0.000 description 1
- 102100039185 Max dimerization protein 1 Human genes 0.000 description 1
- 101710188077 Max dimerization protein 1 Proteins 0.000 description 1
- 102100034820 Mediator of RNA polymerase II transcription subunit 14 Human genes 0.000 description 1
- 101710179415 Mediator of RNA polymerase II transcription subunit 14 Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 101710094503 Metallothionein-1 Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 description 1
- 102100024828 Mitochondrial pyruvate carrier 1 Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 102100025311 Monocarboxylate transporter 7 Human genes 0.000 description 1
- 108010041817 Monocarboxylic Acid Transporters Proteins 0.000 description 1
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100166596 Mus musculus Cd27 gene Proteins 0.000 description 1
- 101100071930 Mus musculus Il17ra gene Proteins 0.000 description 1
- 101100022165 Mus musculus Ms4a6b gene Proteins 0.000 description 1
- 101000779417 Mus musculus RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 102100038751 Muscleblind-like protein 3 Human genes 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 102100035083 Myoferlin Human genes 0.000 description 1
- 108050006329 Myoferlin Proteins 0.000 description 1
- 102100030369 Myosin-IIIb Human genes 0.000 description 1
- 102100024960 Myotubularin-related protein 13 Human genes 0.000 description 1
- 108050003275 Myotubularin-related protein 13 Proteins 0.000 description 1
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 1
- 102100035854 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 Human genes 0.000 description 1
- 108050006009 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 Proteins 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 102100031578 N6-adenosine-methyltransferase non-catalytic subunit Human genes 0.000 description 1
- 101710081491 N6-adenosine-methyltransferase non-catalytic subunit Proteins 0.000 description 1
- 102100038552 NEDD4-binding protein 1 Human genes 0.000 description 1
- 101710081124 NEDD4-binding protein 1 Proteins 0.000 description 1
- 102100027550 NEDD4-like E3 ubiquitin-protein ligase WWP1 Human genes 0.000 description 1
- 108091007369 NEUR proteins Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 108020002144 NR4 subfamily Proteins 0.000 description 1
- 101150103083 NRN1 gene Proteins 0.000 description 1
- 102100031820 Na(+)/H(+) exchange regulatory cofactor NHE-RF4 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 102100023072 Neurolysin, mitochondrial Human genes 0.000 description 1
- 102100030465 Neuron navigator 2 Human genes 0.000 description 1
- 101710145273 Neuron navigator 2 Proteins 0.000 description 1
- 102100033800 Neuronal membrane glycoprotein M6-b Human genes 0.000 description 1
- 102100035483 Neuropilin and tolloid-like protein 1 Human genes 0.000 description 1
- 102100028762 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 102100037413 Neutral alpha-glucosidase C Human genes 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 102000007603 Non-Receptor Type 12 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010032109 Non-Receptor Type 12 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 101710180962 Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 1
- 102100024057 Nuclear pore glycoprotein p62 Human genes 0.000 description 1
- 102100022930 Nuclear receptor coactivator 7 Human genes 0.000 description 1
- 101710115824 Nuclear receptor coactivator 7 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100026499 ORM1-like protein 1 Human genes 0.000 description 1
- 101710140197 Olfactory receptor 478 Proteins 0.000 description 1
- 102100032835 Oligoribonuclease, mitochondrial Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 description 1
- 108010084438 Oncogene Protein v-maf Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000016544 Ornithine decarboxylase antizyme 1 Human genes 0.000 description 1
- 102100036199 Ornithine decarboxylase antizyme 1 Human genes 0.000 description 1
- 108050006086 Ornithine decarboxylase antizyme 1 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100032154 Oxysterol-binding protein-related protein 3 Human genes 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 102000002125 PDZK1-interacting protein 1 Human genes 0.000 description 1
- 108050009474 PDZK1-interacting protein 1 Proteins 0.000 description 1
- 102100031152 PH domain leucine-rich repeat-containing protein phosphatase 1 Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100028955 PR domain zinc finger protein 10 Human genes 0.000 description 1
- 102100039157 PTB-containing, cubilin and LRP1-interacting protein Human genes 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102100027370 Parathymosin Human genes 0.000 description 1
- 101710178700 Parathymosin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710167374 Peptidase 1 Proteins 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 102100031166 Peripheral plasma membrane protein CASK Human genes 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 102000009569 Phosphoglucomutase Human genes 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102100038121 Phospholipid phosphatase 1 Human genes 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090000754 Phosphoric Triester Hydrolases Proteins 0.000 description 1
- 102000004203 Phosphoric Triester Hydrolases Human genes 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102100026187 Placenta-specific gene 8 protein Human genes 0.000 description 1
- 101710146232 Placenta-specific gene 8 protein Proteins 0.000 description 1
- 102100030365 Plakophilin-4 Human genes 0.000 description 1
- 108050004723 Plakophilin-4 Proteins 0.000 description 1
- 102100032592 Pleckstrin homology domain-containing family F member 1 Human genes 0.000 description 1
- 102100036265 Pleckstrin homology domain-containing family O member 1 Human genes 0.000 description 1
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 description 1
- 102100035156 Pleckstrin homology-like domain family B member 2 Human genes 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 101710118150 Podoplanin Proteins 0.000 description 1
- 101710101680 Polyadenylate-binding protein-interacting protein 1 Proteins 0.000 description 1
- 102100034080 Polyadenylate-binding protein-interacting protein 1 Human genes 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 102100022798 Potassium channel subfamily K member 10 Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100033406 Probable ATP-dependent RNA helicase DDX28 Human genes 0.000 description 1
- 102100028677 Probable C-mannosyltransferase DPY19L3 Human genes 0.000 description 1
- 102100028695 Probable C-mannosyltransferase DPY19L4 Human genes 0.000 description 1
- 102100029245 Probable RNA-binding protein 18 Human genes 0.000 description 1
- 101710150107 Probable RNA-binding protein 18 Proteins 0.000 description 1
- 102100023886 Probable ribonuclease ZC3H12C Human genes 0.000 description 1
- 102100033874 Probable sodium-coupled neutral amino acid transporter 6 Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 108010049395 Prokaryotic Initiation Factor-2 Proteins 0.000 description 1
- 101710100261 Proline-rich transmembrane protein 2 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100028951 Protein MTSS 1 Human genes 0.000 description 1
- 102100029278 Protein N-terminal glutamine amidohydrolase Human genes 0.000 description 1
- 101710162701 Protein N-terminal glutamine amidohydrolase Proteins 0.000 description 1
- 102100035204 Protein O-glucosyltransferase 2 Human genes 0.000 description 1
- 102100032421 Protein S100-A6 Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100024139 Protein lifeguard 1 Human genes 0.000 description 1
- 102100024136 Protein lifeguard 3 Human genes 0.000 description 1
- 102100028740 Protein phosphatase 1 regulatory inhibitor subunit 16B Human genes 0.000 description 1
- 102100028420 Protein yippee-like 1 Human genes 0.000 description 1
- 102100028367 Protein yippee-like 2 Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100034941 Protocadherin-7 Human genes 0.000 description 1
- 101710141460 Protocadherin-7 Proteins 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102100039233 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 108091008731 RAR-related orphan receptors α Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100022667 RUN domain-containing protein 1 Human genes 0.000 description 1
- 102100021315 Rab11 family-interacting protein 1 Human genes 0.000 description 1
- 102100038203 Rab15 effector protein Human genes 0.000 description 1
- 101710191041 Rab15 effector protein Proteins 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 102100031490 Ras and Rab interactor 2 Human genes 0.000 description 1
- 101710090031 Ras and Rab interactor 2 Proteins 0.000 description 1
- 102100028149 Ras-related protein Rab-18 Human genes 0.000 description 1
- 102100021077 Receptor expression-enhancing protein 5 Human genes 0.000 description 1
- 102100039663 Receptor-type tyrosine-protein phosphatase F Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100029521 Regulatory solute carrier protein family 1 member 1 Human genes 0.000 description 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 1
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 1
- 102100020890 Rho GTPase-activating protein 31 Human genes 0.000 description 1
- 101710110514 Rho GTPase-activating protein 31 Proteins 0.000 description 1
- 102100030748 Rho GTPase-activating protein 39 Human genes 0.000 description 1
- 101710110515 Rho GTPase-activating protein 39 Proteins 0.000 description 1
- 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102100032206 Rho guanine nucleotide exchange factor TIAM2 Human genes 0.000 description 1
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 description 1
- 101710087566 Ribitol-5-phosphate transferase FKTN Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102000004209 Ribosomal protein L5 Human genes 0.000 description 1
- 108090000776 Ribosomal protein L5 Proteins 0.000 description 1
- 102100022945 Ribosome-recycling factor, mitochondrial Human genes 0.000 description 1
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 1
- 101710102802 Runt-related transcription factor 2 Proteins 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 101150015378 SAT5 gene Proteins 0.000 description 1
- 101150097713 SCD1 gene Proteins 0.000 description 1
- 102100031779 SH2 domain-containing protein 2A Human genes 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 108091006172 SLC21 Proteins 0.000 description 1
- 102100037356 SLIT-ROBO Rho GTPase-activating protein 1 Human genes 0.000 description 1
- 101710104382 SLIT-ROBO Rho GTPase-activating protein 1 Proteins 0.000 description 1
- 102100022320 SPRY domain-containing SOCS box protein 1 Human genes 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102100031029 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 Human genes 0.000 description 1
- 101150064154 SYCP3 gene Proteins 0.000 description 1
- 101000918648 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Cyanamide hydratase DDI2 Proteins 0.000 description 1
- 102100023152 Scinderin Human genes 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 102000013008 Semaphorin-3A Human genes 0.000 description 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 1
- 102100027746 Semaphorin-3D Human genes 0.000 description 1
- 102100037548 Semaphorin-6D Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100022261 Serine/threonine-protein kinase RIO1 Human genes 0.000 description 1
- 101710121265 Serine/threonine-protein kinase RIO1 Proteins 0.000 description 1
- 102100036141 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform Human genes 0.000 description 1
- 102100036140 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Human genes 0.000 description 1
- 102100035547 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform Human genes 0.000 description 1
- 102100037576 Sestrin-2 Human genes 0.000 description 1
- 101710186851 Sestrin-2 Proteins 0.000 description 1
- 102100037575 Sestrin-3 Human genes 0.000 description 1
- 101710186850 Sestrin-3 Proteins 0.000 description 1
- 102100034106 Short transient receptor potential channel 4-associated protein Human genes 0.000 description 1
- 102100028756 Sialidase-3 Human genes 0.000 description 1
- 102100023105 Sialin Human genes 0.000 description 1
- 102100023776 Signal peptidase complex subunit 2 Human genes 0.000 description 1
- 101710164605 Signal peptidase complex subunit 2 Proteins 0.000 description 1
- 108700015968 Slam family Proteins 0.000 description 1
- 101150116431 Slc44a2 gene Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
- 102100021485 Solute carrier family 15 member 3 Human genes 0.000 description 1
- 102100029608 Sorting nexin-10 Human genes 0.000 description 1
- 101710182523 Sorting nexin-10 Proteins 0.000 description 1
- 102100029606 Sorting nexin-13 Human genes 0.000 description 1
- 101710182509 Sorting nexin-13 Proteins 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 101710089264 Sperm motility kinase Proteins 0.000 description 1
- 101710163956 Sperm motility kinase 3A Proteins 0.000 description 1
- 101710163955 Sperm motility kinase 3B Proteins 0.000 description 1
- 102100032313 Spermatogenesis-defective protein 39 homolog Human genes 0.000 description 1
- 108010051753 Spermidine Synthase Proteins 0.000 description 1
- 102100030413 Spermidine synthase Human genes 0.000 description 1
- 102100024471 Stabilin-1 Human genes 0.000 description 1
- 101710164042 Stabilin-1 Proteins 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 102100021685 Stomatin Human genes 0.000 description 1
- 108700037714 Stomatin Proteins 0.000 description 1
- 102000000322 Stonin-1 Human genes 0.000 description 1
- 108050008772 Stonin-1 Proteins 0.000 description 1
- 102100021250 Stromal membrane-associated protein 2 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100031138 Sulfide:quinone oxidoreductase, mitochondrial Human genes 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 102100035604 Synaptopodin Human genes 0.000 description 1
- 101710119889 Synaptopodin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010091885 T-box transcription factor TBX21 Proteins 0.000 description 1
- 102100025039 T-cell acute lymphocytic leukemia protein 2 Human genes 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 102100036074 TIR domain-containing adapter molecule 2 Human genes 0.000 description 1
- 102100031022 Telomerase-binding protein EST1A Human genes 0.000 description 1
- 108010077673 Tetraspanin 29 Proteins 0.000 description 1
- 102100035873 Tetraspanin-2 Human genes 0.000 description 1
- 101710151638 Tetraspanin-2 Proteins 0.000 description 1
- 102100040874 Tetraspanin-3 Human genes 0.000 description 1
- 101710151650 Tetraspanin-3 Proteins 0.000 description 1
- 102100036923 Thioredoxin-related transmembrane protein 4 Human genes 0.000 description 1
- 101710203067 Thioredoxin-related transmembrane protein 4 Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102100028788 Thymocyte selection-associated high mobility group box protein TOX Human genes 0.000 description 1
- 102100029689 Thyroid hormone receptor-associated protein 3 Human genes 0.000 description 1
- 108050009589 Thyroid hormone receptor-associated protein 3 Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 101710124862 Transcobalamin-2 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100026222 Transmembrane gamma-carboxyglutamic acid protein 4 Human genes 0.000 description 1
- 102100028599 Transmembrane protein 120B Human genes 0.000 description 1
- 101710169547 Transmembrane protein 120B Proteins 0.000 description 1
- 102100036380 Transmembrane protein 176A Human genes 0.000 description 1
- 101710198249 Transmembrane protein 176A Proteins 0.000 description 1
- 102100036387 Transmembrane protein 176B Human genes 0.000 description 1
- 101710198250 Transmembrane protein 176B Proteins 0.000 description 1
- 102100036921 Transmembrane protein 70, mitochondrial Human genes 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- 102100026248 Tubulin beta-2B chain Human genes 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 1
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 1
- 102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 102100037932 Ubiquitin D Human genes 0.000 description 1
- 101710138219 Ubiquitin D Proteins 0.000 description 1
- 102100037184 Ubiquitin carboxyl-terminal hydrolase 22 Human genes 0.000 description 1
- 102100021015 Ubiquitin carboxyl-terminal hydrolase 6 Human genes 0.000 description 1
- 102100028462 Ubiquitin-60S ribosomal protein L40 Human genes 0.000 description 1
- 101710200656 Ubiquitin-60S ribosomal protein L40 Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102100020704 Ubiquitin-conjugating enzyme E2 E2 Human genes 0.000 description 1
- 102100020698 Ubiquitin-conjugating enzyme E2 H Human genes 0.000 description 1
- 101710192902 Ubiquitin-conjugating enzyme E2 H Proteins 0.000 description 1
- 244000025271 Umbellularia californica Species 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 101710174353 Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102100034324 Vacuolar protein sorting-associated protein 37A Human genes 0.000 description 1
- 102100035288 Vacuolar protein sorting-associated protein 54 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
- 102100038345 Vomeronasal type-1 receptor 3 Human genes 0.000 description 1
- 102100027543 WD repeat domain phosphoinositide-interacting protein 1 Human genes 0.000 description 1
- 102100032803 Y+L amino acid transporter 2 Human genes 0.000 description 1
- 101100060528 Zea mays CNR8 gene Proteins 0.000 description 1
- 102100026420 Zinc finger FYVE domain-containing protein 1 Human genes 0.000 description 1
- 102100023253 Zinc finger and BTB domain-containing protein 1 Human genes 0.000 description 1
- 102100021135 Zinc finger and BTB domain-containing protein 32 Human genes 0.000 description 1
- 102100024727 Zinc finger protein 580 Human genes 0.000 description 1
- 101710143343 Zinc finger protein 580 Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010054347 alcohol dehydrogenase IV Proteins 0.000 description 1
- 108091022872 aldose 1-epimerase Proteins 0.000 description 1
- 108010058061 alpha E integrins Proteins 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 102000006614 amidinotransferase Human genes 0.000 description 1
- 108020004134 amidinotransferase Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 101150103980 ced-12 gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 102000018123 coronin Human genes 0.000 description 1
- KRQUGYHEWIVMJV-UHFFFAOYSA-N coronin Natural products CCCCCCCCCCCCC=C/CCC1OC1CCC2OC2CCCCCCCCCCC3=CC(C)OC3=O KRQUGYHEWIVMJV-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 108010012154 cytokine inducible SH2-containing protein Proteins 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 108010037434 early endosome antigen 1 Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 102000054078 gamma Catenin Human genes 0.000 description 1
- 108010084448 gamma Catenin Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000017941 granulin Human genes 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 108010070387 guanylate cyclase 1 Proteins 0.000 description 1
- 102000006638 guanylate kinase Human genes 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 102000053370 human PRRT2 Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010021506 integrin beta8 Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- HSMPDPBYAYSOBC-UHFFFAOYSA-N khellin Chemical compound O1C(C)=CC(=O)C2=C1C(OC)=C1OC=CC1=C2OC HSMPDPBYAYSOBC-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229950007254 mavrilimumab Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 102100030898 p53 apoptosis effector related to PMP-22 Human genes 0.000 description 1
- 101710098858 p53 apoptosis effector related to PMP-22 Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108091000115 phosphomannomutase Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 101150006789 pld3 gene Proteins 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108010025396 ribosomal protein L34 Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 101150024819 s1pr1 gene Proteins 0.000 description 1
- 108010073419 scinderin Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 108010014501 sphingosine 1-phosphate lyase (aldolase) Proteins 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 108010016093 sterol O-acyltransferase 1 Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 102000042356 sulfotransferase 2 family Human genes 0.000 description 1
- 108091077836 sulfotransferase 2 family Proteins 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 102100034332 von Willebrand factor A domain-containing protein 5A Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464439—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/53—Colony-stimulating factor [CSF]
- G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5403—IL-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5418—IL-7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Definitions
- T H CD4 + helper T
- TCR T-cell receptor
- RA rheumatoid arthritis
- TNF- ⁇ tumor necrosis factor ⁇
- the present disclosure relates, in part, to the identification of an interleukin-7 (IL-7)/signal transducer and activator of transcription 5 (STAT5)-regulated granulocyte macrophage colony-stimulating factor (GM-CSF)/IL-3-producing T H cells, termed T H -GM, which represent a distinct helper T cell subset with unique developmental and functional characteristics.
- T H -GM an interleukin-7
- STAT5 granulocyte macrophage colony-stimulating factor
- GM-CSF granulocyte macrophage colony-stimulating factor
- T H -GM which represent a distinct helper T cell subset with unique developmental and functional characteristics.
- T H -GM-GM an inflammatory pathway mediated by T H -GM cells
- T H -GM-mediated inflammatory pathway which represents an independent inflammatory pathway apart from known non-T H -GM-mediated inflammatory pathways (e.g., TNF-a, IL-6, and IL-1b pathways of inflammation).
- the present disclosure provides a method of diagnosing a T H -GM-mediated inflammatory disorder in a patient suffering from an inflammatory disorder, comprising: a) contacting a sample collected from a patient suffering from an inflammatory disorder with a detecting agent that detects a polypeptide or nucleic acid level of STAT5 (e.g., phospho-STAT5 (Tyr694)).
- a detecting agent that detects a polypeptide or nucleic acid level of STAT5 (e.g., phospho-STAT5 (Tyr694)).
- IL-7 IL-7, GM-CSF or IL-3, or a combination thereof; and h) quantifying the polypeptide or nucleic acid level of STAT5 (e.g., phospho-STAT5 (Tyr694)), IL-7, GM-CSF or IL-3, or a combination thereof, wherein an increased level of STAT5 (e.g., phospho-STAT5 (Tyr694)), interleukin-7 (IL-7), GM-CSF or interleukin-3 (IL-3), or a combination thereof relative to a reference level indicates that the patient suffers from a T H -GM-mediated inflammatory disorder.
- STAT5 e.g., phospho-STAT5 (Tyr694)
- IL-7 interleukin-7
- IL-3 interleukin-3
- the present disclosure provides an isolated population of GM-CSF-secreting T-helper cells (T H -GM), wherein the T H -GM cells are differentiated from cluster of differentiation 4 (CD4+) precursor cells in the presence of IL-7 and activated STAT5, and wherein the T H -GM cells express GM-CSF and IL-3.
- T H -GM GM-CSF-secreting T-helper cells
- the present disclosure provides a method of modulating T H -GM function, comprising contacting the T H -GM, or CD4+ precursor cells, or both, with a modulating agent that modulates T H -GM function.
- the present disclosure provides a method of treating a T H -GM-mediated inflammatory disorder in a patient in need thereof, comprising administering to said patient an effective amount of a modulating agent that modulates T H -GM cell function.
- the present disclosure provides a method of treating rheumatoid arthritis in a patient who exhibits limited response to anti-tumor necrosis factor alpha (TNF- ⁇ ) therapy, comprising administering to said patient an effective amount of a modulating agent that modulates T H -GM function.
- TNF- ⁇ anti-tumor necrosis factor alpha
- the present disclosure provides a method of treating a STAT5-mediated inflammatory disorder in a patient in need thereof, comprising administering to the patient an effective amount of an agent that modulates STAT5 function.
- the present disclosure provides a method of screening to identify a modulator of T H -GM cell function, comprising contacting an isolated population of T H -GM cells, or an isolated population of CD4+ precursor cells, with a candidate agent, and determining a readout of T H -GM function in the presence or absence of the candidate agent, wherein a change in the readout of T H -GM function indicates that the candidate agent is a modulator of T H -GM function.
- the present disclosure enables the identification or classification between inflammatory disorders that are either primarily T H -GM-mediated, or primarily non-T H -GM-mediated (e.g., mediated by TNF- ⁇ , IL-6, and/or IL-1 ⁇ ), or both.
- T H -GM-mediated e.g., mediated by TNF- ⁇ , IL-6, and/or IL-1 ⁇
- RA a patient suffering from, e.g., RA
- This differentiation allows for a more targeted and tailored method of treating inflammatory disorders such as RA, for which current treatments are only 40% effective.
- compositions for prognosing the progression of an inflammatory disorder so as to tailor the treatment according to the stage of the disease.
- compositions and methods for and the treatment of inflammatory disorders particularly those that are T H -GM-mediated.
- FIGS. 1A-1D depict Stat5-conditional mutant mice are resistant to EAE.
- Clinical EAE scores FIG. 1A
- incidence FIG. 1B
- immunized twice with MOG 35-55 /LPS FIG. 1D
- Data are representative of two independent experiments.
- FIGS. 3A and 3B depict the resistance to EAE in Stat5-deficient mice is independent of T H 1, T H 17 or T reg cells.
- Flow cytometric analysis of IL-17 and IFN- ⁇ expression by CNS-infiltrating CD4 + T cells at peak of disease FIG. 3A .
- Data are representative of three independent experiments.
- Percentage of CD25 + among CD4 + T cells in the CNS of Stat5 +/+ and Stat5 ⁇ / ⁇ EAE mice at peak of disease were analyzed by flow cytometry ( FIG. 3B ).
- FIGS. 4A-4C depict conditional Stat5 mutant mice have no defect in CD4 + T cell generation in periphery.
- Spleens were obtained from MOG 35-55 /CFA-immunized Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 ( FIG. 4A ) and day 21 ( FIG. 4B ).
- the proportions of CD4 + and CD8 + T cells were analyzed by flow cytometry.
- the absolute number of CD4 + T cells was calculated (right panels).
- Data are representative of two independent experiments ( FIG. 4A ) or pooled from two independent experiments ( FIG. 4B ).
- IL-17 and IFN- ⁇ expression by splenic CD4 + T cells of Stat5 +/+ and Stat5 ⁇ / ⁇ EAE mice was determined by intracellular cytokine staining ( FIG. 4C ). Data are representative of three independent experiments. *p ⁇ 0.5, **p ⁇ 0.005, ***p ⁇ 0.0005.
- FIGS. 5A-5D depict Stat5-deficient CD4 + T cells can infiltrate CNS but fail to induce effective neuroinflammation.
- Data are representative of two independent experiments with three to five mice per group ( FIG. 5A ).
- CNS-infiltrating CD4 + T cells were analyzed at day 7, 9 and 21 after first MOG 35-55 /CFA immunization ( FIGS. 5B-5D ). Cell numbers were calculated ( FIG. 5D ). Data are representative of two independent experiments with three mice per group. *p ⁇ 0.5.
- FIGS. 6A-6C show resistance to EAE in Stat5 ⁇ / ⁇ mice is not caused by any defect in the survival of CD4 + T cells in the absence of STAT5.
- CD4 + T cell infiltration FIG. 6A
- clinical scores FIG. 6B
- Clinical scores and frequencies of CD4 + T cells in the CNS at day 21 (disease peak) of EAE induction FIG. 6C ). *p ⁇ 0.05. ***p ⁇ 0.0005.
- FIGS. 7A-7C depict the intrinsic defect of Stat5-deficient CD4 + T cells in encephalitogenicity.
- Clinical EAE scores FIG. 7A
- incidence FIG. 7B
- IL-17 and IFN- ⁇ expression by CNS-infiltrating CD4 + T cells was measured at peak of disease ( FIG. 7C ).
- Data represent two independent experiments, *p ⁇ 0.05.
- FIGS. 8A-8D depict the diminished induction of GM-CSF in splenic Stat5 ⁇ / ⁇ CD4 + T cells.
- GM-CSF secretion was measured by ELISA ( FIG. 8A ).
- Golgiplug was added in the last 4 h of MOG 35-55 (20 ⁇ g/ml) challenge and the frequencies of IL-17 + and GM-CSF + cells among CD4 + CD44 hi T cells were measured ( FIG.
- FIGS. 8C and 8C splenocytes were obtained from MOG 35-55 /CFA-immunized Stat5 ⁇ / ⁇ , Stat3 ⁇ / ⁇ or wild-type control mice and stimulated with PMA/Ionomycin in the presence of Golgiplug for 4 h.
- the frequencies of IL-17 + and GM-CSF + cells among splenic CD4 + CD44 hi T cells were measured by intracellular cytokine staining. *p ⁇ 0.05, ***p ⁇ 0.001.
- FIGS. 9A-9C depict the diminished induction of GM-CSF in CNS-infiltrating Stat5 ⁇ / ⁇ CD4 + T cells.
- FIG. 9A IL-17, IFN- ⁇ and GM-CSF expression by CNS-infiltrating CD4 + T cells of Stat5 +/+ and Stat5 ⁇ / ⁇ mice was measured at peak of disease. The percentage of GM-CSF + cells among IL-17 + or IFN- ⁇ + cells was calculated (bottom right. FIG. 9A ).
- IL-17 IFN- ⁇ and GM-CSF expression by CNS-infiltrating CD4 + T cells of Rag2 ⁇ / ⁇ recipient mice at peak of disease in adoptive transfer EAE ( FIG. 9B ).
- FIGS. 10A-10C show STAT5-mediated GM-CSF induction is independent of IL-23 or IL-1 ⁇ signaling.
- FIG. 10A purified CD4 + T cells were cultured with TGF- ⁇ and IL-6 for 3 days, followed by starvation for 6 h. Then cells were treated with various cytokines for 30 min. and pSTAT3 and pSTAT5 was determined by immunoblotting. STAT3 and STAT5 were further detected after stripping.
- splenocytes were obtained from MOG 35-55 /CFA-immunized WT mice before disease onset and challenged with MOG 35-55 (20 ⁇ g/ml) in the absence or presence of IL-2 for 48 h.
- the frequencies of GM-CSF + and IL-17 + cells among CD4 + CD44 hi T cells were measured by flow cytometry. *p ⁇ 0.05.
- FIGS. 11A-11C depict IL-7-induced STAT5 activation promotes GM-CSF expression in autoreactive CD4 + T cells.
- Splenocytes were obtained from MOG 35-55 /CFA-immunized Stat5 +/+ and Stat5 ⁇ / ⁇ mice before disease onset and challenged with MOG 35-55 (20 ⁇ g/ml) in the absence or presence of IL-7 for 48 h.
- Frequencies of GM-CSF + and IL-17 + cells among CD4 + CD44 hi T cells were measured by flow cytometry ( FIG. 11A ).
- GM-CSF secretion was measured by ELISA ( FIG. 11B ). Data represent two independent experiments with two to three mice per group.
- FIGS. 12A-12F depict IL-7R ⁇ neutralization attenuates GM-CSF expression and ameliorates EAE.
- Data represent two independent experiments ( FIG. 12A ).
- Spinal cord sections were obtained from EAE mice at day 11 after 2 nd immunization. Immune cell infiltration was assessed histologically. Images shown are representative of three individuals per group. Scale bars, 200 ⁇ m (top), 50 ⁇ m ( FIG. 12B , bottom). The percentages of CD4 + and CD8 + T cells in spleens of EAE mice. Data represent two independent experiments ( FIG.
- FIGS. 12D and 12E illustrate the frequencies of GM-CSF + , IL-17 + and IFN- ⁇ + cells among CD4 + T cells in the CNS of EAE mice receiving different treatment.
- the mRNA expression of IFN- ⁇ , IL-17 and GM-CSF in the CNS of EAE mice ( FIG. 12F ). *p ⁇ 0.05
- FIGS. 13A and 13B depict the differentiation of GM-CSF-expressing T H cells is distinct from T H 17 and T H 1.
- Na ⁇ ve CD4 + T cells were primed with plate-bound anti-CD3 and soluble anti-CD28 in the presence of a combination of various cytokines and neutralizing antibodies as indicated.
- GM-CSF, IL-17 and IFN- ⁇ expression was analyzed by intracellular staining ( FIG. 13A ) or RT-PCR ( FIG. 13B )
- FIGS. 14A-14D show the effect of IL-2 and IL-6 on T H -GM differentiation from na ⁇ ve T cells.
- GM-CSF and IFN- ⁇ expression in naive CD4 + T cells activated for 72 h with anti-CD3 alone or plus anti-CD28 ( FIG. 14A ).
- FIG. 14B sorted na ⁇ ve CD4 + T cells were stimulated with anti-CD3 and anti-CD28 in the presence of neutralizing antibodies against IL-12 and IFN- ⁇ without or with the addition of IL-6.
- the frequencies of GM-CSF + and IL-17 + cells were measured by intracellular staining ( FIG. 14B ).
- FIG. 14B shows the effect of IL-2 and IL-6 on T H -GM differentiation from na ⁇ ve T cells.
- na ⁇ ve CD4 + T cells from Stat3 +/+ and Stat3 ⁇ / ⁇ mice were polarized under conditions as indicated for 72 h. The frequencies of GM-CSF + and IL-17 + cells were analyzed. In FIG. 14D , na ⁇ ve CD4 + T cells were activated with anti-CD3 and anti-CD28 in the presence of IL-2 or anti-IL-2. The frequencies of GM-CSF + , IL-17 + and IFN- ⁇ + cells were analyzed.
- FIGS. 15A-15F depict IL-7-STAT5 signaling programs T H -GM differentiation from na ⁇ ve precursor cells.
- Na ⁇ ve CD4 + T cells were primed with plate-hound anti-CD3 and soluble anti-CD28 in the presence of various concentration of IL-7 as indicated.
- GM-CSF and IFN- ⁇ expression was analyzed by intracellular staining ( FIG. 15A ) or ELISA ( FIG. 15B ).
- FIGS. 15C and 15D Stat5 +/+ and Stat5 ⁇ / ⁇ na ⁇ ve CD4 + T cells were activated with anti-CD3 and anti-CD28 in the presence IL-7 for 3 days.
- GM-CSF, IL-17 and IFN- ⁇ expression was analyzed by intracellular cytokine staining ( FIG. 15C ).
- GM-CSF secretion was measured by ELISA ( FIG. 15D ).
- the ChIP assay was performed with Stat5 +/+ and Stat5 ⁇ / ⁇ CD4 + T cells using normal IgG or STAT5-specific antibody.
- the binding of antibodies to Csf2 promoter region was detected by RT-PCR ( FIG. 15F ).
- FIGS. 16A and 16B depict the differentiation conditions for T H -GM subset.
- Na ⁇ ve CD4 + T cells were activated with anti-CD3 and anti-CD28 in the presence of IL-7 or/and anti-IFN- ⁇ as indicated.
- GM-CSF. IL-17 and IFN- ⁇ expression was analyzed ( FIG. 16A ).
- T H 1 IL-12+anti-IL- ⁇
- T H 17 TGF- ⁇ +IL-6+anti-IFN- ⁇ +anti-IL-4)
- T H -GM cells IL-7 anti-IFN- ⁇
- FIGS. 17A-17E illustrate that IL-7 but not IL-2 induces STAT5 activation and GM-CSF expression in na ⁇ ve CD4 + T cells.
- FIGS. 17A-17C show flow cytometry of CD25 and CD127 on the surface of na ⁇ ve CD4 + T cells or cells activated with anti-CD3 and anti-CD28 at various time points as indicated. Activation of STAT5 in na ⁇ ve CD4 + T cells stimulated with IL-2 or IL-7 for 30 min ( FIG. 17D ).
- FIG. 17E shows the mRNA expression of GM-CSF in na ⁇ ve CD4 + T cells stimulated with anti-CD3 and anti-CD28 in the presence of IL-2 or IL-7.
- the RT-PCR data were normalized to ⁇ -Actin, and expression in na ⁇ ve T cells activated for 2 h without cytokine was set to 1.
- FIGS. 18A-18C show that both IL-2 and IL-7 can induce STAT5 activation and GM-CSF expression in activated CD4 + T cells.
- CD4 + T cells were activated with anti-CD3 and anti-CD28 for 3 days. After resting in fresh medium, cells were stimulated with IL-2 or IL-7 at various time points. The pTyr-STAT5 and ⁇ -Actin were detected by immunoblotting ( FIG. 18A ).
- GM-CSF mRNA expression was measured by RT-PCR ( FIG. 18B ).
- the RT-PCR data were normalized to 13-Actin, and expression in cells without cytokine stimulation was set to 1.
- the ChIP assay shown in FIG. 18C was performed with normal IgG or STAT5-specific antibody. The binding of antibodies to Csf2 promoter region was detected by RT-PCR.
- FIG. 19 depicts surface molecules selectively expressed at high level or low level in T H -GM subset as characterized by microarray analysis. These surface molecules specific for each lineage serves as markers, signatures and potential targets for novel diagnosis, treatment and prevention of autoimmune inflammation including, but not limited to multiple sclerosis and rheumatoid arthritis. These cell surface molecules are listed in detail in Table 1. The order of na ⁇ ve, Th1, Th17, and Th-GM as indicated in the figure insert is the same as that appears for the bars in each graph.
- FIGS. 20A-20D show that IL-3 is preferentially expressed in T H -GM cells.
- na ⁇ ve CD4 + T cells were activated with anti-CD3 and anti-CD28 under T H 1—(IL-12+anti-IL-4), T H 17 ⁇ (TGF- ⁇ +IL-6+anti-IFN- ⁇ +anti-IL-4) and T H -GM—(GM-CSF + T H , IL-7+anti-IFN- ⁇ +anti-IL-4) polarizing conditions.
- GM-CSF and IL-3 expression was analyzed by intracellular staining ( FIG. 20A ).
- IL-3, EBI-3, PENK or RANKL cytokines was measured by RT-PCR ( FIG. 20B ).
- Frequency of IL-3+ cells differentiated without or with IL-7 FIG. 20C .
- GM-CSF and IL-3 expression by WT or STAT5-deficient GM-CSF-producing TH cells FIG. 20D ).
- FIGS. 22A-27E depict inhibition of STAT5 activation suppresses T H -GM cell differentiation in vitro.
- CD4 + T cells were pre-incubated with STAT5 inhibitor (Calbiochem) ( FIG. 22A ) or JAK3 inhibitor ( FIG. 22B ) at indicated concentrations or vehicle ( ⁇ ) for 1 h before stimulation with IL-7 for 30 min.
- Activation (Tyr694 phosphorylation) of STAT5 was determined by immunoblotting.
- CD4 + T cells were pre-incubated with STAT5 inhibitor at indicated concentrations or vehicle ( ⁇ ) for 1 h before stimulation with IL-6 for 30 min.
- Activation (Tyr705 phosphorylation) of STAT3 was determined by immunoblotting ( FIG. 22C ).
- FIG. 22C depict inhibition of STAT5 activation suppresses T H -GM cell differentiation in vitro.
- CD4 + T cells were pre-incubated with STAT5 inhibitor at indicated concentrations or vehicle ( ⁇ ) for 1 h before stimulation with IFN- ⁇ for 30 min.
- Activation (Tyr701 phosphorylation) of STAT1 was determined by immunoblotting.
- na ⁇ ve CD4 + T cells were isolated and activated under neutral condition or T H -GM cell-favoring condition with the addition of different concentrations of STAT5 inhibitor for 3 days.
- GM-CSF and IFN- ⁇ expression was analyzed by intracellular cytokine staining and flow cytometry.
- FIGS. 23A-23D depict targeting STAT5 activation by chemical inhibitor ameliorates EAE.
- FIG. 23B Histology of spinal cords at clay 18 of EAE mice receiving different treatments.
- FIG. 23C Intracellular staining and flow cytometry of CNS-infiltrating CD4 + T cells at peak of disease.
- FIG. 23D Whole CNS was harvest for RNA extraction. GM-CSF mRNA expression was analyzed by RT-PCR. Data represent two independent experiments. *p ⁇ 0.05.
- FIGS. 24A-24E depict GM-CSF-producing T H cells are in association with human RA.
- FIGS. 24B and 24C peripheral blood mononuclear cells (PBMCs) were collected from healthy control (HC) and rheumatoid arthritis (RA) patients, and were stimulated for 4 h with PMA/lonomycin in the presence of Golgiplug, followed by intracellular cytokine staining. Representative flow cytometry of GM-CSF, IFN- ⁇ and IL-17 in CD4 + T cells ( FIG.
- Cytokine expression by CD4 + T cells derived from synovial fluid of RA patients was analyzed by intracellular cytokine staining and flow cytometry ( FIG. 24E ). A representative image of three cases was shown. *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001; ns, not significant.
- FIGS. 25A-25E depict distinguishable effects of GM-CSF and TNF- ⁇ in mouse AIA.
- FIG. 25D at day 7 after arthritis induction as in FIG. 25C .
- FIGS. 26A-26D depicts mice with Stat5 deletion in T cells are resistant to CIA.
- FIG. 26A Representative images of paw swelling of Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 40 after collagen II/CFA immunization in CIA model.
- FIG. 26C Representative images of paw sections stained with H&E at clay 40.
- FIGS. 27A-27E depicts STAT5-deficient CD4 + T cells are defective in arthritogenic potential.
- FIGS. 27A and 27B Representative flow cytometry of CD4 + T cells in spleens ( FIG. 27A ) and inguinal lymph nodes ( FIG. 27B ) of Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 after AIA induction.
- FIGS. 27C and 27D Synovial tissues were harvested from Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 after AIA induction, and dissociated into single cells. Cell numbers of CD45 + leukocytes were calculated ( FIG. 27C ).
- FIG. 27D The percentages of CD4 + T cells among CD45 + fraction were analyzed by flow cytometry, and cell numbers were calculated ( FIG. 27D ).
- FIG. 27E Histological analysis of joint sections from wild-type na ⁇ ve mice at day 7 after being transferred with in vitro-expanded antigen-reactive CD4 + T cells and followed with intraarticular injection of mBSA. Bars, 100 ⁇ m. Data represent two independent experiments. *p ⁇ 0.05; ns, not significant.
- FIGS. 28A-28G depicts STAT5-regulated GM-CSF-producing T H cells are crucial for AIA.
- Spleens and synovial tissues were collected from Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 after arthritis induction.
- FIGS. 28B-28D Intracellular staining and flow cytometry of GM-CSF, IL-17 and IFN- ⁇ in splenic CD4 + CD44 hi effector T cells ( FIG.
- FIG. 28E Protein expression of several proinflammatory cytokines in synovial tissues was measured by ELISA.
- FIGS. 28F and 28G Representative images of joint sections stained with H&E ( FIG. 28F ) or Safranin-O/Fast Green ( FIG.
- FIGS. 29A-29C depicts loss of STAT5 results in impaired GM-CSF production by antigen-specific CD4 + T cells.
- Spleens and inguinal LNs were collected from Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 after arthritis induction, and dissociated into single cell suspensions. Then, cells were stimulated with mBSA (20 ⁇ g/ml) for 24 h.
- FIG. 29A Golgiplug was added in the last 4 h of culture, followed by intracellular staining and flow cytometry. Representative plots of GM-CSF, IL-17 and IFN- ⁇ expression in CD4 + CD44 hi effector T cells was shown, representing two independent experiments.
- FIGS. 30A-30C depicts loss of STAT5 impairs IL-6 and IL-1 ⁇ expression in synovial tissues of arthritic mice.
- FIGS. 31A-31D depicts SAT5-induced GM-CSF expression mediates CD11b + cell accumulation in inflamed synovial tissues.
- FIG. 31B Synovial tissues were harvested
- FIG. 31C Representative flow cytometry of CD11b + and CD4 + cells gated on synovial CD45 + fraction over 7 days after arthritis induction.
- FIG. 31D Flow cytometric analysis of CD4 + , CD11b + and B220 + cell infiltration in synovial tissues of Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 after intraarticular injection of mBSA alone to the right knee joints and mBSA supplemented with GM-CSF to the left knee joints. Representative images were shown. All data shown are representative of two independent experiments. **p ⁇ 0.01; ns, not significant.
- FIGS. 32A-32D depicts GM-CSF mediates neutrophil accumulation in arthritic mice.
- FIG. 32A Flow cytometric analysis of Ly6C and Ly6G expression gated on synovial CD45 + CD11b + fraction over 7 days after arthritis induction.
- FIG. 32B Giemsa stain of sorted Ly6C hi Ly6G ⁇ and Ly6C lo Ly6G hi cells from synovial tissues of AIA mice. Scale bar, 100 ⁇ m (left) or 20 ⁇ m (right).
- FIG. 32A Flow cytometric analysis of Ly6C and Ly6G expression gated on synovial CD45 + CD11b + fraction over 7 days after arthritis induction.
- FIG. 32B Giemsa stain of sorted Ly6C hi Ly6G ⁇ and Ly6C lo Ly6G hi cells from synovial tissues of AIA mice. Scale bar, 100 ⁇ m (left) or 20 ⁇ m (right).
- FIG. 32C Flow cytometric analysis of Ly6C hi Ly6G ⁇ and Ly6C lo Ly6G hi populations in synovial tissues of Stat5 +/+ and Stat5 ⁇ / ⁇ mice at day 7 after intraarticular injection of mBSA alone to the right knee joints and mBSA supplemented with GM-CSF to the left knee joints.
- FIGS. 33A-33C depicts GM-CSF enhances neutrophil transmigration and delay apoptosis in vitro.
- FIG. 33A Percentages of migrated neutrophils with or without GM-CSF as chemoattractant in transmigration assay at 3 h post start.
- FIG. 33B Microscopic images of CFSE-labeled neutrophils in the bottom of the lower chamber in transmigration assay.
- FIG. 33C Sorted neutrophils were cultured in vitro with or without GM-CSF (20 ng/ml) for 24 h. Neutrophils undergoing apoptosis were examined by Annexin V and propidium iodide (PI) co-staining. A representative flow cytometry of three repeats was shown. *p ⁇ 0.05.
- FIGS. 34A-34I depicts GM-CSF mediates proinflammatory cytokine expression by myeloid cells and synovial fibroblasts in arthritic mice. Synovial tissues were dissected from wild-type AIA mice and dissociated into single cell suspensions.
- FIG. 34A Flow cytometry plots depicting the fractionation into different populations based on differential expression of surface markers.
- FIG. 34B The mRNA expression of several proinflammatory cytokines in sorted CD45 + TCR ⁇ + (TCR ⁇ + in short). CD45 + TCR ⁇ ⁇ CD11c ⁇ CD11b + (CD11b + ) and CD45 + TCR ⁇ ⁇ CD11c + (CD11c + ) populations was measured by qPCR.
- FIG. 34C The mRNA expression of IL-6, IL-1 ⁇ and TNF- ⁇ in sorted Ly6C hi Ly6G ⁇ and Ly6C lo Ly6G hi populations (gated on CD11b + cells).
- the qPCR data were normalized to GAPDH.
- FIGS. 34D and 34E The mRNA expression of IL-6 and IL-1 ⁇ by BMDMs ( FIG. 34D ) and BMDCs ( FIG. 34E ) upon stimulation with 20 ng/ml GM-CSF for 1 h.
- the qPCR data were normalized to GAPDH.
- FIGS. 34F and 34G BMDMs ( FIG.
- FIG. 34F BMDCs
- FIG. 34G BMDCs
- the secretion of IL-1 ⁇ in the culture supernatant was quantified by ELISA.
- T H -GM granulocyte macrophage colony stimulating factor
- IL-7/STAT5 signaling programs the differentiation of precursor CD4+ cells to T H -GM, a process which is further modulated by IL-2 and IL-23 signaling.
- T H -GM cells are characterized by, e.g., GM-CSF and IL-3 production.
- T H -GM cells are distinct from the known helper T cells T H 1 and T H 17, with respect to, e.g., differentiation conditions, transcriptional regulation and effector cytokine expression.
- IL-12/IFN- ⁇ and TGF-0/IL-6 which mediate (e.g., promote the development of) T H 1 and T H 17, respectively, potently suppress the development of T H -GM from na ⁇ ve CD4 + precursor cells, establishing that T H -GM cells develop via a lineage distinct from T H 1 and T H 17.
- the present disclosure provides a distinct network of factors, unique from factors known to mediate T H 1 or T H 17, that mediate T H -GM function (e.g., its differentiation and pathogenicity).
- T H -GM cells preferentially induce EAE as compared with T H 1 and T H 17 cells, indicating that T H -GM cells represent the primary effectors in the pathogenesis of autoimmune neuroinflammation in humans.
- blockade of IL-7 signaling and/or inhibition of STAT5 function e.g., abrogation of expression or inhibition of STAT5 activity attenuates autoimmune neuroinflammation associated with diminished GM-CSF production by T H -GM cells.
- blockade of T H -GM cell-secreted GM-CSF ameliorates experimental arthritis in a TNT- ⁇ -independent manner, indicating an approach for the treatment of, e.g., rheumatoid arthritis patients who are unresponsive to TNF- ⁇ antagonistic drugs.
- the present disclosure enables one to distinguish between an inflammatory disorder (e.g., RA) that is mediated by the T H -GM pathway (e.g., a disorder that results from T H -GM pathogenicity through the action of, e.g., GM-CSF and/or IL-3, or any factor associated with the T H -GM pathway), or an inflammatory disorder that is mediated by, e.g., TNF- ⁇ , IL-6, and/or IL-1 ⁇ pathways (i.e., non-T H -GM-mediated pathway).
- an inflammatory disorder e.g., RA
- T H -GM pathway e.g., a disorder that results from T H -GM pathogenicity through the action of, e.g., GM-CSF and/or IL-3, or any factor associated with the T H -GM pathway
- an inflammatory disorder that is mediated by, e.g., TNF- ⁇ , IL-6, and/or IL-1 ⁇ pathways
- a patient who has, e.g., RA may be afflicted with a type of RA that is primarily T H -GM-mediated, or primarily non-T H -GM-mediated (e.g., TNF- ⁇ -mediated or IL-6 mediated).
- a type of RA that is primarily T H -GM-mediated, or primarily non-T H -GM-mediated (e.g., TNF- ⁇ -mediated or IL-6 mediated).
- the present disclosure enables the classification between T H -GM-mediated and non-T H -GM-mediated inflammation, allowing for a more precise diagnosis, prognosis, and treatment in an individual who is afflicted with an inflammatory disorder such as RA or MS.
- T H -GM helper T cell subset
- T H -GM helper T cell subset
- TNF- ⁇ therapy e.g., TNF- ⁇ inhibitor based therapy
- compositions and methods for modulating T H -GM function to treat autoimmune and inflammatory disorders are provided herein.
- the methods of modulating T H -GM function include, e.g., administering agents to modulate the function (e.g., signaling, expression or activity) of the network of factors (e.g., IL-2/IL-7/STAT5/GM-CSF/IL-3) that mediate T H -GM function in an effective amount to modulate the function (e.g., development and pathogenicity) of T H -GM cells.
- the disclosure provides methods and composition for differentiating and diagnosing an inflammatory disorder, e.g., multiple sclerosis (MS), rheumatoid arthritis (RA) as primarily mediated by either T H -GM cells (i.e.
- compositions and methods for and the treatment of inflammatory disorders particularly those that are T H -GM-mediated.
- the present disclosure provides a method of diagnosing a T H -GM-mediated inflammatory disorder in a patient suffering from an inflammatory disorder.
- the method comprises contacting a sample collected from a patient suffering from an inflammatory disorder with a detecting agent that detects a polypeptide or nucleic acid level of a T H -GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof; and quantifying the polypeptide or nucleic acid level of the T H -GM-mediating factor (e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof), wherein an increased level of a T H -GM-mediating factor (e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof) relative to a reference level indicates that the patient suffers from a T H -GM-mediated inflammatory disorder,
- a detecting agent that detects
- a “T H -GM-mediated” inflammatory disorder refers to a subtype of an inflammatory disorder (e.g., a subtype of RA or MS) that results from the physiological action of any one or more of the network of factors in the pathway that modulate T H -GM function (a “T H -GM-mediating factor”), as described herein.
- factors include, e.g., GM-CSF, activated STAT5, IL-7, IL-2, and IL-3.
- STAT5 is activated STAT5, wherein tyrosine at position 694 is phosphorylated.
- the level of a T H -GM-mediating factor (e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof) that is not increased relative to a reference level indicates that the patient suffers from a non-T H -GM-mediated inflammatory disorder.
- a T H -GM-mediating factor e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof
- the method further comprises administering to the patient a TNF- ⁇ therapy, as described herein, if the level of a T H -GM-mediating factor (e.g. STAT5, IL-7, GM-CSF or IL-3, or a combination thereof) is not increased relative to a reference level.
- a T H -GM-mediating factor e.g. STAT5, IL-7, GM-CSF or IL-3, or a combination thereof
- a “non-T H -GM-mediated” inflammatory disorder refers to an inflammatory disorder (e.g., RA or MS) that is primarily caused by, e.g., TNF- ⁇ , IL-6, or IL-1 ⁇ (and/or factors in the TNF- ⁇ , IL-6, or IL-1 ⁇ pathway).
- a “T H -GM-mediated” inflammatory disorder results primarily (or exclusively) from a pathway that is distinct from one or more of the pathways that leads to a “non-T H -GM-mediated” inflammatory disorder (e.g., the pathways associated with TNF- ⁇ , IL-6, or IL-1 ⁇ ).
- a T H -GM-mediated inflammatory disorder does not necessarily exclude the possibility that the inflammatory disorder could also be partially non-T H -GM-mediated (e.g., mediated by TNF- ⁇ , IL-6, or IL- and/or factors in the TNF- ⁇ , IL-6, or IL-1 ⁇ pathway).
- T H -GM-mediated is synonymous with “primarily/predominantly T H -GM-mediated”
- non-T H -GM-mediated is synonymous with “primarily/predominantly non-T H -GM-mediated.”
- an inflammatory disorder in its early stage may be T H -GM-mediated.
- the inflammatory condition advances to a late stage characterized by, e.g., tissue damage, the inflammatory disorder becomes progressively non-T H -GM-mediated.
- a T H -GM-mediated inflammatory disorder is a condition that is responsive to modulation of T H -GM function, as determined by clinical standards;
- a non-T H -GM-mediated inflammatory disorder is a condition that is responsive to, e.g., TNF- ⁇ , IL-6, or IL-1 ⁇ therapy, as determined by clinical standards.
- an inflammatory disorder can be responsive to modulation of T H -GM function as well as TNF- ⁇ , IL-6, and/or IL-1 ⁇ therapy.
- the sample can be e.g., peripheral blood, cerebrospinal fluid, synovial fluid, or synovial membrane, or a combination thereof.
- the inflammatory disorder is an autoimmune disorder.
- the inflammatory disorder can be any inflammatory disorder mediated by T H -GM cells, and includes, but is not limited to rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Crohn's disease, diabetes.
- Hashimoto's thyroiditis hyperthyroidism, hypothyroidism, Irritable Bowel Syndrome (IBS), lupus erythematosus, polymyalgia rheumatic, psoriasis, psoriatic arthritis, Raynaud's syndrome/phenomenon, reactive arthritis (Reiter syndrome), sarcoidosis, scleroderma, Sjögren's syndrome, ulcerative colitis, uveitis, or vasculitis.
- IBS Irritable Bowel Syndrome
- lupus erythematosus polymyalgia rheumatic
- psoriasis psoriatic arthritis
- Raynaud's syndrome/phenomenon reactive arthritis
- Reiter syndrome reactive arthritis
- sarcoidosis scleroderma
- Sjögren's syndrome ulcerative colitis
- uveitis or vasculitis.
- a “detecting agent” refers to, e.g., an antibody, a peptide, a small molecule, or a nucleic acid that binds to a polypeptide or nucleic acid to be detected (e.g., STAT5 (e.g., phospho-STAT5 (Tyr694)), IL-7, GM-CSF or IL-3), and enables the quantification of the polypeptide or nucleic acid to be detected.
- the detecting agent can be detectably labeled, or quantifiable by other means known in the art.
- the detecting agent is an antibody that binds to the polypeptide of STAT5, IL-7, GM-CSF or IL-3.
- the antibody is one that binds to an activated STAT5 (e.g., phosphorylated STAT5), as described herein.
- STAT5 e.g., phospho-STAT5 (Tyr694)
- IL-7 IL-7
- GM-CSF IL-3
- STAT5 Ab C-17 from Santa Cruz Biotech
- IL-7 Ab clone BVD10-40F6 from BD Pharmingen
- IL-7R Ab: clone SB/14 from BD Pharmingen
- GM-CSF clone MP1-22E9 from BD Pharmingen
- IL-3 Ab: clone MP2-8F8 from BD Pharmingen.
- the detecting agent is a nucleic acid that hinds to the nucleic acid of STAT5.
- IL-7, GM-CSF and/or IL-3 sequence, or fragments or oligonucleotides thereof, that hybridize to a nucleic acid molecule encoding a e.g., STAT5, IL-7, GM-CSF and/or IL-3 polypeptide sequence at high stringency may be used as a probe to monitor expression of nucleic acid levels of STAT5, IL-7, GM-CSF and/or IL-3 in a sample for use in the diagnostic methods of the disclosure. Methods of quantifying nucleic acid levels are routine and available in the art.
- the method further comprises contacting the sample with a detecting agent that detects a polypeptide or nucleic acid level of one or more genes (as well as the gene product) listed in Table 1.
- a detecting agent that detects a polypeptide or nucleic acid level of one or more genes (as well as the gene product) listed in Table 1.
- Table 1 lists genes that are differentially expressed in T H -GM cells as well as genes that are differentially expressed on the surface of T H -GM cells, as compared to T H 1 or T H 17 cells.
- the method further comprises contacting the sample with a detecting agent that detects the polypeptide or nucleic acid level of basic helix-loop-helix family member e40 (BHLHe40), chemokine (C-C Motif) Receptor 4 (CCR4), and/or CCR6.
- a detecting agent that detects the polypeptide or nucleic acid level of basic helix-loop-helix family member e40 (BHLHe40), chemokine (C-C Motif) Receptor 4 (CCR4), and/or CCR6.
- Standard methods may be used to quantify polypeptide levels in any sample. Such methods include, e.g., ELISA, Western blotting, immunohistochemistry, fluorescence activated cells sorting (FACS) using antibodies directed to a polypeptide, and quantitative enzyme immunoassay techniques known in the art. Such methods are routine and available in the art. Similarly, methods for quantifying nucleic acid levels (e.g., mRNA) are known in the art.
- an increased level of STAT5 e.g., activated phospho-STAT5 (Tyr694)
- IL-7 e.g., IL-7
- GM-CSF e.g., IL-3
- a STAT5 e.g., activated phospho-STAT5 (Tyr694)
- IL-7 e.g., IL-7
- GM-CSF e.g., IL-3
- IL-3 level that is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 160%, at least 170%, at least 180%, at least 190%, at least 200%, at least 220%, at least 240%, at least 260%, at least 280%, at least 300%, at least 350%, at least 400%, at least 450%, at least 500%, at least 550%, or at least 600% relative to a reference level indicates that the patient suffers from a T H -GM-mediated inflammatory disorder.
- an increase of at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150% relative to a reference level indicates that the patient suffers from a T H -GM-mediated inflammatory disorder.
- a STAT5 e.g., activated phospho-STAT5 (Tyr694)
- IL-7 e.g., IL-7
- GM-CSF e.g., IL-3
- IL-3 level that is not increased by at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150% relative to a reference level indicates that the patient suffers from a non-T H -GM-mediated inflammatory disorder.
- a STAT5 e.g., activated phospho-STAT5 (Tyr694)
- IL-7 e.g., IL-7
- GM-CSF e.g., IL-3
- IL-3 e.g., IL-3
- a level that is “comparable” to that of a reference level refers to a level that is unchanged, or a change relative to the reference level that is statistically insignificant according to clinical standards.
- a comparable level can include a level that is not increased by at least 40%, at least 50%, at least 60%, or at least 70% relative to a reference level as, for example, it may not indicate a clinically significant change.
- a level of a T H -GM-mediating factor e.g., STAT5 (e.g., activated phospho-STAT5 (Tyr694)).
- STAT5 e.g., activated phospho-STAT5 (Tyr694)
- IL-7, GM-CSF, and/or IL-3 that is decreased relative to a reference level can also indicate that the patient suffers from a non-T H -GM-mediated disorder.
- the reference level is a level that is used for comparison purposes, and may be obtained from, for example, a prior sample taken from the same patient; a normal healthy subject; a sample from a subject not having an autoimmune disease or an inflammatory disorder; a subject that is diagnosed with a propensity to develop an autoimmune disease but does not yet show symptoms of the disease; a patient that has been treated for an autoimmune disease; or a sample of a purified reference polypeptide or nucleic acid molecule of the disclosure (e.g., STAT5) at a known normal concentration.
- a purified reference polypeptide or nucleic acid molecule of the disclosure e.g., STAT5
- reference standard or level is meant a value or number derived from a reference sample, or a value or range accepted in the art as indicative of being healthy (e.g., an individual that does not have an inflammatory disorder).
- a normal reference standard or level can also be a value or number derived from a normal subject who does not have an autoimmune disease.
- the reference sample, standard, or level is matched to the sample subject by at least one of the following criteria; age, weight, body mass index (BMI), disease stage, and overall health.
- BMI body mass index
- a standard curve of levels of purified DNA. RNA or mRNA within the normal reference range can also be used as a reference.
- a standard curve of levels of purified protein within the normal reference range can also be used as a reference.
- the patient afflicted with an inflammatory disorder who has been diagnosed or classified as having a T H -GM-mediated inflammatory disorder does not have a non-T H -GM-mediated inflammatory disorder (i.e., does not have a TNF- ⁇ , IL-6, or IL-1 ⁇ -mediated inflammatory disorder). That is, the patient diagnosed as suffering from a T H -GM-mediated inflammatory disorder responds to modulation of T H -GM function (e.g., inhibition of STAT5, IL-7, GM-CSF and/or IL-3), but does not respond (or exhibits a limited response) to TNF- ⁇ therapy, as determined by clinical standards.
- T H -GM function e.g., inhibition of STAT5, IL-7, GM-CSF and/or IL-3
- a T H -GM-mediated inflammatory disorder does not exclude the possibility that the inflammatory disorder is also partially (though not primarily) contributed by a non-T H -GM-mediated pathway (e.g., TNF- ⁇ , IL-6, IL-1 ⁇ ).
- a non-T H -GM-mediated pathway e.g., TNF- ⁇ , IL-6, IL-1 ⁇ .
- the methods of the present disclosure further comprise administering an effective amount of a modulating agent that modulates T H -GM cell function to the patient diagnosed or classified as having a T H -GM-mediated inflammatory disorder.
- the modulating agent inhibits T H -GM function.
- the methods of the present disclosure further comprise administering an effective amount of, e.g., a TNF- ⁇ therapy, an IL-6 therapy, or an IL-1 ⁇ therapy to a patient diagnosed or classified as having a non-T H -GM-mediated inflammatory disorder, as described herein.
- an effective amount of, e.g., a TNF- ⁇ therapy, an IL-6 therapy, or an IL-1 ⁇ therapy to a patient diagnosed or classified as having a non-T H -GM-mediated inflammatory disorder, as described herein.
- the present disclosure also provides a method of classifying a patient suffering from an inflammatory disorder as having a T H -GM-mediated inflammatory disorder or a non-T H -GM-mediated inflammatory disorder.
- the method comprises contacting a sample collected from a patient suffering from an inflammatory disorder with a detecting agent that detects a polypeptide or nucleic acid level of a T H -GM-mediating factor, such as, e.g., STAT5 (e.g., phosphorylated STAT5, Tyr694), IL-7, GM-CSF or IL-3, or a combination thereof.
- STAT5 e.g., phosphorylated STAT5, Tyr694
- IL-7 e.g., IL-7
- GM-CSF GM-CSF
- IL-3 e.g., IL-3
- the method further comprises quantifying the polypeptide or nucleic acid level of the T H -GM-mediating factor, such as, e.g., STAT5. IL-7, GM-CSF or IL-3, or a combination thereof, wherein an increased level of the T H -GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to a reference level indicates that the patient suffers from a T H -GM-mediated inflammatory disorder; or a comparable level of the T H -GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to a reference level indicates that the patient suffers from a non-T H -GM-mediated inflammatory disorder, thereby classifying the patient suffering from an inflammatory disorder as a T H -GM-mediated inflammatory disorder or a non-T H -GM-mediated inflammatory disorder.
- the methods disclosed herein can further comprise measuring the polypeptide or nucleic acid level of a factor that mediates a non-T H -GM-mediated inflammatory disorder.
- factors include, e.g., TNF- ⁇ , IL-6, and IL-1 ⁇ .
- the present disclosure provides a method of determining a treatment regimen in a patient suffering from an inflammatory disorder.
- the method comprises quantifying a polypeptide or nucleic acid level of, e.g., activated STAT5 or GM-CSF in a sample collected from a patient suffering from an inflammatory disorder, and quantifying the polypeptide or nucleic acid level of, e.g., TNF- ⁇ in a sample collected from the patient.
- At least four scenarios can be considered.
- the activated STAT5 or GM-CSF level is increased (e.g., by at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150%) relative to a first reference level and the TNF- ⁇ level is comparable to a second reference level, then the patient is classified as having a T H -GM-mediated inflammatory disorder and the patient can be treated with an agent that modulates T H -GM function, as described herein.
- the activated STAT5 or GM-CSF level is comparable to the first reference level and the TNF- ⁇ level is increased (e.g., by at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150%) relative to the second reference level, then the patient is classified as having a non-T H -GM-mediated inflammatory disorder and the patient can be treated with, e.g., a TNF- ⁇ therapy.
- the patient is classified as having an inflammatory disorder that is equally T H -GM-mediated and non-T H -GM mediated (e.g., TNF- ⁇ -mediated).
- the patient can be treated with an effective amount of an agent that modulates T H -GM function and an effective amount of, e.g., a TNF- ⁇ therapy.
- the combination of both agents can have a synergistic effect.
- the inflammatory disorder is primarily mediated by the pathway that shows a greater increase. For example, if GM-CSF is increased by 40% relative to a reference level, and TNF- ⁇ is increased by 90% relative to a reference level, then the inflammatory disorder is primarily non-T H -GM-mediated.
- the patient may receive a combined treatment with an agent that modulates T H -GM function as well a TNF- ⁇ therapy (e.g., anti-TNF- ⁇ therapy), since GM-CSF is increased by, e.g., at least 40% relative to a reference level.
- a TNF- ⁇ therapy e.g., anti-TNF- ⁇ therapy
- the first and second reference levels are obtained from the same reference sample.
- the disclosure also provides a method of tailoring the treatment of a patient suffering from an inflammatory disorder according to the progression of a patient's inflammatory disorder.
- the first scenario increased T H -GM-mediating factor, e.g. STAT5 or GM-CSF but TNF- ⁇ level is comparable to a reference level
- the first scenario may indicate that the patient is in an early stage of an inflammatory disorder.
- na ⁇ ve T cells are stimulated by antigen and programmed by IL-7/STAT5 to differentiate into GM-CSF/IL-3 producing T H -GM cells.
- T H -GM cytokines e.g., IL-3 and GM-CSF
- TNF- ⁇ , IL-6, IL-1 ⁇ progressively stimulate more inflammatory cells such as macrophages and neutrophils resulting in the production of, e.g., TNF- ⁇ , IL-6, IL-1 ⁇ , resulting in full-scale inflammation.
- the second scenario activated STAT5 Or GM-CSF level is comparable to the first reference level and the TNF- ⁇ level is increased
- the patient is in a late stage of an inflammatory disorder characterized by, e.g., tissue damage.
- the present disclosure enables the prognosis of a patient depending on the quantifiable level of one or more T H -GM-mediating factor (e.g., STAT5 (e.g., activated phospho-STAT5 (Tyr694)), IL-7, GM-CSF, and/or IL-3) and one or more non-T H -GM-mediating factor (e.g., TNF- ⁇ , IL-6, IL-1 ⁇ ), thereby tailoring the treatment according to the progression of the disease.
- T H -GM-mediating factor e.g., STAT5 (e.g., activated phospho-STAT5 (Tyr694)
- IL-7 e.g., activated phospho-STAT5 (Tyr694)
- IL-7 e.g., IL-7
- GM-CSF e.g., CD34
- IL-1 ⁇ e.g., TNF- ⁇ , IL-6, IL-1 ⁇
- a patient suffering from an inflammatory disorder can be monitored for disease progression to ensure effective and tailored treatment according to the level of one or more T H -GM-mediating factor, as described herein, and one or more non-T H -GM-mediating factor (e.g., TNF- ⁇ , IL-6, IL-1 ⁇ ).
- T H -GM-mediating factor e.g., TNF- ⁇ , IL-6, IL-1 ⁇ .
- non-T H -GM-mediating factor e.g., TNF- ⁇ , IL-6, IL-1 ⁇ .
- the present disclosure also provides a method of prognosing progression of an inflammatory disorder in a patient in need thereof.
- the method comprises a) quantifying a polypeptide or nucleic acid level of a T H -GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof, in a first sample collected from a patient suffering from an inflammatory disorder, and b) quantifying a polypeptide or nucleic acid level of, e.g., TNF- ⁇ , IL-6, or IL-1 ⁇ , or a combination thereof, in a second sample collected from the patient, wherein i) an increased level of the T H -GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to a first reference level and an unchanged level of TNF- ⁇ , IL-6, or IL-1 ⁇ , or a combination
- the first sample and the second sample are the same.
- the present disclosure also provides an isolated population of GM-CSF-secreting T-helper cells (T H -GM).
- T H -GM cells are differentiated from a precursor cell (e.g., CD4+ cells) in the presence of signal transducer and activator of transcription 5 (STAT5) and/or IL-7, and wherein the T H -GM cells express GM-CSF and IL-3.
- STAT5 signal transducer and activator of transcription 5
- IL-7 IL-7
- the T H -GM cells are differentiated from a precursor cell (e.g., CD4+ cells) in the presence of an agent that inhibits IL-12, IFN- ⁇ . TGF- ⁇ , and/or IL-6.
- a precursor cell e.g., CD4+ cells
- the differentiation of a precursor cell (e.g., CD4+ precursor cell) into a T H -GM cell is inhibited by IL-12, IFN- ⁇ , TFG- ⁇ , and/or IL-6.
- the T H -GM cells are differentiated from a precursor cell in vitro, under artificial conditions, but wherein the T H -GM cells retain physiological properties as described herein.
- the T H -GM cells are further characterized by an overexpression of one or more genes listed in Table 1.
- the T H -GM cells are further characterized by an overexpression of, for example, basic helix-loop-helix family, member e40 (BHLHe40), preproenkephalin (PENK), IL-2, serine (or cysteine) peptidase inhibitor, Glade B member 6 h (Serpinb6b), neuritin 1 (Nrn1), stearoyl-Coenzyme A desaturase 1 (Scd1), or phosphotriesterase related C1q-like 3 (Pter), or a combination thereof.
- the T H -GM cells are further characterized by an underexpression of one or more genes listed in Table 1.
- the T H -GM cells are further characterized an underexpression of lymphocyte antigen 6 complex, locus A (Ly6a); CD27; or selectin, lymphocyte (Sell).
- the identification of a distinct network of factors (unique from factors known to mediate T H 1 or T H 17) that mediate T H -GM function enables targeted modulation of T H -GM function to treat T H -GM-mediated disorders, e.g., disorders that result from aberrant T H -GM function.
- the present disclosure provides a method of modulating T H -GM function, comprising contacting the T H -GM, or cluster of differentiation 4 (CD4+) precursor cells, or both, with a modulating agent that modulates T H -GM function.
- the modulating agent is contacted with the T H -GM cells or CD4+ precursor cells in vitro or in VIVO.
- T H -GM function refers to the commitment, development, maintenance, survival, proliferation, or activity, or a combination thereof, of T H -GM cells.
- an agent that modulates (e.g., enhances or inhibits) T H -GM function is one that modulates T H -GM commitment, development, survival, proliferation, or activity, or combination thereof, of T H -GM cells.
- T H -GM function can be modulated by modulating its: commitment from a CD4 + precursor T cell; development of a CD4 + precursor cell that has been committed to the T H -GM developmental pathway; maintenance of a T H -GM phenotype; survival or proliferation under development or effector T H -GM cells; and/or activity of effector T H -GM cells (e.g., modulating function of a secreted factor such as GM-CSF or IL-3).
- a secreted factor such as GM-CSF or IL-3
- a modulation in T H -GM function includes, but is not limited to, a modulation in: the number of T H -GM cells; the survival of T H -GM cells; the proliferation of T H -GM cells; and/or the activity of T H -GM cells.
- the activity of T H -GM cells herein includes the activity induced by the cytokines, chemokines, growth factors, enzymes and other factors secreted by T H -GM cells, as described herein, and the activity induced by direct contact with T H -GM cells.
- a T helper subset cell “T H -GM” refers to a cell that, similar to T H 1 and T H 17 cells, differentiates from precursor CD4+ precursor cells, but which commits and develops through a pathway that is mediated by a subset of factors (the T H -GM-mediating factors) that is distinct and unique from the known subset of factors that commit and develop T H 1 or T H 17 cell subtypes, as described herein.
- a T H -GM cell produces a distinct and unique set of genes (see, e.g., Table 1) and effects pathogenicity through a different mechanism and pathway than the known factors that mediate pathogenicity of T H 1 or T H 17 cell subtypes.
- a T H -GM cell commits and develops by IL-7/STAT5 function (its regulators), and effects pathogenicity by GM-CSF/IL-3 (its effectors).
- the present disclosure provides a method of treating a T H -GM-mediated inflammatory disorder in a patient in need thereof, comprising administering to said patient an effective amount of a modulating agent that modulates T H -GM cell function.
- the patient is previously diagnosed as having a T H -GM-mediated inflammatory disorder, as described herein.
- the present disclosure also provides a method of treating rheumatoid arthritis in a patient who exhibits limited response to TNF- ⁇ therapy, comprising administering to said patient an effective amount of a modulating agent that modulates T H -GM function.
- limited response refers to no response or insignificant response such that a patient is not treated by the therapy, as determined by clinical standards.
- Treatment refers to therapy, prevention and prophylaxis and particularly refers to the administration of medicine or the performance of medical procedures with respect to a patient, for either prophylaxis (prevention) or to reduce the extent of or likelihood of occurrence of the condition or event in the instance where the patient is afflicted. It also refers to reduction in the severity of one or more symptoms associated with the disease or condition. In the present application, it may refer to amelioration of one or more of the following: pain, swelling, redness or inflammation associated with an inflammatory condition or an autoimmune disease.
- treatment is an approach for obtaining beneficial or desired results, including clinical results.
- beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, and/or amelioration or palliation of the disease state. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
- an “effective amount” of an agent is that amount sufficient to effect beneficial or desired results, including clinical results.
- An “effective amount” depends upon the context in which it is being applied. In the context of administering a composition that modulates an autoimmune response, an effective amount of an agent which is a modulator of T H -GM function is an amount sufficient to achieve such a modulation as compared to the response obtained when there is no agent administered.
- An effective amount can confer immediate, short term or long term benefits of disease modification, such as suppression and/or inhibition of T H -GM function, as defined herein.
- An effective amount can be administered in one or more administrations.
- An “effective amount” as used herein, is intended to mean an amount sufficient to reduce by at least 10%, at least 25%, at least 50%, at least 75%, or an amount that is sufficient to cause an improvement in one or more clinically significant symptoms in the patient.
- the modulating agent inhibits T H -GM function to, e.g., reduce inflammation.
- the inhibition conferred by the modulating agent does not imply a specific mechanism of biological action.
- the term “antagonist” or “inhibitor” as used herein includes all possible pharmacological, physiological, and biochemical interactions with factors that mediate T H -GM function (e.g., IL-7, IL-7 receptor, STAT5, GM-CSF, IL-3, IL-2, IL-2 receptor, PENK, RANKL, JAK1/3, or any of the genes that are differentially expressed in T H -GM cells, e.g., genes in Tables 1 and 2), whether direct or indirect, and includes interaction with a factor (or its active fragment) that mediates T H -GM function at the protein and/or nucleic acid level, or through another mechanism.
- a modulating agent that inhibits T H -GM function includes an antibody, a polypeptide (e.g., a soluble receptor that hinds and inhibits, for example, IL-7), a small molecule, a nucleic acid (e.g., antisense, small interfering RNA molecule, short hairpin RNA, microRNA), or a protein (e.g., cytokine), or a combination thereof that prevents the function (e.g., expression and/or activity) of a factor that mediates T H -GM function.
- a polypeptide e.g., a soluble receptor that hinds and inhibits, for example, IL-7
- a small molecule e.g., a nucleic acid (e.g., antisense, small interfering RNA molecule, short hairpin RNA, microRNA), or a protein (e.g., cytokine), or a combination thereof that prevents the function (e.g., expression and/or
- binds is used interchangeably with “specifically binds,” which means a polypeptide (e.g., a soluble receptor) or antibody which recognizes and hinds a polypeptide of the present disclosure, but that does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the present disclosure.
- an antibody specifically binds an activated STAT5 polypeptide does not hind a non-STAT5 polypeptide.
- antibody refers to an intact antibody or antigen-binding fragment of an antibody, including an intact antibody or antigen-binding fragment that has been modified or engineered, or that is a human antibody.
- the antibody binds to and inhibits the function of any one or more of the factors that mediate T H -GM function.
- the antibody binds to and inhibits the function of a gene listed in Table 1.
- the antibody hinds to and inhibits the protein or any functional fragment thereof.
- Methods of designing, producing and using suitable antibodies are known and available to those of skill in the art. Examples of antibodies suitable for use in the present disclosure include. e.g., daclizumab, basiliximab, methosimumab, MOR103, KB003, namilumab, and MOR Ab-022.
- protein and “polypeptide” are used interchangeably, and can include full-length polypeptide or functional fragments thereof (e.g., degradation products, alternatively spliced isoforms of the polypeptide, enzymatic cleavage products of the polypeptide), the polypeptide hound to a substrate or ligand, or free (unbound) forms of the polypeptide.
- functional fragment refers to a portion of a full-length protein that retains some or all of the activity (e.g., biological activity, such as the ability to bind a cognate ligand or receptor) of the full-length polypeptide.
- the modulating agent that inhibits T H -GM function can be a particular biological protein (e.g., cytokines) that inhibits, directly or indirectly, one or more of the factors that mediate T H -GM function.
- cytokines include, e.g., IL-12, IFN- ⁇ , TGF- ⁇ , and IL-6.
- the modulating agent that inhibits T H -GM function can be a small molecule that inhibits, directly or indirectly, one or more of the factors that mediate T H -GM function.
- a “small molecule” is an organic compound or such a compound complexed with an inorganic compound (e.g., metal) that has biological activity and is not a polymer.
- a small molecule generally has a molecular weight of less than about 3 kilodaltons. Examples of known small molecules include CAS 285986-31-4 (Calbiochem), pimozide, and tofacitinib.
- the modulating agent enhances T H -GM function in disorders such as, e.g., viral, fungal and bacterial infections, cancers and/or conditions associated with therewith.
- modulating agents that enhance T H -GM function include. e.g., CD28 activator; IL-7 and/or IL-2 on na ⁇ ve (precursor) CD4 + T cells; activator of STAT5; or effectors of T H -GM cells (e.g., GM-CSF. IL-3).
- the present disclosure provides a method of treating a STAT5-mediated inflammatory disorder in a patient in need thereof, comprising administering to the patient an effective amount of an agent that modulates STAT5 function.
- STAT5-mediated inflammatory disorder refers to an inflammatory disorder that is caused by aberrant STAT5 function (aberrantly enhanced or inhibited), and which is responsive to modulation of STAT5 function, as determined by clinical standards.
- the STAT5 is activated STAT5 (e.g., phospho-STAT5, Tyr694).
- the inflammatory disorder is an autoimmune disorder.
- the inflammatory disorder can be any inflammatory disorder mediated by STAT5 (e.g., activated STAT5), and includes, but is not limited to rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis. Crohn's disease, diabetes. Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism, Irritable Bowel Syndrome (IBS), lupus erythematosus, polymyalgia rheumatic, psoriasis, psoriatic arthritis. Raynaud's syndrome/phenomenon, reactive arthritis (Reiter syndrome), sarcoidosis, scleroderma. Sjögren's syndrome, ulcerative colitis, uveitis, or vasculitis.
- STAT5 e.g., activated STAT5
- STAT5 e.g., activated STAT5
- IBS Irritable
- the term “patient” refers to a mammal, preferably human, but can also include an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like), and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- companion animals e.g., dogs, cats, and the like
- farm animals e.g., cows, sheep, pigs, horses, and the like
- laboratory animals e.g., rats, mice, guinea pigs, and the like.
- the agent inhibits STAT5 function (e.g., expression and/or activity).
- STAT5 function e.g., expression and/or activity.
- agents that inhibit STAT5 e.g., activated STAT5, Tyr694 are described herein.
- the methods of the present disclosure further comprise administering to the patient a TNF- ⁇ c therapy.
- TNF- ⁇ therapy is administered in a patient determined to have an inflammatory condition that is non-T H -GM-mediated.
- a TNF- ⁇ therapy is administered if a quantified TNF- ⁇ level is increased by, e.g., at least 40% relative to a reference level.
- TNF- ⁇ therapy examples include those that are TNF- ⁇ -inhibitor based, and those that are non-TNF- ⁇ -inhibitor based.
- TNF- ⁇ -inhibitor based therapy includes etanercept, adalimuinab, infliximab, golimumab, and certolizumab pegol.
- non-TNF- ⁇ -inhibitor based therapy includes corticosteroid medications (e.g., prednisone), nonsteroidal anti-inflammatory drugs (e.g., methotrexate), and JAK inhibitors (e.g., tofacitinib).
- Other examples of non-TNF- ⁇ -inhibitor based therapy include anakinra, abatacept, rituximab and tocilizumab.
- the TNF- ⁇ therapy can be administered before, simultaneously with, or alter the administration of an effective amount of an agent that modulates T H -GM function.
- an agent that modulates T H -GM function and the TNF- ⁇ therapy can be administered together in a single dose, or can be administered in separate doses, e.g., either simultaneously or sequentially, or both.
- the duration of time between the administration of an agent that modulates T H -GM function and a TNF- ⁇ therapy will depend on the nature of the therapeutic agent(s).
- an agent that modulates T H -GM function and a TNF- ⁇ therapy may or may not be administered on similar dosing schedules.
- the agent that modulates T H -GM function and the TNF- ⁇ therapy may have different half-lives and/or act on different time-scales such that the agent that modulates T H -GM function is administered with greater frequency than the TNF- ⁇ therapy, or vice-versa.
- the number of days in between administration of therapeutic agents can be appropriately determined by persons of ordinary skill in the art according to the safety and pharmacodynamics of each drug.
- T H -GM cells as well as the identification of genes differentially produced by T H -GM cells relative to T H 1 or T H 17 enables the use of T H -GM cells to identify novel therapeutics for modulating T H -GM function, thereby enabling new therapeutics for treating T H -GM-mediated disorders (e.g., inflammatory disorders).
- T H -GM-mediated disorders e.g., inflammatory disorders
- the present disclosure provides a method of screening to identify a modulator of T H -GM cell function, comprising contacting an isolated population of T H -GM cells, or an isolated population of CD4+ precursor cells, with a candidate agent, and measuring a readout of T H -GM function in the presence or absence of the candidate agent, wherein a change in the readout of T H -GM function indicates that the candidate agent is a modulator of T H -GM function.
- a candidate agent refers to an agent that may modulate T H -GM function by modulating the function (e.g., expression and/or activity) of a factor that mediates T H -GM function.
- candidate agents include, e.g., an antibody, a peptide, a small molecule, a nucleic acid (e.g., antisense, small interfering RNA molecule), or a protein (e.g., cytokine), or a combination thereof.
- a candidate agent can be designed to target any of the factors (at the protein and/or nucleic acid level) that mediate T H -GM function, as described herein, including the genes listed in Table 1 (e.g., genes preferentially upregulated in T H -GM cells, genes preferentially overexpressed/underexpressed on the surface of T H -GM cells).
- readout refers to any change (or lack of change) in T H -GM function that can be measured or quantified.
- a candidate agent can be assessed for its effect on, e.g., GM-CSF secretion by T H -GM cells, or its effect on the abundance of T H -GM cells (through an effect on the commitment/development/proliferation of T H -GM cells), as described herein.
- Assays for determining such readouts are known and available in the art, and are exemplified herein.
- the change in the presence of the candidate agent is a reduction in the measurement of the readout, indicating an inhibition of T H -GM function (e.g., decrease in GM-CSF or IL-3 production, or decrease in the abundance of T H -GM cells), thereby identifying the candidate agent as an inhibitor of T H -GM function.
- an inhibition of T H -GM function e.g., decrease in GM-CSF or IL-3 production, or decrease in the abundance of T H -GM cells
- the change in the presence of the candidate agent is an increase in the measurement of the readout, indicating an enhancement of T H -GM function (e.g., increase in GM-CSF or IL-3 production, or increase in the abundance of T H -GM cells), thereby identifying the candidate agent as an enhancer of T H -GM function.
- an enhancement of T H -GM function e.g., increase in GM-CSF or IL-3 production, or increase in the abundance of T H -GM cells
- the readout can be any one or more of the genes listed in Tables 1 and 2 which are preferentially upregulated or downregulated in T H -GM cells.
- a candidate agent that downregulates a gene that is preferentially upregulated in a T H -GM cell is a inhibitor of T H -GM function.
- a candidate agent that upregulates a gene that is preferentially downregulated in a T H -GM cell is an enhancer of T H -GM function.
- the method of screening if performed with precursor CD4+ cells, is performed under T H -GM polarizing conditions, as described herein.
- the method can be performed in the presence of IL-7/STAT5, TCR activation, CD28 co-stimulation, in combination with the blockade of IFN-gamma and IL-4.
- the practice of the present disclosure includes use of conventional techniques of molecular biology such as recombinant DNA, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology as described for example in: Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989) and Molecular Cloning: A Laboratory Manual, third edition (Sambrook and Russel, 2001), jointly and individually referred to herein as “Sambrook”); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Animal Cell Culture (R. I. Freshney, ed., 1987); Handbook of Experimental Immunology (D. M. Weir & C. C.
- Stat5 f/f mice were provided by L. Hennighausen (National Institute of Diabetes and Digestive and Kidney Diseases).
- Stat3 f/f mice were generated as described 2 .
- Cd4-Cre transgenic mice were purchased from Taconic Farms.
- Rag2 ⁇ / ⁇ mice were obtained from Jean-Pierre Abastado (Singapore Immunology Network). All mice are on a C57BL/6 genetic background and housed under specific-pathogen-free conditions at National University of Singapore. All experiments were performed with mice 6 ⁇ 8 weeks old and approved by the Institutional Animal Care and Use Committee of NUS.
- CD4 + T cells were obtained from spleens and lymph nodes by positive selection and magnetic separation (Miltenyi Biotech), followed by purification of na ⁇ ve CD4 + T cell population (CD4 + CD25 ⁇ CD62L hi CD44 lo ) sorted with FACS Aria.
- Na ⁇ ve CD4 + T cells were stimulated with plate-hound anti-CD3 (3 ⁇ g/ml; BD Pharmingen) and anti-CD28 (1 ⁇ g/ml; BD Pharmingen) in presence of different combinations of neutralizing antibodies and cytokines for 3 ⁇ 4 days: for neutral conditions, no addition of any cytokine or neutralizing antibody; for T H 1 conditions, IL-12 (10 ng/ml), and anti-IL-4 (10 ⁇ g/ml, BD Pharmingen); for T H 17 conditions, hTGF- ⁇ (3 ng/ml), IL-6 (20 ng/ml), anti-IFN- ⁇ (10 ⁇ g/ml, eBioscience), and anti-IL-4 (10 ⁇ g/ml); for an alternative T H 17 conditions, IL-6 (20 ng/ml), IL-23 (10 ng/ml), IL-1 (10 ng/ml), anti-IFN- ⁇ (10 ⁇ g/ml), and anti-IL-4 (10 ⁇ g/ml
- na ⁇ ve CD4 + T cells were stimulated with plate-bound anti-CD3 (2 ⁇ g/ml) and soluble anti-D28 (1 ⁇ g/ml) with the addition of IL-7 and/or anti-IFN- ⁇ (10 ⁇ g/ml) as indicated. All cytokines were obtained from R&D Systems. All cells were cultured in RPMI 1640 supplemented with 10% FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acid and 5 ⁇ M beta-mercaptoethanol.
- EAE induction procedures were modified from previous report 3 .
- mice were immunized in two sites on the hind flanks with 300 ⁇ g MOG 35-55 in 100 ⁇ l CFA containing 5 mg/ml heat-killed M. tuberculosis strain H37Ra (Difco) at day 0 and day 7.
- Pertussis toxin List Bio Lab
- the similar procedure was performed at day 0 and day 1 only.
- LPS 600 ⁇ g/ml in IFA, O111:B4 from Sigma
- Clinical symptoms were scored as follows: 0, no clinical sign; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paralysis; 4, hind and fore limb paralysis; 5, death.
- IL-7R ⁇ neutralizing antibody (SB/14, BD Pharmingen) and isotype control was administrated intraperitoneally at 200 ⁇ g per mouse every other day.
- SB/14 BD Pharmingen
- isotype control was administrated intraperitoneally at 200 ⁇ g per mouse every other day.
- CNS-infiltrating cells both spinal cord and brain were collected and minced from perfused mice, and mononuclear cells were isolated by gradient centrifuge with Percoll (GE Healthcare).
- splenocytes and LNs were harvested 10-14 days post-immunization and passed through a 70 ⁇ m cell strainer (BD Falcon). Cells were cultured in vitro for 3 days with MOG 35-55 (20 ⁇ g/ml) in the presence of IL-23 (5 ng/ml) and IL-1 ⁇ (2 ng/ml). After harvesting, CD4 + T cells were purified by positive selection to a purity >90%. CD4 + T cells (2 million in sterile PBS) were injected intraperitoneally into Rag2 ⁇ / ⁇ mice, followed by Pertussis toxin administration on the following day.
- T H mice were observed daily for the signs of EAE as described above.
- EAE induction by transferring various T H subsets similar procedures was performed as described above. Different subsets skewing conditions were as follows: Non-skewed, MOG 35-55 only; T H 1: MOG 35-55 plus IL-12 (10 ng/ml) and anti-IL-4 (5 ⁇ g/ml); T H 17: MOG 35-55 plus TGF- ⁇ (3 ng/ml), IL-6 (10 ng/ml), anti-IFN- ⁇ (5 ⁇ g/ml) and anti-IL-4 (5 ⁇ g/ml); GM-CSF-expressing T H : MOG 35-55 plus IL-7 (2 ng/ml) and anti-IFN- ⁇ (5 ⁇ g/ml). 6 ⁇ 10 5 CD4 + T cells were transferred per recipient mouse.
- AIA Antigen-Induced Arthritis
- mice were immunized subcutaneously in two sites on the hind flanks with 100 ⁇ g methylated bovine serum albumin (mBSA, Sigma) in 100 ⁇ l complete Freund's adjuvant (CFA) containing 5 mg/ml heat-killed M. tuberculosis strain H37Ra (Difco) at day 0.
- CFA complete Freund's adjuvant
- Pertussis toxin List Bio Lab was administrated intraperitoneally at the dosage of 250 ng per mouse at day 1.
- Arthritis was induced by intraarticular injection of 100 ⁇ g mBSA (in 10 saline) into the hind right knee joint at day 7 after immunization. The hind left knee joint was injected with same volume of saline as control.
- splenocytes and inguinal LN cells were isolated from mBSA/CFA-immunized mice at day 7, and cultured in vitro with mBSA (10 ⁇ g/ml) in the presence of IL-7 (2 ng/ml) for 3 days. After harvesting, CD4 + T cells were purified by positive selection (Miltenyi Biotec) to a purity >90%. Then CD4 + T cells (1 million in sterile PBS) were transferred into WT na ⁇ ve mice, followed by intraarticular injection of mBSA on the next day.
- CIA was induced in a similar procedure as AIA as described above, by immunizing mice with chicken collagen II/CFA emulsion (purchased from Chondrex, Inc), followed with pertussis toxin injection. Mice were monitored and scored for arthritis; 0, normal; 1, mild swelling of ankle or wrist, or apparent swelling limited to individual digits; 2, moderate swelling of entire paw; 3, severe swelling of entire paw with ankylosis. Scores for four limbs were summed for each mouse.
- Sections (10 ⁇ m) were fixed in ice-cold acetone and stained with primary anti-CD4 (Biolegend) and anti-CD11b (eBioscience), followed by incubation with fluorescence-conjugated secondary antibodies (Invitrogen).
- ALA experiments knee joint were fixed in 10% formalin for 5 days, followed by decalcification in 5% formic acid for 5 clays.
- Sections (10 ⁇ m) were stained with hematoxylin and eosin (H&E) to assess immune cell infiltration and inflammation, or stained with Safranin-O/fast green to access cartilage destruction.
- H&E hematoxylin and eosin
- Monocytes/macrophages (Ly6C hi Ly6G ⁇ ) and neutrophils (Ly6C lo Ly6G hi ) gated on CD45 + CD11b + were sorted with FACS Aria from spleens or synovial single cell suspensions. Sorted cells were cytospun onto glass slides and subsequently stained with May Grünwald and Giemsa dye following a standard procedure.
- Complementary DNA (cDNA) was synthesized with Superscript reverse transcriptase (Invitrogen). Gene expressions were measured by 7500 real-time PCR system (Applied Biosystems) with SYBR qPCR kit (KAPA). Actinb, Gapdh or Rn18S was used as internal control. The primer sequences are available upon request.
- TNF- ⁇ , IL-6, IL-1 ⁇ , IFN- ⁇ , GM-CSF and IL-2 levels were assayed by Ready-SET-Go ELISA kit (eBioscience), and IL-17 level was measured by DuoSet ELISA kit (R&D Systems) according to the manufactures' instructions.
- Cell lysates were fragmented by sonication and precleared with protein G Dynabeals, and subsequently precipitated with anti-STAT5 antibody (Santa Cruz) or normal rabbit IgG (Santa Cruz) overnight at 4° C.
- crosslink reversal was clone by incubating at 65° C. for 8 hr.
- the eluted DNA was purified and analyzed by RT-PCR with primers specific to C42 promoter as described previously 5 .
- STAT5 negatively regulates T H 17 differentiation by restraining IL-17 production (Laurence et al., 2007; Yang et al., 2011). However, the function of STAT5 in T H 17-mediated pathogenesis is not well understood.
- EAE was induced in Cd4-Cre; Stat5 f/f (Stat5 ⁇ / ⁇ ) mice, where Stat5 was specifically deleted in T cell compartment, and in littermate controls by immunizing the mice with MOG 35-55 /CFA at day 0 and day 7. Development of paralysis was assessed by daily assignment of clinical scores. Surprisingly, diminished occurrence and severity of clinical disease in Stat5 ⁇ / ⁇ mice was observed ( FIGS.
- FIGS. 1A and 1B a result that was opposite to expectations based on an antagonistic role for STAT5 in T H 17 generation. Similar results were observed when a single MOG 35-55 /CFA immunization was performed or replaced CFA with LPS as the adjuvant to induce EAE ( FIGS. 1C and 1D ). Consistent with reduced EAE disease in Stat5 ⁇ / ⁇ mice, a remarkable reduction of immune cell infiltration in the spinal cord of Stat5 ⁇ / ⁇ mice was observed ( FIG. 2A ). Furthermore, the infiltration of various immune cell populations, including CD4 + , CD8 + . B220 + and CD11b + cells was reduced in Stat5 ⁇ / ⁇ mice ( FIGS. 2B-D and data not shown).
- Stat5 deletion (Cd4-cre; Stat5 f/ ⁇ ) mice was reported to develop peripheral lymphopenia, with a reduction of both CD4 + and CD8 + T cells (Yao et al., 2006). However, another study showed that Stat5 deletion (Cd4-cre; Stat5 f/f ) did not affect the proportion of peripheral CD4 + T cells (Burchill et al., 2007). In the experimental setting, a change in the absolute number of peripheral CD4 + T cells was not detected by Stat5 deletion during EAE development ( FIGS. 4A and 4B ), suggesting the resistance to EAE in Stat5 ⁇ / ⁇ mice was not caused by peripheral lymphopenia.
- mice receiving Stat5 +/+ CD4 + T cells spontaneously developed EAE disease 1 week after transfer.
- mice receiving Stat5 ⁇ / ⁇ CD4 + T cells had significantly reduced disease severity and incidence.
- the frequencies of IL-17 + and IFN- ⁇ + cells among CD4 + T cells in the CNS of Rag2 ⁇ / ⁇ mice were comparable between two groups ( FIG.
- GM-CSF production was impaired by Stat5 deletion, its expression was examined in MOG 35-53 -specific Stat5 +/+ and Stat5 +/+ CD4 + T cells.
- Splenocytes derived from MOG 35-55 /CFA-immunized Stat5 +/+ and Stat5 ⁇ / ⁇ mice were challenged with various concentrations of MOG 35-55 for 24 h, to examine the secretion of GM-CSF.
- GM-CSF production was observed to increase in a MOG 35-55 dose-dependent manner in Stat5 +/+ cells ( FIG. 8A ). In contrast, GM-CSF production was severely diminished in Stat5 +/ ⁇ cells in all conditions.
- splenocytes derived from mice were stimulated during the development of EAE with PMA/Ionomycin in the presence of GolgiPlug for GM-CSF and IL-17 intracellular staining.
- IL-17 expression was enhanced in Stat5 ⁇ / ⁇ cells, a significantly reduced proportion of GM-CSF + IL-17′′ and GM-CSF + IL-17 + cells was observed among CD4 + CD44 hi cells in the absence of STAT5 ( FIG. 8B ).
- the frequency of MOG 35,55 -specific GM-CSF + T cells was also significantly reduced in spleens of Stat5 ⁇ / ⁇ mice ( FIG. 8C ). Together, these results indicate that STAT5 is required for GM-CSF expression in autoreactive CD4 + T cells.
- STAT5 an important transcription factor in T H 17 differentiation, was required for GM-CSF expression ( FIG. 8D ).
- GM-CSF induction in the CNS during EAE development was examined. Although IL-17 and IFN- ⁇ production by CNS-infiltrating CD4 + T cells was not impaired by Stat5 deficiency, a diminished frequency of CD4 + GM-CSF + cells in the CNS of Stat5 ⁇ / ⁇ mice was detected compared with control mice ( FIG. 9A ). Further analysis showed a reduced GM-CSF + percentage among CD4 + IL-17; cells and among CD4 + IFN- ⁇ + cells ( FIG. 9A ).
- FIG. 9B GM-CSF mRNA expression in the CNS of Stat5 ⁇ / ⁇ mice was markedly lower than that of Stat5 +/+ mice at day 8 after EAE induction ( FIG. 9C ), when comparable CD4 + T cell infiltration was detected in Stat5 ⁇ / ⁇ and Stat5 +/+ mice ( FIGS. 5C and 5D ). Meanwhile, no significant difference of IL-17 and IFN- ⁇ expression was detected between Stat5 ⁇ / ⁇ and Stat5 +/+ mice ( FIG. 9C ).
- IL-7 carried out this function in a STAT5-dependent manner, as Stat5 deletion abrogated its effect on GM-CSF expression as assessed by intracellular cytokine staining and ELISA ( FIG. 11A , lower panels, and FIG. 11B ).
- IL-7R ⁇ is expressed in both CD62L hi CD44 lo T cells and CD62 lo CD44 hi T cells, suggesting IL-7 may directly act on CD4 + T cells to regulate GM-CSF expression.
- CD62L hi CD44 lo and CD62L lo CD44 hi T cells were sorted from Stat5 ⁇ / ⁇ mice and littermate controls during EAE development, and then activated cells in the presence or absence of IL-7.
- CD62L lo CD44 hi T cells potently expressed GM-CSF
- STAT5 deletion resulted in reduced basal GM-CSF production in CD62L lo CD44 hi T cells.
- IL-7 promoted GM-CSF expression in both subsets of CD4 + T cells in a STAT5-dependent manner ( FIG. 11C ).
- mice were treated with IL-7R ⁇ -specific antibody (clone SB/14) during EAE development.
- the treatment resulted in a significant reduction of disease severity, which was accompanied with reduced CNS inflammation ( FIGS. 12A and 12B ).
- this neutralizing antibody did not have T cell depleting activity ( FIG. 12C ).
- the blocking of IL-7 signaling resulted in decreased GM-CSF expression in CNS-infiltrating CD4 + T cells ( FIGS. 120-12F ).
- the present findings indicate that IL-7 induces STAT5-dependent GM-CSF expression in autoreactive CD4 + T cells, which contributes to the development of neuroinflammation.
- Example 5 GM-CSF-Expressing T H Cells are Distinct from T H 17 and T H 1
- T H 17 and T H 1 can produce GM-CSF, it was determined if the IL-7-stimulated phenotype was related to either of these subsets.
- na ⁇ ve CD4 + T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 under T H 1- or T H 17-polarizing conditions. It was observed that anti-CD3 together with anti-CD28 induced the expression of GM-CSF ( FIG. 14A ).
- T H 1 differentiation conditions promoted IFN- ⁇ expression
- T H 17 conditions promoted IL-17 expression as expected
- both T H 1 and T H 17 differentiation conditions greatly suppressed the production of GM-CSF ( FIGS.
- FIG. 13A and 13B Conversely, IL-12 and IFN- ⁇ neutralization promoted GM-CSF-expressing cell generation ( FIG. 13A ), consistent with a previous report (Codarri et al., 2011). IL-23 and IL-1 ⁇ did not increase GM-CSF-expressing cell differentiation from na ⁇ ve CD4 + T cells ( FIG. 13A ), which was consistent with the finding that na ⁇ ve CD4 + T cells did not express their receptors. TGF- ⁇ inhibits GM-CSF expression (El-Behi et al., 2011). IL-6, an essential cytokine for T H 17 differentiation, had a profound inhibitory effect on GM-CSF expression ( FIG.
- the present findings disclosed herein (including .g., diminished GM-CSF expression in Stat5 ⁇ / ⁇ CD4 + T cells in vivo, IL-7/STAT5-mediated induction of GM-CSF expression in na ⁇ ve CD4 + T cells, and the distinct features of GM-CSF-expressing T H cells versus T H 1 and T H 17 cells) indicates a distinct T H cell subset that is regulated by IL-7-STAT5 signaling.
- This finding was further explored by examining GM-CSF-expressing T H cell differentiation in vitro by activating na ⁇ ve CD4 + T cells with anti-CD3 and anti-CD28 in the presence of different concentrations of IL-7. As shown in FIGS.
- IL-7 strongly promoted the generation of GM-CSF-expressing cells and GM-CSF secretion. Moreover, the generation of GM-CSF-expressing T H by IL-7 was mediated by STAT5. Without STAT5, IL-7 was unable to promote the generation of GM-CSF-expressing cells ( FIGS. 15C and 15D ). Further investigation showed that IL-7-induced STAT5 activation directly hound promoter regions of the Csf2 gene ( FIGS. 15E and 15F ).
- T H -GM novel GM-CSF-expressing helper T cell subset
- IL-2 signaling could influence T H -GM differentiation from na ⁇ ve CD4 + T cells.
- the addition of IL-2 or antibody against IL-2 only had modest effect on the frequency of GM-CSF + cells ( FIG. 14D ), indicating a minimal effect of IL-2 on T H -GM differentiation.
- IL-2 high-affinity receptor IL-2Ra was not expressed in na ⁇ ve CD4 + T cells, but its expression was gradually induced by TCR activation ( FIGS. 17A-17C ).
- the minimal effect of IL-2 at least in part is due to the unresponsiveness of na ⁇ ve CD4 + T cells to IL-2 stimulation.
- IL-7 induced STAT5 activation and upregulated GM-CSF mRNA expression in na ⁇ ve CD4 + T cells ( FIGS. 17D and 17E ).
- activated CD4 + T cells were stimulated with IL-2 or IL-7, which showed that both cytokines induced STAT5 activation, Csf2 promoter binding and GM-CSF mRNA upregulation ( FIGS. 18A-18C ).
- IL-2 induced a prolonged STAT5 activation compared with IL-7 ( FIG. 18A ).
- T H -GM as distinct from known T cell subsets (e.g., T H 1 and T H 17)
- a whole transcriptome analysis was performed by microarray to validate its specificity compared with known T cell subsets, in particular T H 17 cells.
- Na ⁇ ve CD4 + T cells were differentiated into T H 1, T H 17 and T H -GM.
- Microarray analysis was performed to examine their gene expression profiles.
- Whole transcriptome clustering indicates T H -GM cells as representing a novel subset distinct from T H 1 or T H 17 cells. T cell lineage-specific gene expression is shown in Table 1.
- T H 1 cells A list of 202 genes preferentially expressed in T H 1 cells were identified, compared with na ⁇ ve, T H 17 or T H -GM cells (fold change >1.7), among which IFN- ⁇ and T-bet are on the top of the list (Table 1).
- T H 17-feature genes such as IL-17, IL-17F, ROR ⁇ t and ROR ⁇ , were identified in the list including 411 genes specific to T H 17 cells (Table 1).
- the T H -GM cell-specific gene list (“Genes preferentially upregulated in T H -GM” the T H -GM signature genes) contains 210 genes including the gene encoding GM-CSF as the top gene in the list (Table 1).
- T H -GM signature genes can be used for further characterization by surface markers to identify the T H -GM subset of T cells.
- genes of interest were also identified, including genes encoding cytokines and transcriptional factors, in particular IL-3.
- helper T cells were differentiated in vitro and confirmed that T H -GM cells are potent IL-3 producers as compared with T H 1 and T H 17 cells ( FIGS. 20A, 20C and 20D ).
- cytokines including EBI-3, PENL and RANKL were found preferentially expressed in T H -GM cells ( FIG. 20B ), indicating diverse biological functions of T H -GM cells.
- T H -GM Cells are the Primary Pathogenic Population
- T H subset (T H -GM) was the primary encephalitogenic effector cells
- adoptive transfer of different subsets of MOG 35-55 -specific CD4 + T cells was performed into Rag2 ⁇ / ⁇ mice for EAE induction.
- GM-CSF-expressing T H cells were preferentially able to induce EAE compared with T H 17 and T H 1 subsets.
- Example 9 The Suppression of STAT5 Activity by Chemical Inhibitor Attenuates GM-CSF Expression by T H -GM and Ameliorates EAE
- the effect of disrupting STAT5 activation by chemical inhibitor was examined to explore possible methods of treating autoimmune neuroinflammation.
- the phosphorylation on the key tyrosine residue in SH2 domain is crucial for STAT5 activation and function.
- a commercial STAT5 inhibitor (CAS 285986-31-4, Calbiochem) has been reported to selectively disrupt tyrosine phosphorylation and DNA binding of STAT5 (Muller et al., 2008).
- the inhibitory effect of this inhibitor on STAT5 activation upon IL-7 stimulation in CD4+ T cells was tested. At a concentration of 50 ⁇ M, the inhibitor had about 50% inhibitory effect, which was further enhanced with the increase of concentration ( FIG. 22A ).
- STAT5 inhibitor had low affinity and thus required a high concentration to fully block STAT5 activation, whereas JAK3 inhibitor showed potent inhibitory effect even at low concentration ( FIG. 22B ).
- the specificity of STAT5 inhibitor was next tested by examining its effect on the activation of STAT3 and STAT1. As shown in FIGS. 22C and 22D , this STAT5 inhibitor at relatively lower concentration (50 or 100 ⁇ M) showed minimal inhibitory effect on both STAT3 and STAT1 activation.
- STAT5 inhibition The effect of STAT5 inhibition on T H -GM differentiation was examined. As shown, STAT5 inhibitor suppressed T H -GM differentiation in a dosage-dependent manner ( FIG. 22E ). Reduced T H 1 differentiation upon STAT5 inhibitor treatment was observed (data not shown), but T H 17 differentiation was not suppressed by STAT5 inhibitor (data not shown).
- STAT5 inhibition ameliorated EAE severity, associated with reduced immune cell infiltration in the CNS ( FIGS. 23A and 23B ).
- JAK3 inhibitor can potently block STAT5 activation ( FIG. 22B ), it showed detrimental effect on EAE ( FIG. 23B ).
- STAT5 inhibitor resulted in reduced GM-CSF production in CNS-infiltrating CD4 + T cells ( FIGS. 23C and 23D ). This study indicates that targeting STAT5 by chemical inhibitor is useful in therapeutic intervention in MS.
- Plasma concentrations of GM-CSF and TNF- ⁇ in peripheral blood of RA patients were examined in comparison with gender/age-matched healthy control (HC), and found that both cytokines were elevated in RA ( FIG. 24A ).
- Ex vivo frequencies of IFN- ⁇ -, IL-17- or GM-CSF-producing T H cells were quantified in RA and HC. High frequencies of IFN- ⁇ - and/or GM-CSF-producing T H cells were detected in all samples, but observed low frequency ( ⁇ 1%) of IL-17-producing T H cells ( FIG. 24B ).
- GM-CSF-single-producing (GM-CSF + IFN- ⁇ ⁇ ) T H cells represented a substantial population in both RA and HC ( FIG. 24B ).
- GM-CSF-producing T H cells were isolated from synovial fluid of RA patients and analyzed the abundance of these cells.
- a marked elevation of GM-CSF-producing T H cell frequency was observed in synovial fluid compared with peripheral blood, but most of these cells co-expressed IFN- ⁇ ( FIG. 24E ).
- both T H 1 and T H 17 frequencies were also increased in synovial fluid, with T H 17 remaining to be a minor population compared with T H 1 ( FIG. 24E ).
- GM-CSF and TNF- ⁇ level in plasma of RA in comparison to HC may suggest a therapeutic approach by targeting these two cytokines.
- the efficacy of blocking both GM-CSF and TNF- ⁇ was tested in treating arthritic mice in antigen-induced arthritis (AIA) model, which is a T-cell driven RA model and is easily inducible in C57BL/6 strain with a rapid and synchronized disease onset, facilitating the exploration of RA pathogenesis.
- AIA antigen-induced arthritis
- Either GM-CSF or TNF- ⁇ individual blockade attenuated MA development ( FIG. 25A ).
- the combination of GM-CSF- and TNF- ⁇ -specific neutralizing antibodies showed better efficacy in controlling arthritis development than individual treatments ( FIG.
- GM-CSF may have beneficial efficacy in treating arthritis in a way independent of TNF- ⁇ activity.
- a mouse strain Cd4-Cre; Stat5 f/f , or Stat5 ⁇ / ⁇ in short
- conditional Stat5 deletion was used in T cells for AIA induction.
- These conditional Stat5-knockout mice resisted arthritis development, as exemplified by milder joint selling, fewer immune cell infiltration in synovia, and reduced joint destruction ( FIGS. 25B-25D ), even though they had markedly increased level of serum TNF- ⁇ as well as IFN- ⁇ ( FIG. 25E ).
- Splenocytes were collected from wild-type AIA mice and separated cells into three fractions: splenocytes, splenocytes depleted of CD4 + T cells and CD4 + T cells; and stimulated each fraction at same cell numbers under various conditions. Splenocytes produced low but detectable level of GM-CSF without stimulation, which was markedly increased by PMA/Ionomycin or mBSA antigen stimulation ( FIG. 28A ). Under all conditions, splenocytes depleted of CD4 + T cells almost completely abrogated GM-CSF production ( FIG.
- CD4 + T cells produced dramatically elevated GM-CSF in comparison to splenocytes under all conditions ( FIG. 28A ).
- CD4 + T cells are predominant producers of GM-CSF at least in spleens of arthritic mice, which is somehow consistent the observed correlation of plasma GM-CSF concentration with GM-CSF-single-producing T H cell frequency in RA ( FIG. 24D ).
- the functional significance of T H -cell-secreted GM-CSF was examined in arthritis development.
- T H 1 is a predominant population among synovial infiltrating CD4 + T cells in human RA (Berner et al., 2000; Yamada et al., 2008), defective IFN- ⁇ signaling results in increased disease susceptibility in animal models of arthritis (Guedez et al., 2001; Irmler et al., 2007; Manoury-Schwartz et al., 1997; Vermeire et al., 1997).
- T H 17 cells are proven crucial in animal models of arthritis (Pernis, 2009), but predominance of T H 17 cells is limited in both peripheral blood and synovial compartment of human RA (Yamada et al., 2008) and ( FIGS. 1B and 1E ). As demonstrated herein, STAT5-regulated GM-CSF-producing T H cells potentiate arthritis pathogenesis.
- splenocytes derived from AIA mice were stimulated with PMA/Ionomycin plus Golgiplug ex viva, followed by intracellular cytokine staining and flow cytometry.
- the frequency of GM-CSF-single-producing cells among CD4 + CD44 hi population was significantly decreased in Stat5 ⁇ / ⁇ mice ( FIG. 28 34 B).
- no significant differences were observed in frequencies of IL-17-single-producing (T H 17) or IFN- ⁇ -single-producing (T H 1) cells between two groups ( FIG. 28B ).
- both T H 1 and T H 17 cells exhibited similar percentages between two groups ( FIG. 28C ).
- inflamed synovial tissues were harvested from AIA mice for RNA and protein extraction to examine cytokine level by qPCR and ELISA.
- lower synovial GM-CSF but not IFN- ⁇ or IL-17 was detected in Stat5 ⁇ / ⁇ mice than Stat5 +/+ mice at day 5 or 7 after arthritis induction ( FIGS. 28E and 30A-30C ).
- FIGS. 28E and 30A-30C two important proinflammatory cytokines IL-6 and IL-1 ⁇ were also found persistently and significantly reduced in STAT5-deficient mice ( FIGS. 28E and 30A-30C ), indicating the attenuated synovial inflammation. Notably. TNF- ⁇ production was reduced at day 7 but not at day 5 in STAT5-deficient mice ( FIGS. 28E and 30A -C). Together, these results indicate that STAT5-regulated GM-CSF expression by arthritogenic T H cells is crucial for evoking synovial inflammation.
- GM-CSF was administered via intra-articular injection in mixture with mBSA to the left knee joints of mBSA/CFA-immunized mice, whereas mBSA was injected alone to the right knee joints. Injection with mBSA alone was sufficient to induce abundant immune cell infiltration in the synovial compartments of Stat5 +/+ mice but failed to do so in Stat5 ⁇ / ⁇ mice ( FIG. 28F ). Administration of GM-CSF together with mBSA efficiently restored synovial inflammation in Stat5 ⁇ / ⁇ mice ( FIG. 34F ).
- GM-CSF-producing Th cells evoke synovial inflammation and drive arthritis development was examined.
- Myeloid lineage-derived cells including neutrophils, DCs and macrophages, express GM-CSF receptor and are common targets of GM-CSF (Hamilton, 2008).
- those cells invade synovial compartments in RA patients and mouse arthritis models, and contribute to synovitis (McInnes and Schett, 2011).
- the infiltration of myeloid lineage-derived cells in synovial compartments of ALA mice was examined.
- CD11b + myeloid cells represented a predominant population ( ⁇ 70%) among synovial infiltrating leukocytes ( FIG. 31B ).
- CD4 + T H cell infiltration was not altered by STAT5 deletion, synovial CD11b + cell infiltration was significantly reduced in Stat5 ⁇ / ⁇ mice compared with Stat5 +/+ mice when examined at day 7 after arthritis induction ( FIG. 31B ). This reduction is unlikely due to defective hematopoiesis, as similar frequencies of CD11b + cells were detected in spleens of two group ( FIG. 31A ). Further, CD11b + cells continuously increased in synovial tissues of wild-type mice, but not STAT5-deficient mice, over a 7-day time course ( FIG. 31C ).
- MoDCs Monocyte-derived dendritic cells
- mBSA/IL-1 ⁇ arthritis model Campbell et al., 2011
- MoDCs were identified at low abundance in spleens and synovial tissues (data not shown).
- comparable frequencies of MoDCs were detected in both peripheral lymphoid tissues and synovial tissues between Stat5 +/+ and Stat5 ⁇ / ⁇ mice (data not shown).
- Neutrophils have great cytotoxic potential and contribute to the RA initiation and progression in multiple ways (Wright et al., 2014). It has been suggested that RA disease activity and joint destruction directly correlates with neutrophil influx to joints (Wright et al., 2014). Based on the differential expression of Ly6C and Ly6G, CD11b + myeloid cells can be classified into Ly6C lo Ly6G hi population (neutrophils) and Ly6C hi Ly6G ⁇ population (monocytes/macrophages).
- Ly6C lo Ly6G hi population continued to accumulate in synovial tissues over a 7-clay time course, and represented a predominant population among synovial CD11b + cells in wild-type mice at day 7 after AIA induction, whereas this population was persistently and dramatically diminished in STAT5-deficient mice ( FIG. 32A ).
- Giemsa stain it was validated that synovial-infiltrating Ly6C lo Ly6G hi population were neutrophils, which displayed typical polymorphonuclear characteristics with ring-shaped nuclei ( FIG. 32B ).
- synovial-infiltrating Ly6C hi Ly6G ⁇ population had mononuclear morphology and were likely monocytes/macrophages ( FIG.
- Neutrophils are recruited during inflammation, in which complex interactions between neutrophils and vascular endothelial cells direct neutrophil adhesion and transmigration from circulation to inflamed tissues (Kolaczkowska and Kubes, 2013).
- neutrophil adhesion and migration across monolayers of endothelial cells was significantly enhanced by GM-CSF as chemoattractant ( FIGS. 33A and 33B ), suggesting GM-CSF may mediate neutrophil recruitment to inflamed joints in AIA.
- Effective neutrophil apoptosis is crucial for the resolution of inflammation.
- neutrophil apoptosis is delayed with a result of extended survival and persistent inflammation (Wright et al., 2014).
- GM-CSF may mediate neutrophil recruitment and sustain neutrophil survival in synovial compartments and contribute to persistent synovitis.
- ⁇ a neutralizing antibody (1A8) specific for Ly6G was used to deplete neutrophils in vivo.
- the administration of neutralizing antibody resulted in significant improvement of joint swelling in AIA ( FIG. 32D ).
- neutrophils accumulation mediated by T H -cell-derived GM-CSF are important for AIA development.
- Cytokines are important mediators in the cross-talk between innate and adaptive immunity. As shown herein, several proinflammatory cytokines (IL-6, IL-1 ⁇ and TNF- ⁇ ), which are in association with RA pathogenesis (Choy and Panayi, 2001), were significantly reduced in synovial tissues of STAT5-deficient AIA mice ( FIGS. 28E and 30A-30C ). To gain insights into the mechanism underlying the observed cytokine reduction, the cellular sources of these proinflammatory cytokines were examined by fractionating synovial cells into different populations based the differential expression of surface markers ( FIG. 34A ).
- Cytokine mRNA expression level in CD45 + TCR ⁇ + population (T cells), CD45 + TCR ⁇ ⁇ CD11c ⁇ CD11b + population (mostly monocytes/macrophages and neutrophils) and CD45 + TCR ⁇ ⁇ CD11c + population (dendritic cells) was assessed by RT-PCR.
- GM-CSF as similar to IL-17 (as a control), was predominantly produced by synovial T cells ( FIG. 34B ), further reinforcing the importance of GM-CSF-producing T H cells.
- IL-6 and IL-1 ⁇ were mainly produced by myeloid cells, e.g. CD11b + population and CD11c + population ( FIG. 34B ).
- TNF- ⁇ was expressed by all three populations, with relatively lower abundance in T cells ( FIG. 34B ).
- Ly6C lo Ly6G hi population (neutrophils) and Ly6C hi Ly6G ⁇ population (monocytes/macrophages) were further analyzed, which showed that monocytes/macrophages were likely the major IL-6 producers whereas neutrophils seemed to be better producers of IL-1 ⁇ and TNF- ⁇ ( FIG. 34C ).
- BMDMs bone marrow-derived macrophages
- BMDCs bone marrow-derived dendritic cells
- BMDMs were primed with LPS for 6 h during which different concentrations of GM-CSF was added, followed by ATP stimulation.
- the addition of GM-CSF significantly enhanced the secretion of IL-1 ⁇ into culture supernatant as measured by ELISA ( FIG. 34H ).
- Synovial fibroblasts the active players in synovial inflammation (Muller-Ladner et al., 2007), also showed increased IL-1 ⁇ mRNA expression upon GM-CSF stimulation ( FIG. 34I ).
- An inducible effect of GM-CSF on TNF- ⁇ expression was not observed in BMDMs, BMDCs or synovial fibroblasts (data not shown).
- T H -cell-secreted GM-CSF may mediate synovial inflammation also via eliciting the expression of IL- and IL-1 ⁇ from myeloid cells and synovial fibroblasts.
- elegans 10526941 RIKEN cDNA 10394816 predicted gene D830046C22 gene 9282 10567448 dynein, axonemal, 10587503 SH3 domain heavy chain 3 binding glutamic acid-rich protein like 2 10437885 myosin, heavy 10411359 proteolipid polypeptide 11, protein 2 smooth muscle 10600122 X-linked 10579939 ubiquitin specific lymphocyte- peptidase 38 /// regulated 3B /// X- predicted gene linked lymphocyte- 9725 regulated 3C /// X- linked lymphocyte- regulated 3A 10587665 RIKEN cDNA 10370242 poly(rC) binding 4930579C12 gene protein 3 10350753 glutamate- ammonia ligase (glutamine synthetase) 10456296 mucosa associated lymphoid tissue lymphoma translocation gene 1 10380571 guanine nucleotide binding protein (G protein), gamm
- RNA exonuclease 2 homolog 10560791 predicted gene, EG381936 /// predicted gene 6176 10407159 ankyrin repeat domain 55 10603659 mediator complex subunit 14 10576854 cortexin 1 10353775 BEN domain containing 6 10573865 predicted gene 3579 10356886 solute carrier organic anion transporter family, member 4C1 10507273 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) 10424252 WDYHV motif containing 1 10518735 splA/ryanodine receptor domain and SOCS box containing 1 10562576 pleckstrin homology domain containing, family F (with FYVE domain) member 1 10375667 ring finger protein 130 10528268 protein tyrosine phosphatase, non- receptor type 12 10593205 REX2, RNA exonuclease 2 homolog ( S.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Oncology (AREA)
Abstract
Disclosed herein is a T-helper cell (“TH-GM” cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating TH-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying TH-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-TH-GM-mediated (e.g., TNF-α-mediated) inflammatory disorders, are also provided.
Description
- This application claims the benefit of Singapore Patent Application No. 10201406130P, filed Sep. 26, 2014. The entire teachings of the above application are incorporated herein by reference.
- A significant body of research has led to the current model of immunity and inflammation, as well as the dysregulation in immune and inflammatory disorders. It is currently understood that CD4+ helper T (TH) cells play a crucial role in host defense against various pathogens by orchestrating adaptive and innate immune responses. Upon T-cell receptor (TCR) activation by cognate antigen, naïve CD4+ T cells are committed to differentiate into at least live major subsets:
T H1,T H2,T H17, iTreg and TFH, which are modulated by cytokine milieus.T H1 andT H17 cells are known to be the primary effectors of inflammation. However, the pathogenic roles of eitherT H1 orT H17 in various inflammatory disorders remain unclear. For example, recent studies conflict with previously understood paradigm ofT H17 in multiple sclerosis (MS) pathogenicity (Haak et al., 2009), making it more challenging to identify potential drug targets for MS therapy. Similarly, while rheumatoid arthritis (RA) is traditionally understood to be a disorder mediated by tumor necrosis factor α (TNF-α), up to 40% of RA patients fail to respond to anti-TNF-α treatment. - Accordingly, there remains a significant unmet need for effective treatment methods for autoimmune and inflammatory disorders such as, e.g., MS and RA.
- The present disclosure relates, in part, to the identification of an interleukin-7 (IL-7)/signal transducer and activator of transcription 5 (STAT5)-regulated granulocyte macrophage colony-stimulating factor (GM-CSF)/IL-3-producing TH cells, termed TH-GM, which represent a distinct helper T cell subset with unique developmental and functional characteristics. Identified herein is an inflammatory pathway mediated by TH-GM cells (TH-GM-mediated inflammatory pathway), which represents an independent inflammatory pathway apart from known non-TH-GM-mediated inflammatory pathways (e.g., TNF-a, IL-6, and IL-1b pathways of inflammation). The present disclosure provides methods and compositions for diagnosing inflammatory disorders that are TH-GM-mediated, and modulating TH-GM cell function for the treatment of inflammatory disorders mediated by the TH-GM pathway.
- Accordingly, in one aspect, the present disclosure provides a method of diagnosing a TH-GM-mediated inflammatory disorder in a patient suffering from an inflammatory disorder, comprising: a) contacting a sample collected from a patient suffering from an inflammatory disorder with a detecting agent that detects a polypeptide or nucleic acid level of STAT5 (e.g., phospho-STAT5 (Tyr694)). IL-7, GM-CSF or IL-3, or a combination thereof; and h) quantifying the polypeptide or nucleic acid level of STAT5 (e.g., phospho-STAT5 (Tyr694)), IL-7, GM-CSF or IL-3, or a combination thereof, wherein an increased level of STAT5 (e.g., phospho-STAT5 (Tyr694)), interleukin-7 (IL-7), GM-CSF or interleukin-3 (IL-3), or a combination thereof relative to a reference level indicates that the patient suffers from a TH-GM-mediated inflammatory disorder.
- In another aspect, the present disclosure provides an isolated population of GM-CSF-secreting T-helper cells (TH-GM), wherein the TH-GM cells are differentiated from cluster of differentiation 4 (CD4+) precursor cells in the presence of IL-7 and activated STAT5, and wherein the TH-GM cells express GM-CSF and IL-3.
- In another aspect, the present disclosure provides a method of modulating TH-GM function, comprising contacting the TH-GM, or CD4+ precursor cells, or both, with a modulating agent that modulates TH-GM function.
- In some aspects, the present disclosure provides a method of treating a TH-GM-mediated inflammatory disorder in a patient in need thereof, comprising administering to said patient an effective amount of a modulating agent that modulates TH-GM cell function.
- In other aspects, the present disclosure provides a method of treating rheumatoid arthritis in a patient who exhibits limited response to anti-tumor necrosis factor alpha (TNF-α) therapy, comprising administering to said patient an effective amount of a modulating agent that modulates TH-GM function.
- In another aspect, the present disclosure provides a method of treating a STAT5-mediated inflammatory disorder in a patient in need thereof, comprising administering to the patient an effective amount of an agent that modulates STAT5 function.
- In further aspects, the present disclosure provides a method of screening to identify a modulator of TH-GM cell function, comprising contacting an isolated population of TH-GM cells, or an isolated population of CD4+ precursor cells, with a candidate agent, and determining a readout of TH-GM function in the presence or absence of the candidate agent, wherein a change in the readout of TH-GM function indicates that the candidate agent is a modulator of TH-GM function.
- The present disclosure enables the identification or classification between inflammatory disorders that are either primarily TH-GM-mediated, or primarily non-TH-GM-mediated (e.g., mediated by TNF-α, IL-6, and/or IL-1β), or both. Thus, using the methods described herein, it is possible to determine whether a patient suffering from, e.g., RA, suffers from an RA that is primarily TH-GM-mediated, or primarily non-TH-GM-mediated, or both. This differentiation allows for a more targeted and tailored method of treating inflammatory disorders such as RA, for which current treatments are only 40% effective. Further, the present disclosure provides methods and compositions for prognosing the progression of an inflammatory disorder so as to tailor the treatment according to the stage of the disease. Also provided herein are compositions and methods for and the treatment of inflammatory disorders, particularly those that are TH-GM-mediated.
- The foregoing will be apparent from the following more particular description of example embodiments of the invention.
-
FIGS. 1A-1D depict Stat5-conditional mutant mice are resistant to EAE. Clinical EAE scores (FIG. 1A ) and incidence (FIG. 1B ) of Stat5+/+ and Stat5−/− mice immunized twice with MOG35-55/CFA. Data are representative of three independent experiments (FIG. 1A ) or pooled from three experiments (FIG. 1B , n=18 per group). Clinical scores of EAE mice immunized once with MOG35-55/CFA (FIG. 1C , n=5 per group) or immunized twice with MOG35-55/LPS (FIG. 1D ). Data are representative of two independent experiments. -
FIGS. 2A-2D depict reduced neuroinflammation in Stat5 conditional mutant mice. Histology of spinal cord sections obtained from EAE mice atday 9 after 2nd immunization (FIG. 1A ). Images shown are representative of two independent experiments with three mice per group. Scale bars, 200 μm (top), 50 μm (bottom). CD4+ and CD11b+ cells in spinal cord sections were stained by immunofluorescence (FIG. 1B ). Images shown are representative of two independent experiments with three mice per group. Scale bars, 200 μm. CNS mononuclear cells were analyzed by flow cytometry at peak of disease (FIGS. 2C and 2D ). Right panels are cell proportions (FIG. 2C , right) or cell numbers (FIG. 2D , right) pooled from two experiments (n=9). -
FIGS. 3A and 3B depict the resistance to EAE in Stat5-deficient mice is independent ofT H1,T H17 or Treg cells. Flow cytometric analysis of IL-17 and IFN-γ expression by CNS-infiltrating CD4+ T cells at peak of disease (FIG. 3A ). Data are representative of three independent experiments. Percentage of CD25+ among CD4+ T cells in the CNS of Stat5+/+ and Stat5−/− EAE mice at peak of disease were analyzed by flow cytometry (FIG. 3B ). -
FIGS. 4A-4C depict conditional Stat5 mutant mice have no defect in CD4+ T cell generation in periphery. Spleens were obtained from MOG35-55/CFA-immunized Stat5+/+ and Stat5−/− mice at day 7 (FIG. 4A ) and day 21 (FIG. 4B ). The proportions of CD4+ and CD8+ T cells were analyzed by flow cytometry. The absolute number of CD4+ T cells was calculated (right panels). Data are representative of two independent experiments (FIG. 4A ) or pooled from two independent experiments (FIG. 4B ). IL-17 and IFN-γ expression by splenic CD4+ T cells of Stat5+/+ and Stat5−/− EAE mice was determined by intracellular cytokine staining (FIG. 4C ). Data are representative of three independent experiments. *p<0.5, **p<0.005, ***p<0.0005. -
FIGS. 5A-5D depict Stat5-deficient CD4+ T cells can infiltrate CNS but fail to induce effective neuroinflammation. CCR6, CXCR3 and CD69 expression by splenic CD4+ T cells of Stat5+/+ and Stat5−/− EAE mice was measured. Data are representative of two independent experiments with three to five mice per group (FIG. 5A ). CNS-infiltrating CD4+ T cells were analyzed atday FIGS. 5B-5D ). Cell numbers were calculated (FIG. 5D ). Data are representative of two independent experiments with three mice per group. *p<0.5. -
FIGS. 6A-6C show resistance to EAE in Stat5−/− mice is not caused by any defect in the survival of CD4+ T cells in the absence of STAT5. CD4+ T cell infiltration (FIG. 6A ) and clinical scores (FIG. 6B ) of Rag2−/− recipient mice transferred with different numbers of Stat5+/+ and Stat5−/− CD4+ T cells. Clinical scores and frequencies of CD4+ T cells in the CNS at day 21 (disease peak) of EAE induction (FIG. 6C ). *p<0.05. ***p<0.0005. -
FIGS. 7A-7C depict the intrinsic defect of Stat5-deficient CD4+ T cells in encephalitogenicity. Clinical EAE scores (FIG. 7A ) and incidence (FIG. 7B ) of Rag2−/− mice (n=5 per group) after adoptive transfer of 2 million MOG35-55-specific Stat5+/+ or Stat5−/− CD4+ T cells respectively. IL-17 and IFN-γ expression by CNS-infiltrating CD4+ T cells was measured at peak of disease (FIG. 7C ). Data represent two independent experiments, *p<0.05. -
FIGS. 8A-8D depict the diminished induction of GM-CSF in splenic Stat5−/− CD4+ T cells. InFIGS. 8A-8D , splenocytes were obtained from MOG35-55/CFA-immunized Stat5+/+ and Stat5−/− mice (n=3 per group) before disease onset and challenged with MOG35-55 at various concentrations for 24 h. GM-CSF secretion was measured by ELISA (FIG. 8A ). Golgiplug was added in the last 4 h of MOG35-55 (20 μg/ml) challenge and the frequencies of IL-17+ and GM-CSF+ cells among CD4+CD44hi T cells were measured (FIG. 8B ). InFIGS. 8C and 8C , splenocytes were obtained from MOG35-55/CFA-immunized Stat5−/−, Stat3−/− or wild-type control mice and stimulated with PMA/Ionomycin in the presence of Golgiplug for 4 h. The frequencies of IL-17+ and GM-CSF+ cells among splenic CD4+CD44hi T cells were measured by intracellular cytokine staining. *p<0.05, ***p<0.001. -
FIGS. 9A-9C depict the diminished induction of GM-CSF in CNS-infiltrating Stat5−/− CD4+ T cells. InFIG. 9A , IL-17, IFN-γ and GM-CSF expression by CNS-infiltrating CD4+ T cells of Stat5+/+ and Stat5−/− mice was measured at peak of disease. The percentage of GM-CSF+ cells among IL-17+ or IFN-γ+ cells was calculated (bottom right.FIG. 9A ). IL-17. IFN-γ and GM-CSF expression by CNS-infiltrating CD4+ T cells of Rag2−/− recipient mice at peak of disease in adoptive transfer EAE (FIG. 9B ). Time-course analysis of cytokine mRNA expression in the CNS of naïve and MOG35-55/CFA-immunized Stat5+/+ and Stat5−/− mice (n=3 per group at each time point). The RT-PCR data were normalized to Rn18S, and expression in naïve mice was set to 1 (FIG. 9C ). Data represent two independent experiments. *p<0.05. -
FIGS. 10A-10C show STAT5-mediated GM-CSF induction is independent of IL-23 or IL-1β signaling. InFIG. 10A , purified CD4+ T cells were cultured with TGF-β and IL-6 for 3 days, followed by starvation for 6 h. Then cells were treated with various cytokines for 30 min. and pSTAT3 and pSTAT5 was determined by immunoblotting. STAT3 and STAT5 were further detected after stripping.FIG. 10B shows the mRNA expression of IL-23R and IL-1R1 in splenic CD4+ T cells of Stat5+/+ and Stat5−/− EAE mice (n=3 per group). The RT-PCR data were normalized to β-Actin. InFIG. 10C , splenocytes were obtained from MOG35-55/CFA-immunized WT mice before disease onset and challenged with MOG35-55 (20 μg/ml) in the absence or presence of IL-2 for 48 h. The frequencies of GM-CSF+ and IL-17+ cells among CD4+CD44hi T cells were measured by flow cytometry. *p<0.05. -
FIGS. 11A-11C depict IL-7-induced STAT5 activation promotes GM-CSF expression in autoreactive CD4+ T cells. Splenocytes were obtained from MOG35-55/CFA-immunized Stat5+/+ and Stat5−/− mice before disease onset and challenged with MOG35-55 (20 μg/ml) in the absence or presence of IL-7 for 48 h. Frequencies of GM-CSF+ and IL-17+ cells among CD4+CD44hi T cells were measured by flow cytometry (FIG. 11A ). GM-CSF secretion was measured by ELISA (FIG. 11B ). Data represent two independent experiments with two to three mice per group. Splenic CD62LhiCD44lo and CD62LloCD44hi T cells from MOG35-55/CFA-immunized mice were sorted out. Cells were stimulated with anti-CD3 and anti-CD28 in the absence or presence of IL-7 for 4 h and then harvested for the analysis of GM-CSF expression by RT-PCR (FIG. 11C ). *p<0.05 -
FIGS. 12A-12F depict IL-7Rα neutralization attenuates GM-CSF expression and ameliorates EAE. Clinical scores of EAE mice (n=5) treated with anti-IL-7Rα or normal IgG given every other day fromday 5 after 2nd immunization, as indicated by arrows. Data represent two independent experiments (FIG. 12A ). Spinal cord sections were obtained from EAE mice atday 11 after 2nd immunization. Immune cell infiltration was assessed histologically. Images shown are representative of three individuals per group. Scale bars, 200 μm (top), 50 μm (FIG. 12B , bottom). The percentages of CD4+ and CD8+ T cells in spleens of EAE mice. Data represent two independent experiments (FIG. 12C ).FIGS. 12D and 12E illustrate the frequencies of GM-CSF+, IL-17+ and IFN-γ+ cells among CD4+ T cells in the CNS of EAE mice receiving different treatment. The mRNA expression of IFN-γ, IL-17 and GM-CSF in the CNS of EAE mice (FIG. 12F ). *p<0.05 -
FIGS. 13A and 13B depict the differentiation of GM-CSF-expressing TH cells is distinct fromT H17 andT H1. Naïve CD4+ T cells were primed with plate-bound anti-CD3 and soluble anti-CD28 in the presence of a combination of various cytokines and neutralizing antibodies as indicated. GM-CSF, IL-17 and IFN-γ expression was analyzed by intracellular staining (FIG. 13A ) or RT-PCR (FIG. 13B ) -
FIGS. 14A-14D show the effect of IL-2 and IL-6 on TH-GM differentiation from naïve T cells. GM-CSF and IFN-γ expression in naive CD4+ T cells activated for 72 h with anti-CD3 alone or plus anti-CD28 (FIG. 14A ). InFIG. 14B , sorted naïve CD4+ T cells were stimulated with anti-CD3 and anti-CD28 in the presence of neutralizing antibodies against IL-12 and IFN-γ without or with the addition of IL-6. The frequencies of GM-CSF+ and IL-17+ cells were measured by intracellular staining (FIG. 14B ). InFIG. 14C , naïve CD4+ T cells from Stat3+/+ and Stat3−/− mice were polarized under conditions as indicated for 72 h. The frequencies of GM-CSF+ and IL-17+ cells were analyzed. InFIG. 14D , naïve CD4+ T cells were activated with anti-CD3 and anti-CD28 in the presence of IL-2 or anti-IL-2. The frequencies of GM-CSF+, IL-17+ and IFN-γ+ cells were analyzed. -
FIGS. 15A-15F depict IL-7-STAT5 signaling programs TH-GM differentiation from naïve precursor cells. Naïve CD4+ T cells were primed with plate-hound anti-CD3 and soluble anti-CD28 in the presence of various concentration of IL-7 as indicated. GM-CSF and IFN-γ expression was analyzed by intracellular staining (FIG. 15A ) or ELISA (FIG. 15B ). InFIGS. 15C and 15D , Stat5+/+ and Stat5−/− naïve CD4+ T cells were activated with anti-CD3 and anti-CD28 in the presence IL-7 for 3 days. GM-CSF, IL-17 and IFN-γ expression was analyzed by intracellular cytokine staining (FIG. 15C ). GM-CSF secretion was measured by ELISA (FIG. 15D ). Immunoblotting of pSTAT5 and STAT5 in IL-7-stimulated CD4+ T cells isolated from Stat5−/− or control mice (FIG. 15E ). The ChIP assay was performed with Stat5+/+ and Stat5−/− CD4+ T cells using normal IgG or STAT5-specific antibody. The binding of antibodies to Csf2 promoter region was detected by RT-PCR (FIG. 15F ). -
FIGS. 16A and 16B depict the differentiation conditions for TH-GM subset. Naïve CD4+ T cells were activated with anti-CD3 and anti-CD28 in the presence of IL-7 or/and anti-IFN-γ as indicated. GM-CSF. IL-17 and IFN-γ expression was analyzed (FIG. 16A ). The mRNA expression of T-bet and RORγt in naïve. TH1 (IL-12+anti-IL-γ), TH17 (TGF-β+IL-6+anti-IFN-γ+anti-IL-4) and TH-GM cells (IL-7 anti-IFN-γ) (FIG. 16B ). The RT-PCR data were normalized to Gapdh, and expression in naïve T cells was set to 1. -
FIGS. 17A-17E illustrate that IL-7 but not IL-2 induces STAT5 activation and GM-CSF expression in naïve CD4+ T cells.FIGS. 17A-17C show flow cytometry of CD25 and CD127 on the surface of naïve CD4+ T cells or cells activated with anti-CD3 and anti-CD28 at various time points as indicated. Activation of STAT5 in naïve CD4+ T cells stimulated with IL-2 or IL-7 for 30 min (FIG. 17D ).FIG. 17E shows the mRNA expression of GM-CSF in naïve CD4+ T cells stimulated with anti-CD3 and anti-CD28 in the presence of IL-2 or IL-7. The RT-PCR data were normalized to β-Actin, and expression in naïve T cells activated for 2 h without cytokine was set to 1. -
FIGS. 18A-18C show that both IL-2 and IL-7 can induce STAT5 activation and GM-CSF expression in activated CD4+ T cells. As shown inFIGS. 1.8A and 18B , CD4+ T cells were activated with anti-CD3 and anti-CD28 for 3 days. After resting in fresh medium, cells were stimulated with IL-2 or IL-7 at various time points. The pTyr-STAT5 and β-Actin were detected by immunoblotting (FIG. 18A ). GM-CSF mRNA expression was measured by RT-PCR (FIG. 18B ). The RT-PCR data were normalized to 13-Actin, and expression in cells without cytokine stimulation was set to 1. The ChIP assay shown inFIG. 18C was performed with normal IgG or STAT5-specific antibody. The binding of antibodies to Csf2 promoter region was detected by RT-PCR. -
FIG. 19 depicts surface molecules selectively expressed at high level or low level in TH-GM subset as characterized by microarray analysis. These surface molecules specific for each lineage serves as markers, signatures and potential targets for novel diagnosis, treatment and prevention of autoimmune inflammation including, but not limited to multiple sclerosis and rheumatoid arthritis. These cell surface molecules are listed in detail in Table 1. The order of naïve, Th1, Th17, and Th-GM as indicated in the figure insert is the same as that appears for the bars in each graph. -
FIGS. 20A-20D show that IL-3 is preferentially expressed in TH-GM cells. InFIGS. 20A and 20B , naïve CD4+ T cells were activated with anti-CD3 and anti-CD28 underT H1—(IL-12+anti-IL-4),T H17−(TGF-β+IL-6+anti-IFN-γ+anti-IL-4) and TH-GM—(GM-CSF+ TH, IL-7+anti-IFN-γ+anti-IL-4) polarizing conditions. GM-CSF and IL-3 expression was analyzed by intracellular staining (FIG. 20A ). The mRNA expression of IL-3, EBI-3, PENK or RANKL cytokines was measured by RT-PCR (FIG. 20B ). Frequency of IL-3+ cells differentiated without or with IL-7 (FIG. 20C ). GM-CSF and IL-3 expression by WT or STAT5-deficient GM-CSF-producing TH cells (FIG. 20D ). -
FIG. 21 depicts clinical EAE scores of Rag2−/− mice (n=3˜6 mice per group) after adoptive transfer of 6×105 various MOG35-55-specific TH subsets. -
FIGS. 22A-27E depict inhibition of STAT5 activation suppresses TH-GM cell differentiation in vitro. CD4+ T cells were pre-incubated with STAT5 inhibitor (Calbiochem) (FIG. 22A ) or JAK3 inhibitor (FIG. 22B ) at indicated concentrations or vehicle (−) for 1 h before stimulation with IL-7 for 30 min. Activation (Tyr694 phosphorylation) of STAT5 was determined by immunoblotting. CD4+ T cells were pre-incubated with STAT5 inhibitor at indicated concentrations or vehicle (−) for 1 h before stimulation with IL-6 for 30 min. Activation (Tyr705 phosphorylation) of STAT3 was determined by immunoblotting (FIG. 22C ). InFIG. 221 ), CD4+ T cells were pre-incubated with STAT5 inhibitor at indicated concentrations or vehicle (−) for 1 h before stimulation with IFN-γ for 30 min. Activation (Tyr701 phosphorylation) of STAT1 was determined by immunoblotting. InFIG. 22E , naïve CD4+ T cells were isolated and activated under neutral condition or TH-GM cell-favoring condition with the addition of different concentrations of STAT5 inhibitor for 3 days. GM-CSF and IFN-γ expression was analyzed by intracellular cytokine staining and flow cytometry. -
FIGS. 23A-23D depict targeting STAT5 activation by chemical inhibitor ameliorates EAE. (FIG. 23A ) Clinical EAE scores of wild-type control mice (n=5) or administrated with STAT5 inhibitor (Calbiochem). Arrow indicates the treatment points. (FIG. 23B ) Histology of spinal cords atclay 18 of EAE mice receiving different treatments. (FIG. 23C ) Intracellular staining and flow cytometry of CNS-infiltrating CD4+ T cells at peak of disease. (FIG. 23D ) Whole CNS was harvest for RNA extraction. GM-CSF mRNA expression was analyzed by RT-PCR. Data represent two independent experiments. *p<0.05. -
FIGS. 24A-24E depict GM-CSF-producing TH cells are in association with human RA. Plasma concentrations of GM-CSF and TNF-α in healthy control HC (n=32) and RA (n=47) were quantified by ELISA (FIG. 24A ). InFIGS. 24B and 24C , peripheral blood mononuclear cells (PBMCs) were collected from healthy control (HC) and rheumatoid arthritis (RA) patients, and were stimulated for 4 h with PMA/lonomycin in the presence of Golgiplug, followed by intracellular cytokine staining. Representative flow cytometry of GM-CSF, IFN-γ and IL-17 in CD4+ T cells (FIG. 24B ) and statistics of n>=9 per group (FIG. 24C ) are shown.FIG. 241D shows the correlation between the frequency of GM-CSF+IFN-γ TH cells and the level of plasma GM-CSF in peripheral blood of RA patients (n=18). Cytokine expression by CD4+ T cells derived from synovial fluid of RA patients was analyzed by intracellular cytokine staining and flow cytometry (FIG. 24E ). A representative image of three cases was shown. *p<0.05, **p<0.01, ***p<0.001; ns, not significant. -
FIGS. 25A-25E depict distinguishable effects of GM-CSF and TNF-α in mouse AIA.FIG. 25A shows knee joint swelling of wild-type mice over 7 days after intraarticular injection of 100 μg mBSA in AIA model, receiving treatment with control IgG, GM-CSF-specific and TNF-α-specific neutralizing antibodies separately or in combination (n=5 per group) at indicated times (arrows).FIG. 25B shows knee joint swelling of Stat5+/+ and Stat5−/− mice (n=6 per group) over 7 days after arthritis induction. Data are representative of more than three independent experiments. Representative images of joint sections stained with H&E (FIG. 25C ) or Safranin-O/Fast Green (FIG. 25D ) atday 7 after arthritis induction as inFIG. 25C . Bars, 500 μm (FIG. 25C upper panels andFIG. 25D ) or 100 μm (FIG. 25C lower panels). Arrow in upper panels (FIG. 25C ) indicated hone destruction. InFIG. 25E , serum concentrations of GM-CSF, IFN-γ and TNF-α in Stat5+/+ and Stat5−/− AIA mice were quantified by ELISA. Statistics of n>=8 per group were shown. *p<0.05, **p<0.01, ***p<0.001. -
FIGS. 26A-26D depicts mice with Stat5 deletion in T cells are resistant to CIA. (FIG. 26A ) Representative images of paw swelling of Stat5+/+ and Stat5−/− mice atday 40 after collagen II/CFA immunization in CIA model. (FIG. 26B ) Clinical score of Stat5+/+ and Stat5−/− mice (n=5 per group) over 40 days after collagen II/CFA immunization. Data are representative of two independent experiments. (FIG. 26C ) Representative images of paw sections stained with H&E atclay 40. (FIG. 26D ) Serum concentrations of TNF-α (n=8 per group) were quantified by ELISA. *p<0.05, **p<0.01, ***p<0.001. -
FIGS. 27A-27E depicts STAT5-deficient CD4+ T cells are defective in arthritogenic potential. (FIGS. 27A and 27B ) Representative flow cytometry of CD4+ T cells in spleens (FIG. 27A ) and inguinal lymph nodes (FIG. 27B ) of Stat5+/+ and Stat5−/− mice atday 7 after AIA induction. (FIGS. 27C and 27D ) Synovial tissues were harvested from Stat5+/+ and Stat5−/− mice atday 7 after AIA induction, and dissociated into single cells. Cell numbers of CD45+ leukocytes were calculated (FIG. 27C ). The percentages of CD4+ T cells among CD45+ fraction were analyzed by flow cytometry, and cell numbers were calculated (FIG. 27D ). (FIG. 27E ) Histological analysis of joint sections from wild-type naïve mice atday 7 after being transferred with in vitro-expanded antigen-reactive CD4+ T cells and followed with intraarticular injection of mBSA. Bars, 100 μm. Data represent two independent experiments. *p<0.05; ns, not significant. -
FIGS. 28A-28G depicts STAT5-regulated GM-CSF-producing TH cells are crucial for AIA. Spleens and synovial tissues were collected from Stat5+/+ and Stat5−/− mice atday 7 after arthritis induction. (FIG. 28A ) Splenic fractions of wild-type AIA mice (n=3) were stimulated under indicated conditions for 18 h. GM-CSF levels in supernatant were quantified by ELISA. (FIGS. 28B-28D ) Intracellular staining and flow cytometry of GM-CSF, IL-17 and IFN-γ in splenic CD4+CD44hi effector T cells (FIG. 28B ) or in synovial infiltrating CD4+ T cells (FIGS. 28C and 28D ) after restimulation for 4 h with PMA/Ionomycin in the presence of Golgiplug. Representative images and statistics of n=5 (FIG. 28B , right panels) or n=3 (FIG. 28D , right panels) per group were shown. Data represent two independent experiments. (FIG. 28E ) Protein expression of several proinflammatory cytokines in synovial tissues was measured by ELISA. (FIGS. 28F and 28G ) Representative images of joint sections stained with H&E (FIG. 28F ) or Safranin-O/Fast Green (FIG. 28G ) atday 7 after intraarticular injection of mBSA alone to the right knee joints and mBSA supplemented with GM-CSF to the left knee joints. Bars, 500, 50 or 200 μm as indicated. Data represent two independent experiments.*p<0.05, **p<0.01. ***p<0.001; ns, not significant. “Splenocytes” represent the left-most bars in each group, “splenocytes depleted of CD4+ T cells” represent the middle bars in each group, and “CD4+ T cells” represent the right-most bars in each group. -
FIGS. 29A-29C depicts loss of STAT5 results in impaired GM-CSF production by antigen-specific CD4+ T cells. Spleens and inguinal LNs were collected from Stat5+/+ and Stat5−/− mice atday 7 after arthritis induction, and dissociated into single cell suspensions. Then, cells were stimulated with mBSA (20 μg/ml) for 24 h. (FIG. 29A ) Golgiplug was added in the last 4 h of culture, followed by intracellular staining and flow cytometry. Representative plots of GM-CSF, IL-17 and IFN-γ expression in CD4+CD44hi effector T cells was shown, representing two independent experiments. (FIGS. 29B and 29C ) Secreted cytokines in the supernatant (n=3 per group) were quantified by ELISA. Data represent two independent experiments. *p<0.05; ns, not significant. -
FIGS. 30A-30C depicts loss of STAT5 impairs IL-6 and IL-1β expression in synovial tissues of arthritic mice. (FIGS. 30A-30C ) The mRNA (FIGS. 30A and 30 C) and protein (FIG. 30B ) expression of several proinflammatory cytokines in synovial tissues of Stat5+/+ and Stat5−/− mice (n>=3 per group) atday -
FIGS. 31A-31D depicts SAT5-induced GM-CSF expression mediates CD11b+ cell accumulation in inflamed synovial tissues. (FIG. 31A ) The frequencies of CD11b+ cells in spleens of Stat5+/+ and Stat5−/− AIA mice were analyzed by flow cytometry. Statistics of n=3 per group (right panel) were shown. (FIG. 31B ) Synovial tissues were harvested from Stat5+/+ and Stat5−/− mice atday 7 after arthritis induction, and dissociated into single cell suspensions. The percentage of CD11b+ myeloid cells among CD45+ fraction was analyzed by flow cytometry. Statistics of n=5 per group were shown in right panel. (FIG. 31C ) Representative flow cytometry of CD11b+ and CD4+ cells gated on synovial CD45+ fraction over 7 days after arthritis induction. (FIG. 31D ) Flow cytometric analysis of CD4+, CD11b+ and B220+ cell infiltration in synovial tissues of Stat5+/+ and Stat5−/− mice atday 7 after intraarticular injection of mBSA alone to the right knee joints and mBSA supplemented with GM-CSF to the left knee joints. Representative images were shown. All data shown are representative of two independent experiments. **p<0.01; ns, not significant. -
FIGS. 32A-32D depicts GM-CSF mediates neutrophil accumulation in arthritic mice. (FIG. 32A ) Flow cytometric analysis of Ly6C and Ly6G expression gated on synovial CD45+CD11b+ fraction over 7 days after arthritis induction. (FIG. 32B ) Giemsa stain of sorted Ly6ChiLy6G− and Ly6CloLy6Ghi cells from synovial tissues of AIA mice. Scale bar, 100 μm (left) or 20 μm (right). (FIG. 32C ) Flow cytometric analysis of Ly6ChiLy6G− and Ly6CloLy6Ghi populations in synovial tissues of Stat5+/+ and Stat5−/− mice atday 7 after intraarticular injection of mBSA alone to the right knee joints and mBSA supplemented with GM-CSF to the left knee joints. (FIG. 32D ) Knee joint swelling of wild-type mice treated with Ly6G-specific neutralizing antibody (1A8) or IgG control (n=5 per group) over 3 days after intraarticular injection of mBSA in AIA model. Arrows indicate time points of antibody administration. *p<0.05. -
FIGS. 33A-33C depicts GM-CSF enhances neutrophil transmigration and delay apoptosis in vitro. (FIG. 33A ) Percentages of migrated neutrophils with or without GM-CSF as chemoattractant in transmigration assay at 3 h post start. (FIG. 33B ) Microscopic images of CFSE-labeled neutrophils in the bottom of the lower chamber in transmigration assay. (FIG. 33C ) Sorted neutrophils were cultured in vitro with or without GM-CSF (20 ng/ml) for 24 h. Neutrophils undergoing apoptosis were examined by Annexin V and propidium iodide (PI) co-staining. A representative flow cytometry of three repeats was shown. *p<0.05. -
FIGS. 34A-34I depicts GM-CSF mediates proinflammatory cytokine expression by myeloid cells and synovial fibroblasts in arthritic mice. Synovial tissues were dissected from wild-type AIA mice and dissociated into single cell suspensions. (FIG. 34A ) Flow cytometry plots depicting the fractionation into different populations based on differential expression of surface markers. (FIG. 34B ) The mRNA expression of several proinflammatory cytokines in sorted CD45+TCRβ+ (TCRβ+ in short). CD45+TCRβ−CD11c−CD11b+ (CD11b+) and CD45+TCRβ−CD11c+ (CD11c+) populations was measured by qPCR. The qPCR data were normalized to GAPDH. (FIG. 34C ) The mRNA expression of IL-6, IL-1β and TNF-α in sorted Ly6ChiLy6G− and Ly6CloLy6Ghi populations (gated on CD11b+ cells). The qPCR data were normalized to GAPDH. (FIGS. 34D and 34E ) The mRNA expression of IL-6 and IL-1β by BMDMs (FIG. 34D ) and BMDCs (FIG. 34E ) upon stimulation with 20 ng/ml GM-CSF for 1 h. The qPCR data were normalized to GAPDH. (FIGS. 34F and 34G ) BMDMs (FIG. 34F ) and BMDCs (FIG. 34G ) were stimulated with GM-CSF at indicated concentrations (n=3 per group) for 18 h. The secretion of IL-6 in the culture supernatant was quantified by ELISA. (FIG. 34H ) BMDMs were primed with LPS (100 μg/ml) in the presence of GM-CSF at indicated concentrations (n=3 per group) for 6 h, followed by stimulation with ATP (5 mM) for 30 min. The secretion of IL-1β in the culture supernatant was quantified by ELISA. (FIG. 34I ) Cells were cultured in DMEM medium supplemented with 10% PBS for over 20 days with more than 5 passages to obtain synovial fibroblasts. Synovial fibroblasts were stimulated with GM-CSF (20 ng/ml) for 1 h and harvested for RNA extraction. The mRNA expression of IL-1β was measured by qPCR. The qPCR data were normalized to GAPDH. All data shown represent two independent experiments.*p<0.05, **p<0.01. - A description of example embodiments of the invention follows.
- The present disclosure relates, in part, to the identification of a granulocyte macrophage colony stimulating factor (GM-CSF)-secreting T helper cell, termed “TH-GM”. As detailed herein. IL-7/STAT5 signaling programs the differentiation of precursor CD4+ cells to TH-GM, a process which is further modulated by IL-2 and IL-23 signaling. TH-GM cells are characterized by, e.g., GM-CSF and IL-3 production. TH-GM cells are distinct from the known helper
T cells T H1 andT H17, with respect to, e.g., differentiation conditions, transcriptional regulation and effector cytokine expression. For example, IL-12/IFN-γ and TGF-0/IL-6, which mediate (e.g., promote the development of)T H1 andT H17, respectively, potently suppress the development of TH-GM from naïve CD4+ precursor cells, establishing that TH-GM cells develop via a lineage distinct fromT H1 andT H17. Thus, the present disclosure provides a distinct network of factors, unique from factors known to mediateT H1 orT H17, that mediate TH-GM function (e.g., its differentiation and pathogenicity). - As shown herein, TH-GM cells preferentially induce EAE as compared with
T H1 andT H17 cells, indicating that TH-GM cells represent the primary effectors in the pathogenesis of autoimmune neuroinflammation in humans. Moreover, blockade of IL-7 signaling and/or inhibition of STAT5 function (e.g., abrogation of expression or inhibition of STAT5 activity) attenuates autoimmune neuroinflammation associated with diminished GM-CSF production by TH-GM cells. Further, blockade of TH-GM cell-secreted GM-CSF ameliorates experimental arthritis in a TNT-α-independent manner, indicating an approach for the treatment of, e.g., rheumatoid arthritis patients who are unresponsive to TNF-α antagonistic drugs. Thus, the present disclosure enables one to distinguish between an inflammatory disorder (e.g., RA) that is mediated by the TH-GM pathway (e.g., a disorder that results from TH-GM pathogenicity through the action of, e.g., GM-CSF and/or IL-3, or any factor associated with the TH-GM pathway), or an inflammatory disorder that is mediated by, e.g., TNF-α, IL-6, and/or IL-1β pathways (i.e., non-TH-GM-mediated pathway). For example, a patient who has, e.g., RA may be afflicted with a type of RA that is primarily TH-GM-mediated, or primarily non-TH-GM-mediated (e.g., TNF-α-mediated or IL-6 mediated). The present disclosure enables the classification between TH-GM-mediated and non-TH-GM-mediated inflammation, allowing for a more precise diagnosis, prognosis, and treatment in an individual who is afflicted with an inflammatory disorder such as RA or MS. - As demonstrated herein, the present disclosure identifies a helper T cell subset (TH-GM), provides the molecular basis for the commitment and development of this subset from naïve precursor cells in vitro and in vivo, and demonstrates TH-GM cells as the primary pathogenic cells in autoimmune diseases and inflammatory disorders, for example, MS and RA. Thus, provided herein are compositions and methods for diagnosing inflammatory conditions primarily mediated by TH-GM cells, thereby enabling the identification of, e.g., RA patients who are non-responsive to TNF-α therapy (e.g., TNF-α inhibitor based therapy), as well as compositions and methods for modulating TH-GM function to treat autoimmune and inflammatory disorders. The methods of modulating TH-GM function include, e.g., administering agents to modulate the function (e.g., signaling, expression or activity) of the network of factors (e.g., IL-2/IL-7/STAT5/GM-CSF/IL-3) that mediate TH-GM function in an effective amount to modulate the function (e.g., development and pathogenicity) of TH-GM cells. In particular, the disclosure provides methods and composition for differentiating and diagnosing an inflammatory disorder, e.g., multiple sclerosis (MS), rheumatoid arthritis (RA) as primarily mediated by either TH-GM cells (i.e. TH-GM pathway mediated) or by non-TH-GM mechanism (e.g., TNF-α, IL-6, and/or IL-1β pathways), or both. Also provided herein are compositions and methods for and the treatment of inflammatory disorders, particularly those that are TH-GM-mediated.
- Accordingly, in one aspect, the present disclosure provides a method of diagnosing a TH-GM-mediated inflammatory disorder in a patient suffering from an inflammatory disorder. In some embodiments, the method comprises contacting a sample collected from a patient suffering from an inflammatory disorder with a detecting agent that detects a polypeptide or nucleic acid level of a TH-GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof; and quantifying the polypeptide or nucleic acid level of the TH-GM-mediating factor (e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof), wherein an increased level of a TH-GM-mediating factor (e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof) relative to a reference level indicates that the patient suffers from a TH-GM-mediated inflammatory disorder, thereby diagnosing a TH-GM-mediated inflammatory disorder in a patient suffering from an inflammatory disorder.
- As used herein, a “TH-GM-mediated” inflammatory disorder refers to a subtype of an inflammatory disorder (e.g., a subtype of RA or MS) that results from the physiological action of any one or more of the network of factors in the pathway that modulate TH-GM function (a “TH-GM-mediating factor”), as described herein. Such factors include, e.g., GM-CSF, activated STAT5, IL-7, IL-2, and IL-3. In a particular embodiment, STAT5 is activated STAT5, wherein tyrosine at position 694 is phosphorylated.
- In some embodiments, the level of a TH-GM-mediating factor (e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof) that is not increased relative to a reference level indicates that the patient suffers from a non-TH-GM-mediated inflammatory disorder.
- In certain embodiments, the method further comprises administering to the patient a TNF-α therapy, as described herein, if the level of a TH-GM-mediating factor (e.g. STAT5, IL-7, GM-CSF or IL-3, or a combination thereof) is not increased relative to a reference level.
- As used herein, a “non-TH-GM-mediated” inflammatory disorder refers to an inflammatory disorder (e.g., RA or MS) that is primarily caused by, e.g., TNF-α, IL-6, or IL-1β (and/or factors in the TNF-α, IL-6, or IL-1β pathway). As such, a “TH-GM-mediated” inflammatory disorder results primarily (or exclusively) from a pathway that is distinct from one or more of the pathways that leads to a “non-TH-GM-mediated” inflammatory disorder (e.g., the pathways associated with TNF-α, IL-6, or IL-1β).
- However, as those of skill in the art would appreciate, a TH-GM-mediated inflammatory disorder does not necessarily exclude the possibility that the inflammatory disorder could also be partially non-TH-GM-mediated (e.g., mediated by TNF-α, IL-6, or IL- and/or factors in the TNF-α, IL-6, or IL-1β pathway). Thus, a classification or diagnosis as “TH-GM-mediated” is synonymous with “primarily/predominantly TH-GM-mediated”, and a classification as “non-TH-GM-mediated” is synonymous with “primarily/predominantly non-TH-GM-mediated.” For example, without wishing to be bound by any particular theory, an inflammatory disorder in its early stage may be TH-GM-mediated. As the inflammatory condition advances to a late stage characterized by, e.g., tissue damage, the inflammatory disorder becomes progressively non-TH-GM-mediated. In some embodiments, a TH-GM-mediated inflammatory disorder is a condition that is responsive to modulation of TH-GM function, as determined by clinical standards; a non-TH-GM-mediated inflammatory disorder is a condition that is responsive to, e.g., TNF-α, IL-6, or IL-1β therapy, as determined by clinical standards. In certain embodiments, an inflammatory disorder can be responsive to modulation of TH-GM function as well as TNF-α, IL-6, and/or IL-1β therapy.
- In some embodiments, the sample can be e.g., peripheral blood, cerebrospinal fluid, synovial fluid, or synovial membrane, or a combination thereof.
- In some embodiments, the inflammatory disorder is an autoimmune disorder. In certain embodiments, the inflammatory disorder can be any inflammatory disorder mediated by TH-GM cells, and includes, but is not limited to rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Crohn's disease, diabetes. Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism, Irritable Bowel Syndrome (IBS), lupus erythematosus, polymyalgia rheumatic, psoriasis, psoriatic arthritis, Raynaud's syndrome/phenomenon, reactive arthritis (Reiter syndrome), sarcoidosis, scleroderma, Sjögren's syndrome, ulcerative colitis, uveitis, or vasculitis.
- As used herein, a “detecting agent” refers to, e.g., an antibody, a peptide, a small molecule, or a nucleic acid that binds to a polypeptide or nucleic acid to be detected (e.g., STAT5 (e.g., phospho-STAT5 (Tyr694)), IL-7, GM-CSF or IL-3), and enables the quantification of the polypeptide or nucleic acid to be detected. The detecting agent can be detectably labeled, or quantifiable by other means known in the art.
- In some embodiments, the detecting agent is an antibody that binds to the polypeptide of STAT5, IL-7, GM-CSF or IL-3. In one embodiment, the antibody is one that binds to an activated STAT5 (e.g., phosphorylated STAT5), as described herein. Antibodies to STAT5 (e.g., phospho-STAT5 (Tyr694)), IL-7, GM-CSF or IL-3 suitable for use in the present method are known and commercially available in the art (e.g., STAT5 Ab: C-17 from Santa Cruz Biotech; Phospho-STAT5 (Tyr694) Ab: #9351 or #9359 from Cell Signaling; IL-7 Ab: clone BVD10-40F6 from BD Pharmingen; IL-7R Ab: clone SB/14 from BD Pharmingen; GM-CSF Ab: clone MP1-22E9 from BD Pharmingen; IL-3 Ab: clone MP2-8F8 from BD Pharmingen.
- In other embodiments, the detecting agent is a nucleic acid that hinds to the nucleic acid of STAT5. IL-7, GM-CSF and/or IL-3. Nucleic acid molecules encoding a, e.g., STAT5. IL-7, GM-CSF and/or IL-3 sequence, or fragments or oligonucleotides thereof, that hybridize to a nucleic acid molecule encoding a e.g., STAT5, IL-7, GM-CSF and/or IL-3 polypeptide sequence at high stringency may be used as a probe to monitor expression of nucleic acid levels of STAT5, IL-7, GM-CSF and/or IL-3 in a sample for use in the diagnostic methods of the disclosure. Methods of quantifying nucleic acid levels are routine and available in the art.
- In some embodiments, the method further comprises contacting the sample with a detecting agent that detects a polypeptide or nucleic acid level of one or more genes (as well as the gene product) listed in Table 1. As described herein, Table 1 lists genes that are differentially expressed in TH-GM cells as well as genes that are differentially expressed on the surface of TH-GM cells, as compared to
T H1 orT H17 cells. - In a particular embodiment, the method further comprises contacting the sample with a detecting agent that detects the polypeptide or nucleic acid level of basic helix-loop-helix family member e40 (BHLHe40), chemokine (C-C Motif) Receptor 4 (CCR4), and/or CCR6.
- Standard methods may be used to quantify polypeptide levels in any sample. Such methods include, e.g., ELISA, Western blotting, immunohistochemistry, fluorescence activated cells sorting (FACS) using antibodies directed to a polypeptide, and quantitative enzyme immunoassay techniques known in the art. Such methods are routine and available in the art. Similarly, methods for quantifying nucleic acid levels (e.g., mRNA) are known in the art.
- In the diagnostic method of the present disclosure, an increased level of STAT5 (e.g., activated phospho-STAT5 (Tyr694)), IL-7, GM-CSF and/or IL-3 relative to a reference level indicates that the patient suffers from a TH-GM-mediated inflammatory disorder.
- In some embodiments, a STAT5 (e.g., activated phospho-STAT5 (Tyr694)), IL-7, GM-CSF and/or IL-3 level that is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 160%, at least 170%, at least 180%, at least 190%, at least 200%, at least 220%, at least 240%, at least 260%, at least 280%, at least 300%, at least 350%, at least 400%, at least 450%, at least 500%, at least 550%, or at least 600% relative to a reference level indicates that the patient suffers from a TH-GM-mediated inflammatory disorder. In a particular embodiment, an increase of at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150% relative to a reference level indicates that the patient suffers from a TH-GM-mediated inflammatory disorder.
- In some embodiments, a STAT5 (e.g., activated phospho-STAT5 (Tyr694)), IL-7, GM-CSF and/or IL-3 level that is not increased by at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150% relative to a reference level indicates that the patient suffers from a non-TH-GM-mediated inflammatory disorder.
- In certain embodiments, a STAT5 (e.g., activated phospho-STAT5 (Tyr694)), IL-7, GM-CSF and/or IL-3 level that is comparable (or unchanged) relative to a reference level indicates that the patient suffers from a non-TH-GM-mediated disorder. As used herein, a level that is “comparable” to that of a reference level refers to a level that is unchanged, or a change relative to the reference level that is statistically insignificant according to clinical standards. In certain embodiments, a comparable level (or unchanged level) can include a level that is not increased by at least 40%, at least 50%, at least 60%, or at least 70% relative to a reference level as, for example, it may not indicate a clinically significant change. In some embodiments, a level of a TH-GM-mediating factor (e.g., STAT5 (e.g., activated phospho-STAT5 (Tyr694)). IL-7, GM-CSF, and/or IL-3) that is decreased relative to a reference level can also indicate that the patient suffers from a non-TH-GM-mediated disorder.
- In some embodiments, the reference level is a level that is used for comparison purposes, and may be obtained from, for example, a prior sample taken from the same patient; a normal healthy subject; a sample from a subject not having an autoimmune disease or an inflammatory disorder; a subject that is diagnosed with a propensity to develop an autoimmune disease but does not yet show symptoms of the disease; a patient that has been treated for an autoimmune disease; or a sample of a purified reference polypeptide or nucleic acid molecule of the disclosure (e.g., STAT5) at a known normal concentration. By “reference standard or level” is meant a value or number derived from a reference sample, or a value or range accepted in the art as indicative of being healthy (e.g., an individual that does not have an inflammatory disorder). A normal reference standard or level can also be a value or number derived from a normal subject who does not have an autoimmune disease. In one embodiment, the reference sample, standard, or level is matched to the sample subject by at least one of the following criteria; age, weight, body mass index (BMI), disease stage, and overall health. A standard curve of levels of purified DNA. RNA or mRNA within the normal reference range can also be used as a reference. A standard curve of levels of purified protein within the normal reference range can also be used as a reference.
- In some embodiments, the patient afflicted with an inflammatory disorder who has been diagnosed or classified as having a TH-GM-mediated inflammatory disorder does not have a non-TH-GM-mediated inflammatory disorder (i.e., does not have a TNF-α, IL-6, or IL-1β-mediated inflammatory disorder). That is, the patient diagnosed as suffering from a TH-GM-mediated inflammatory disorder responds to modulation of TH-GM function (e.g., inhibition of STAT5, IL-7, GM-CSF and/or IL-3), but does not respond (or exhibits a limited response) to TNF-α therapy, as determined by clinical standards. However, as described herein, a TH-GM-mediated inflammatory disorder does not exclude the possibility that the inflammatory disorder is also partially (though not primarily) contributed by a non-TH-GM-mediated pathway (e.g., TNF-α, IL-6, IL-1β).
- In some embodiments, the methods of the present disclosure further comprise administering an effective amount of a modulating agent that modulates TH-GM cell function to the patient diagnosed or classified as having a TH-GM-mediated inflammatory disorder. As described herein, in some embodiments, the modulating agent inhibits TH-GM function.
- In some embodiments, the methods of the present disclosure further comprise administering an effective amount of, e.g., a TNF-α therapy, an IL-6 therapy, or an IL-1β therapy to a patient diagnosed or classified as having a non-TH-GM-mediated inflammatory disorder, as described herein.
- In some aspects, the present disclosure also provides a method of classifying a patient suffering from an inflammatory disorder as having a TH-GM-mediated inflammatory disorder or a non-TH-GM-mediated inflammatory disorder. In some embodiments, the method comprises contacting a sample collected from a patient suffering from an inflammatory disorder with a detecting agent that detects a polypeptide or nucleic acid level of a TH-GM-mediating factor, such as, e.g., STAT5 (e.g., phosphorylated STAT5, Tyr694), IL-7, GM-CSF or IL-3, or a combination thereof. In certain aspects, the method further comprises quantifying the polypeptide or nucleic acid level of the TH-GM-mediating factor, such as, e.g., STAT5. IL-7, GM-CSF or IL-3, or a combination thereof, wherein an increased level of the TH-GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to a reference level indicates that the patient suffers from a TH-GM-mediated inflammatory disorder; or a comparable level of the TH-GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to a reference level indicates that the patient suffers from a non-TH-GM-mediated inflammatory disorder, thereby classifying the patient suffering from an inflammatory disorder as a TH-GM-mediated inflammatory disorder or a non-TH-GM-mediated inflammatory disorder.
- In other aspects of the present disclosure, the methods disclosed herein can further comprise measuring the polypeptide or nucleic acid level of a factor that mediates a non-TH-GM-mediated inflammatory disorder. Such factors include, e.g., TNF-α, IL-6, and IL-1β.
- For example, in some aspects, the present disclosure provides a method of determining a treatment regimen in a patient suffering from an inflammatory disorder. To illustrate, the method comprises quantifying a polypeptide or nucleic acid level of, e.g., activated STAT5 or GM-CSF in a sample collected from a patient suffering from an inflammatory disorder, and quantifying the polypeptide or nucleic acid level of, e.g., TNF-α in a sample collected from the patient. At least four scenarios can be considered.
- In the first scenario, if the activated STAT5 or GM-CSF level is increased (e.g., by at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150%) relative to a first reference level and the TNF-α level is comparable to a second reference level, then the patient is classified as having a TH-GM-mediated inflammatory disorder and the patient can be treated with an agent that modulates TH-GM function, as described herein.
- In a second scenario, if the activated STAT5 or GM-CSF level is comparable to the first reference level and the TNF-α level is increased (e.g., by at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 150%) relative to the second reference level, then the patient is classified as having a non-TH-GM-mediated inflammatory disorder and the patient can be treated with, e.g., a TNF-α therapy.
- In a third scenario, if the activated STAT5 or GM-CSF level is increased relative to the first reference level and the TNF-α level is also increased relative to the second reference level, and the increase is equivalent within clinical and/or statistical standards (e.g., both GM-CSF and TNF-α are at least 50% increased relative to the respective reference levels), then the patient is classified as having an inflammatory disorder that is equally TH-GM-mediated and non-TH-GM mediated (e.g., TNF-α-mediated). In such a case, the patient can be treated with an effective amount of an agent that modulates TH-GM function and an effective amount of, e.g., a TNF-α therapy. As demonstrated herein, the combination of both agents can have a synergistic effect.
- In a fourth scenario, if the activated STAT5 or GM-CSF level is increased relative to the first reference level and the TNF-α level is also increased relative to the second reference level, but one is increased more than the other, then the inflammatory disorder is primarily mediated by the pathway that shows a greater increase. For example, if GM-CSF is increased by 40% relative to a reference level, and TNF-α is increased by 90% relative to a reference level, then the inflammatory disorder is primarily non-TH-GM-mediated. However, in this scenario, the patient may receive a combined treatment with an agent that modulates TH-GM function as well a TNF-α therapy (e.g., anti-TNF-α therapy), since GM-CSF is increased by, e.g., at least 40% relative to a reference level.
- In some embodiments, the first and second reference levels are obtained from the same reference sample.
- In a related aspect, the disclosure also provides a method of tailoring the treatment of a patient suffering from an inflammatory disorder according to the progression of a patient's inflammatory disorder. In the above illustrative example, the first scenario (increased TH-GM-mediating factor, e.g. STAT5 or GM-CSF but TNF-α level is comparable to a reference level) may indicate that the patient is in an early stage of an inflammatory disorder. Without wishing to be bound by any particular theory, during, for example, the early stages of an inflammatory disorder, naïve T cells are stimulated by antigen and programmed by IL-7/STAT5 to differentiate into GM-CSF/IL-3 producing TH-GM cells. During, for example, the late stages of an inflammatory disorder, TH-GM cytokines (e.g., IL-3 and GM-CSF) progressively stimulate more inflammatory cells such as macrophages and neutrophils resulting in the production of, e.g., TNF-α, IL-6, IL-1β, resulting in full-scale inflammation. Thus, in the above illustrative example, the second scenario (activated STAT5 Or GM-CSF level is comparable to the first reference level and the TNF-α level is increased) may indicate that the patient is in a late stage of an inflammatory disorder characterized by, e.g., tissue damage. Accordingly, the present disclosure enables the prognosis of a patient depending on the quantifiable level of one or more TH-GM-mediating factor (e.g., STAT5 (e.g., activated phospho-STAT5 (Tyr694)), IL-7, GM-CSF, and/or IL-3) and one or more non-TH-GM-mediating factor (e.g., TNF-α, IL-6, IL-1β), thereby tailoring the treatment according to the progression of the disease. Accordingly, as would be appreciated by those of skill in the art, a patient suffering from an inflammatory disorder can be monitored for disease progression to ensure effective and tailored treatment according to the level of one or more TH-GM-mediating factor, as described herein, and one or more non-TH-GM-mediating factor (e.g., TNF-α, IL-6, IL-1β).
- In related aspects, the present disclosure also provides a method of prognosing progression of an inflammatory disorder in a patient in need thereof. In some embodiments, the method comprises a) quantifying a polypeptide or nucleic acid level of a TH-GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof, in a first sample collected from a patient suffering from an inflammatory disorder, and b) quantifying a polypeptide or nucleic acid level of, e.g., TNF-α, IL-6, or IL-1β, or a combination thereof, in a second sample collected from the patient, wherein i) an increased level of the TH-GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to a first reference level and an unchanged level of TNF-α, IL-6, or IL-1β, or a combination thereof relative to a second reference level indicates that the patient is in an early stage of the inflammatory disorder, as described herein; or ii) an unchanged level of the TH-GM-mediating factor, such as, e.g., STAT5, IL-7, GM-CSF or IL-3, or a combination thereof relative to the first reference level and an increased level of TNF-α, IL-6, or IL-43, or a combination thereof relative to the second reference level indicates that the patient is in a late stage of the inflammatory disorder, as described herein. In some embodiments, the method further comprises administering an effective amount of an agent that modulates TH-GM function and/or, e.g., a TNF-α therapy, as described herein.
- In some embodiments, the first sample and the second sample are the same.
- In various aspects, the present disclosure also provides an isolated population of GM-CSF-secreting T-helper cells (TH-GM). In one embodiment, the TH-GM cells are differentiated from a precursor cell (e.g., CD4+ cells) in the presence of signal transducer and activator of transcription 5 (STAT5) and/or IL-7, and wherein the TH-GM cells express GM-CSF and IL-3.
- In some embodiments, the TH-GM cells are differentiated from a precursor cell (e.g., CD4+ cells) in the presence of an agent that inhibits IL-12, IFN-γ. TGF-β, and/or IL-6. Similarly, the differentiation of a precursor cell (e.g., CD4+ precursor cell) into a TH-GM cell is inhibited by IL-12, IFN-γ, TFG-β, and/or IL-6.
- In some embodiments, the TH-GM cells are differentiated from a precursor cell in vitro, under artificial conditions, but wherein the TH-GM cells retain physiological properties as described herein.
- In some embodiments, the TH-GM cells are further characterized by an overexpression of one or more genes listed in Table 1. For example, the TH-GM cells are further characterized by an overexpression of, for example, basic helix-loop-helix family, member e40 (BHLHe40), preproenkephalin (PENK), IL-2, serine (or cysteine) peptidase inhibitor, Glade B member 6 h (Serpinb6b), neuritin 1 (Nrn1), stearoyl-Coenzyme A desaturase 1 (Scd1), or phosphotriesterase related C1q-like 3 (Pter), or a combination thereof.
- In some embodiments, the TH-GM cells are further characterized by an underexpression of one or more genes listed in Table 1. For example, the TH-GM cells are further characterized an underexpression of
lymphocyte antigen 6 complex, locus A (Ly6a); CD27; or selectin, lymphocyte (Sell). - As described herein, the identification of a distinct network of factors (unique from factors known to mediate
T H1 or TH17) that mediate TH-GM function (e.g., its differentiation and pathogenicity) enables targeted modulation of TH-GM function to treat TH-GM-mediated disorders, e.g., disorders that result from aberrant TH-GM function. Thus, in some aspects, the present disclosure provides a method of modulating TH-GM function, comprising contacting the TH-GM, or cluster of differentiation 4 (CD4+) precursor cells, or both, with a modulating agent that modulates TH-GM function. In one embodiment, the modulating agent is contacted with the TH-GM cells or CD4+ precursor cells in vitro or in VIVO. - As used herein, “TH-GM function” refers to the commitment, development, maintenance, survival, proliferation, or activity, or a combination thereof, of TH-GM cells. Thus, an agent that modulates (e.g., enhances or inhibits) TH-GM function is one that modulates TH-GM commitment, development, survival, proliferation, or activity, or combination thereof, of TH-GM cells. For example, TH-GM function can be modulated by modulating its: commitment from a CD4+ precursor T cell; development of a CD4+ precursor cell that has been committed to the TH-GM developmental pathway; maintenance of a TH-GM phenotype; survival or proliferation under development or effector TH-GM cells; and/or activity of effector TH-GM cells (e.g., modulating function of a secreted factor such as GM-CSF or IL-3). For example, a modulation in TH-GM function includes, but is not limited to, a modulation in: the number of TH-GM cells; the survival of TH-GM cells; the proliferation of TH-GM cells; and/or the activity of TH-GM cells. The activity of TH-GM cells herein includes the activity induced by the cytokines, chemokines, growth factors, enzymes and other factors secreted by TH-GM cells, as described herein, and the activity induced by direct contact with TH-GM cells.
- As used herein, a T helper subset cell “TH-GM” refers to a cell that, similar to
T H1 andT H17 cells, differentiates from precursor CD4+ precursor cells, but which commits and develops through a pathway that is mediated by a subset of factors (the TH-GM-mediating factors) that is distinct and unique from the known subset of factors that commit and developT H1 orT H17 cell subtypes, as described herein. In some embodiments, a TH-GM cell produces a distinct and unique set of genes (see, e.g., Table 1) and effects pathogenicity through a different mechanism and pathway than the known factors that mediate pathogenicity ofT H1 orT H17 cell subtypes. For example, a TH-GM cell commits and develops by IL-7/STAT5 function (its regulators), and effects pathogenicity by GM-CSF/IL-3 (its effectors). - In some aspects, the present disclosure provides a method of treating a TH-GM-mediated inflammatory disorder in a patient in need thereof, comprising administering to said patient an effective amount of a modulating agent that modulates TH-GM cell function. In certain embodiments, the patient is previously diagnosed as having a TH-GM-mediated inflammatory disorder, as described herein.
- In some aspects, the present disclosure also provides a method of treating rheumatoid arthritis in a patient who exhibits limited response to TNF-α therapy, comprising administering to said patient an effective amount of a modulating agent that modulates TH-GM function.
- As used herein, “limited response” refers to no response or insignificant response such that a patient is not treated by the therapy, as determined by clinical standards.
- “Treatment” or “treating” refers to therapy, prevention and prophylaxis and particularly refers to the administration of medicine or the performance of medical procedures with respect to a patient, for either prophylaxis (prevention) or to reduce the extent of or likelihood of occurrence of the condition or event in the instance where the patient is afflicted. It also refers to reduction in the severity of one or more symptoms associated with the disease or condition. In the present application, it may refer to amelioration of one or more of the following: pain, swelling, redness or inflammation associated with an inflammatory condition or an autoimmune disease. As used herein, and as well-understood in the art, “treatment” is an approach for obtaining beneficial or desired results, including clinical results. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, and/or amelioration or palliation of the disease state. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
- An “effective amount” of an agent is that amount sufficient to effect beneficial or desired results, including clinical results. An “effective amount” depends upon the context in which it is being applied. In the context of administering a composition that modulates an autoimmune response, an effective amount of an agent which is a modulator of TH-GM function is an amount sufficient to achieve such a modulation as compared to the response obtained when there is no agent administered. An effective amount can confer immediate, short term or long term benefits of disease modification, such as suppression and/or inhibition of TH-GM function, as defined herein. An effective amount can be administered in one or more administrations. An “effective amount” as used herein, is intended to mean an amount sufficient to reduce by at least 10%, at least 25%, at least 50%, at least 75%, or an amount that is sufficient to cause an improvement in one or more clinically significant symptoms in the patient.
- In some embodiments, the modulating agent inhibits TH-GM function to, e.g., reduce inflammation. The inhibition conferred by the modulating agent (the inhibitor) does not imply a specific mechanism of biological action. Indeed, the term “antagonist” or “inhibitor” as used herein includes all possible pharmacological, physiological, and biochemical interactions with factors that mediate TH-GM function (e.g., IL-7, IL-7 receptor, STAT5, GM-CSF, IL-3, IL-2, IL-2 receptor, PENK, RANKL, JAK1/3, or any of the genes that are differentially expressed in TH-GM cells, e.g., genes in Tables 1 and 2), whether direct or indirect, and includes interaction with a factor (or its active fragment) that mediates TH-GM function at the protein and/or nucleic acid level, or through another mechanism.
- In certain embodiments, a modulating agent that inhibits TH-GM function includes an antibody, a polypeptide (e.g., a soluble receptor that hinds and inhibits, for example, IL-7), a small molecule, a nucleic acid (e.g., antisense, small interfering RNA molecule, short hairpin RNA, microRNA), or a protein (e.g., cytokine), or a combination thereof that prevents the function (e.g., expression and/or activity) of a factor that mediates TH-GM function. Methods of designing, producing, and using such inhibitors are known and available in the art.
- As used herein, “binds” is used interchangeably with “specifically binds,” which means a polypeptide (e.g., a soluble receptor) or antibody which recognizes and hinds a polypeptide of the present disclosure, but that does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the present disclosure. In one example, an antibody specifically binds an activated STAT5 polypeptide does not hind a non-STAT5 polypeptide.
- As used herein, “antibody” refers to an intact antibody or antigen-binding fragment of an antibody, including an intact antibody or antigen-binding fragment that has been modified or engineered, or that is a human antibody.
- In a particular embodiment, the antibody binds to and inhibits the function of any one or more of the factors that mediate TH-GM function. For example, the antibody hinds to and inhibits the function of IL-7, IL-7 receptor (IL-7R), IL-2, IL-2 receptor (IL-2R), STAT5 or
janus kinase 1/3 (JAK1/3), or a combination thereof. In other examples, the antibody hinds to and inhibits the function of GM-CSF (or its receptor), IL-3, PENK, or RANKL, or a combination thereof. In some embodiments, the antibody binds to and inhibits the function of a gene listed in Table 1. In some embodiments, the antibody hinds to and inhibits the protein or any functional fragment thereof. Methods of designing, producing and using suitable antibodies are known and available to those of skill in the art. Examples of antibodies suitable for use in the present disclosure include. e.g., daclizumab, basiliximab, mavrilimumab, MOR103, KB003, namilumab, and MOR Ab-022. - The terms “protein” and “polypeptide” are used interchangeably, and can include full-length polypeptide or functional fragments thereof (e.g., degradation products, alternatively spliced isoforms of the polypeptide, enzymatic cleavage products of the polypeptide), the polypeptide hound to a substrate or ligand, or free (unbound) forms of the polypeptide. The term “functional fragment”, refers to a portion of a full-length protein that retains some or all of the activity (e.g., biological activity, such as the ability to bind a cognate ligand or receptor) of the full-length polypeptide.
- In some embodiments, the modulating agent that inhibits TH-GM function can be a particular biological protein (e.g., cytokines) that inhibits, directly or indirectly, one or more of the factors that mediate TH-GM function. Such cytokines include, e.g., IL-12, IFN-γ, TGF-β, and IL-6.
- In some embodiments, the modulating agent that inhibits TH-GM function can be a small molecule that inhibits, directly or indirectly, one or more of the factors that mediate TH-GM function. As used herein a “small molecule” is an organic compound or such a compound complexed with an inorganic compound (e.g., metal) that has biological activity and is not a polymer. A small molecule generally has a molecular weight of less than about 3 kilodaltons. Examples of known small molecules include CAS 285986-31-4 (Calbiochem), pimozide, and tofacitinib.
- In other embodiments, the modulating agent enhances TH-GM function in disorders such as, e.g., viral, fungal and bacterial infections, cancers and/or conditions associated with therewith. In one embodiment, modulating agents that enhance TH-GM function include. e.g., CD28 activator; IL-7 and/or IL-2 on naïve (precursor) CD4+ T cells; activator of STAT5; or effectors of TH-GM cells (e.g., GM-CSF. IL-3).
- In another aspect, the present disclosure provides a method of treating a STAT5-mediated inflammatory disorder in a patient in need thereof, comprising administering to the patient an effective amount of an agent that modulates STAT5 function.
- As used herein, “STAT5-mediated” inflammatory disorder refers to an inflammatory disorder that is caused by aberrant STAT5 function (aberrantly enhanced or inhibited), and which is responsive to modulation of STAT5 function, as determined by clinical standards. In some embodiments, the STAT5 is activated STAT5 (e.g., phospho-STAT5, Tyr694).
- In some embodiments, the inflammatory disorder is an autoimmune disorder. In certain embodiments, the inflammatory disorder can be any inflammatory disorder mediated by STAT5 (e.g., activated STAT5), and includes, but is not limited to rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis. Crohn's disease, diabetes. Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism, Irritable Bowel Syndrome (IBS), lupus erythematosus, polymyalgia rheumatic, psoriasis, psoriatic arthritis. Raynaud's syndrome/phenomenon, reactive arthritis (Reiter syndrome), sarcoidosis, scleroderma. Sjögren's syndrome, ulcerative colitis, uveitis, or vasculitis.
- In some embodiments, the term “patient” refers to a mammal, preferably human, but can also include an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like), and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- In some embodiments, the agent inhibits STAT5 function (e.g., expression and/or activity). Examples of agents that inhibit STAT5 (e.g., activated STAT5, Tyr694) are described herein.
- In certain embodiments, the methods of the present disclosure further comprise administering to the patient a TNF-αc therapy. In certain embodiments, TNF-α therapy is administered in a patient determined to have an inflammatory condition that is non-TH-GM-mediated. As described herein, in certain embodiments, a TNF-α therapy is administered if a quantified TNF-α level is increased by, e.g., at least 40% relative to a reference level.
- Examples of TNF-α therapy include those that are TNF-α-inhibitor based, and those that are non-TNF-α-inhibitor based. In particular, TNF-α-inhibitor based therapy includes etanercept, adalimuinab, infliximab, golimumab, and certolizumab pegol. Examples of non-TNF-α-inhibitor based therapy includes corticosteroid medications (e.g., prednisone), nonsteroidal anti-inflammatory drugs (e.g., methotrexate), and JAK inhibitors (e.g., tofacitinib). Other examples of non-TNF-α-inhibitor based therapy include anakinra, abatacept, rituximab and tocilizumab.
- The TNF-α therapy can be administered before, simultaneously with, or alter the administration of an effective amount of an agent that modulates TH-GM function. Accordingly, an agent that modulates TH-GM function and the TNF-α therapy can be administered together in a single dose, or can be administered in separate doses, e.g., either simultaneously or sequentially, or both. The duration of time between the administration of an agent that modulates TH-GM function and a TNF-α therapy will depend on the nature of the therapeutic agent(s). In addition, an agent that modulates TH-GM function and a TNF-α therapy may or may not be administered on similar dosing schedules. For example, the agent that modulates TH-GM function and the TNF-α therapy may have different half-lives and/or act on different time-scales such that the agent that modulates TH-GM function is administered with greater frequency than the TNF-α therapy, or vice-versa. The number of days in between administration of therapeutic agents can be appropriately determined by persons of ordinary skill in the art according to the safety and pharmacodynamics of each drug.
- The identification of the TH-GM cells as well as the identification of genes differentially produced by TH-GM cells relative to
T H1 orT H17 enables the use of TH-GM cells to identify novel therapeutics for modulating TH-GM function, thereby enabling new therapeutics for treating TH-GM-mediated disorders (e.g., inflammatory disorders). Thus, in further aspects, the present disclosure provides a method of screening to identify a modulator of TH-GM cell function, comprising contacting an isolated population of TH-GM cells, or an isolated population of CD4+ precursor cells, with a candidate agent, and measuring a readout of TH-GM function in the presence or absence of the candidate agent, wherein a change in the readout of TH-GM function indicates that the candidate agent is a modulator of TH-GM function. - As used herein, a candidate agent refers to an agent that may modulate TH-GM function by modulating the function (e.g., expression and/or activity) of a factor that mediates TH-GM function. Such candidate agents include, e.g., an antibody, a peptide, a small molecule, a nucleic acid (e.g., antisense, small interfering RNA molecule), or a protein (e.g., cytokine), or a combination thereof. A candidate agent can be designed to target any of the factors (at the protein and/or nucleic acid level) that mediate TH-GM function, as described herein, including the genes listed in Table 1 (e.g., genes preferentially upregulated in TH-GM cells, genes preferentially overexpressed/underexpressed on the surface of TH-GM cells).
- As used herein, “readout” refers to any change (or lack of change) in TH-GM function that can be measured or quantified. For example, a candidate agent can be assessed for its effect on, e.g., GM-CSF secretion by TH-GM cells, or its effect on the abundance of TH-GM cells (through an effect on the commitment/development/proliferation of TH-GM cells), as described herein. Assays for determining such readouts are known and available in the art, and are exemplified herein.
- In some embodiments, the change in the presence of the candidate agent is a reduction in the measurement of the readout, indicating an inhibition of TH-GM function (e.g., decrease in GM-CSF or IL-3 production, or decrease in the abundance of TH-GM cells), thereby identifying the candidate agent as an inhibitor of TH-GM function.
- In certain embodiments, the change in the presence of the candidate agent is an increase in the measurement of the readout, indicating an enhancement of TH-GM function (e.g., increase in GM-CSF or IL-3 production, or increase in the abundance of TH-GM cells), thereby identifying the candidate agent as an enhancer of TH-GM function.
- In some embodiments, the readout can be any one or more of the genes listed in Tables 1 and 2 which are preferentially upregulated or downregulated in TH-GM cells. Thus, a candidate agent that downregulates a gene that is preferentially upregulated in a TH-GM cell is a inhibitor of TH-GM function. Similarly, a candidate agent that upregulates a gene that is preferentially downregulated in a TH-GM cell is an enhancer of TH-GM function.
- In certain aspects, the method of screening, if performed with precursor CD4+ cells, is performed under TH-GM polarizing conditions, as described herein. For example, the method can be performed in the presence of IL-7/STAT5, TCR activation, CD28 co-stimulation, in combination with the blockade of IFN-gamma and IL-4.
- Unless indicated otherwise, the definitions of terms described herein apply to all aspects and embodiments of the present disclosure
- The practice of the present disclosure includes use of conventional techniques of molecular biology such as recombinant DNA, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology as described for example in: Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989) and Molecular Cloning: A Laboratory Manual, third edition (Sambrook and Russel, 2001), jointly and individually referred to herein as “Sambrook”); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Animal Cell Culture (R. I. Freshney, ed., 1987); Handbook of Experimental Immunology (D. M. Weir & C. C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J. M. Miller & M. P. Calos, eds., 1987); Current Protocols in Molecular Biology (F. M. Ausubel et al., eds., 1987, including supplements through 2001); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (J. E. Coligan et al., eds., 1991); The Immunoassay Handbook (D. Wild. ed., Stockton Press NY, 1994); Bioconjugate Techniques (Greg T. Hermanson, ed., Academic Press, 1996); Methods of Immunological Analysis (R. Masseyeff, W. H. Albert, and N. A. Staines, eds., Weinheim: VCH Verlags gesellschaft mbH, 1993), Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York. and Harlow and Lane (1999) Using Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. jointly and individually referred to herein as “Harlow and Lane”), Beaucage et al. eds., Current Protocols in Nucleic Acid Chemistry (John Wiley & Sons, Inc., New York, 2000); and Aerawal, ed., Protocols for Oligonucleotides and Analogs, Synthesis and Properties (Humana Press Inc., New Jersey, 1993).
- Methods
- Mice
- Stat5f/f mice were provided by L. Hennighausen (National Institute of Diabetes and Digestive and Kidney Diseases). Stat3f/f mice were generated as described2. Cd4-Cre transgenic mice were purchased from Taconic Farms. Rag2−/− mice were obtained from Jean-Pierre Abastado (Singapore Immunology Network). All mice are on a C57BL/6 genetic background and housed under specific-pathogen-free conditions at National University of Singapore. All experiments were performed with
mice 6˜8 weeks old and approved by the Institutional Animal Care and Use Committee of NUS. - Patients and Controls
- Blood samples (n=47) and synovial fluid samples (n=3) were collected from RA patients admitted to the Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School. All patients fulfilled the American College of Rheumatology criteria for the classification of RA. Age and gender matched healthy controls (n=32) were obtained from Medical Examination Center of the Affiliated Drum Tower Hospital. The study protocol was approved by the Ethics Committee of the Affiliate Drum Tower Hospital of Nanjing University Medical School.
- In Vitro T Cell Differentiation
- CD4+ T cells were obtained from spleens and lymph nodes by positive selection and magnetic separation (Miltenyi Biotech), followed by purification of naïve CD4+ T cell population (CD4+CD25−CD62LhiCD44lo) sorted with FACS Aria. Naïve CD4+ T cells were stimulated with plate-hound anti-CD3 (3 μg/ml; BD Pharmingen) and anti-CD28 (1 μg/ml; BD Pharmingen) in presence of different combinations of neutralizing antibodies and cytokines for 3˜4 days: for neutral conditions, no addition of any cytokine or neutralizing antibody; for
T H 1 conditions, IL-12 (10 ng/ml), and anti-IL-4 (10 μg/ml, BD Pharmingen); forT H17 conditions, hTGF-β (3 ng/ml), IL-6 (20 ng/ml), anti-IFN-γ (10 μg/ml, eBioscience), and anti-IL-4 (10 μg/ml); for analternative T H17 conditions, IL-6 (20 ng/ml), IL-23 (10 ng/ml), IL-1 (10 ng/ml), anti-IFN-γ (10 μg/ml), and anti-IL-4 (10 μg/ml). For GM-CSF-expressing cell differentiation, naïve CD4+ T cells were stimulated with plate-bound anti-CD3 (2 μg/ml) and soluble anti-D28 (1 μg/ml) with the addition of IL-7 and/or anti-IFN-γ (10 μg/ml) as indicated. All cytokines were obtained from R&D Systems. All cells were cultured in RPMI 1640 supplemented with 10% FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acid and 5 μM beta-mercaptoethanol. After 3˜4 days polarization, cells were washed and restimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin in presence of Golgiplug for 4-5 h, followed by fixation and intracellular staining with a Cytofix/Cytoperm kit from BD Pharmingen. Foxp3 staining was done with a kit from eBioscience. Cells were acquired on the LSR II (BD Biosciences) and analyzed with FlowJo software (Tree Star). - EAE Induction
- EAE induction procedures were modified from previous report3. For active EAE induction, mice were immunized in two sites on the hind flanks with 300 μg MOG35-55 in 100 μl CFA containing 5 mg/ml heat-killed M. tuberculosis strain H37Ra (Difco) at
day 0 andday 7. Pertussis toxin (List Bio Lab) was administrated intraperitoneally at the dosage of 500 ng per mouse atday 1 andday 8. For single MOG35-55/CFA immunization, the similar procedure was performed atday 0 andday 1 only. In an alternative active EAE induction, LPS (600 μg/ml in IFA, O111:B4 from Sigma) was used as adjuvant. For active EAE induction in Rag2−/− mice, CD4+ T cells derived from Stat5f/f or Cd4-Cre; Stat5f/f mice were transferred, followed by MOG35-55/CFA immunization as described above. Clinical symptoms were scored as follows: 0, no clinical sign; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paralysis; 4, hind and fore limb paralysis; 5, death. IL-7Rα neutralizing antibody (SB/14, BD Pharmingen) and isotype control was administrated intraperitoneally at 200 μg per mouse every other day. For analysis of CNS-infiltrating cells, both spinal cord and brain were collected and minced from perfused mice, and mononuclear cells were isolated by gradient centrifuge with Percoll (GE Healthcare). - For passive EAE induction with Stat5+/+ or Stat5−/− T cells, splenocytes and LNs were harvested 10-14 days post-immunization and passed through a 70 μm cell strainer (BD Falcon). Cells were cultured in vitro for 3 days with MOG35-55 (20 μg/ml) in the presence of IL-23 (5 ng/ml) and IL-1β (2 ng/ml). After harvesting, CD4+ T cells were purified by positive selection to a purity >90%. CD4+ T cells (2 million in sterile PBS) were injected intraperitoneally into Rag2−/− mice, followed by Pertussis toxin administration on the following day. Mice were observed daily for the signs of EAE as described above. For EAE induction by transferring various TH subsets, similar procedures was performed as described above. Different subsets skewing conditions were as follows: Non-skewed, MOG35-55 only; TH1: MOG35-55 plus IL-12 (10 ng/ml) and anti-IL-4 (5 μg/ml); TH17: MOG35-55 plus TGF-β (3 ng/ml), IL-6 (10 ng/ml), anti-IFN-γ (5 μg/ml) and anti-IL-4 (5 μg/ml); GM-CSF-expressing TH: MOG35-55 plus IL-7 (2 ng/ml) and anti-IFN-γ (5 μg/ml). 6×105 CD4+ T cells were transferred per recipient mouse.
- Antigen-Induced Arthritis (AIA)
- Briefly, mice were immunized subcutaneously in two sites on the hind flanks with 100 μg methylated bovine serum albumin (mBSA, Sigma) in 100 μl complete Freund's adjuvant (CFA) containing 5 mg/ml heat-killed M. tuberculosis strain H37Ra (Difco) at
day 0. Pertussis toxin (List Bio Lab) was administrated intraperitoneally at the dosage of 250 ng per mouse atday 1. Arthritis was induced by intraarticular injection of 100 μg mBSA (in 10 saline) into the hind right knee joint atday 7 after immunization. The hind left knee joint was injected with same volume of saline as control. Joint swelling was recorded by measuring the difference between right and left knee joint diameters with a caliper over 7 days after arthritis induction. To assess the effect of GM-CSF administration, MA was induced by intraarticular injection of mBSA alone to the right knee joint or mBSA supplemented with 100 ng GM-CSF (ImmunoTools) to the left knee joint. To assess the effect of GM-CSF and/or TNF-α blockade, mice were administrated intraperitoneally with neutralizing antibodies (100 μg for each antibody per mouse) specific for GM-CSF (MP1-22E9, BD Pharmingen) and/or TNF-α (MP6-XT3. BD Pharmingen) at indicated times. - For AIA induction by adoptive transfer, splenocytes and inguinal LN cells were isolated from mBSA/CFA-immunized mice at
day 7, and cultured in vitro with mBSA (10 μg/ml) in the presence of IL-7 (2 ng/ml) for 3 days. After harvesting, CD4+ T cells were purified by positive selection (Miltenyi Biotec) to a purity >90%. Then CD4+ T cells (1 million in sterile PBS) were transferred into WT naïve mice, followed by intraarticular injection of mBSA on the next day. - Collagen-Induced Arthritis (CIA)
- CIA was induced in a similar procedure as AIA as described above, by immunizing mice with chicken collagen II/CFA emulsion (purchased from Chondrex, Inc), followed with pertussis toxin injection. Mice were monitored and scored for arthritis; 0, normal; 1, mild swelling of ankle or wrist, or apparent swelling limited to individual digits; 2, moderate swelling of entire paw; 3, severe swelling of entire paw with ankylosis. Scores for four limbs were summed for each mouse.
- Histological Analysis
- For paraffin-embedded tissues, spinal cords were fixed in 4% PFA. Knee joints or paws were removed, fixed in 10% formalin and decalcified in 5% formic acid before dehydration and embedding. Sections (5 μm) were stained with hematoxylin and eosin (H&E) to assess immune cell infiltration and inflammation, or with Safranin-O/Fast Green to assess cartilage depletion. For frozen tissues, spinal cords were embedded in OCT (Tissue-Tek) and snap frozen on dry ice. Sections (10 μm) were fixed in ice-cold acetone and stained with primary anti-CD4 (Biolegend) and anti-CD11b (eBioscience), followed by incubation with fluorescence-conjugated secondary antibodies (Invitrogen). For ALA experiments, knee joint were fixed in 10% formalin for 5 days, followed by decalcification in 5% formic acid for 5 clays. Sections (10 μm) were stained with hematoxylin and eosin (H&E) to assess immune cell infiltration and inflammation, or stained with Safranin-O/fast green to access cartilage destruction.
- Cell Sorting and May Grünwald-Giemsa Staining
- Monocytes/macrophages (Ly6ChiLy6G−) and neutrophils (Ly6CloLy6Ghi) gated on CD45+CD11b+ were sorted with FACS Aria from spleens or synovial single cell suspensions. Sorted cells were cytospun onto glass slides and subsequently stained with May Grünwald and Giemsa dye following a standard procedure.
- Real-Time PCR
- Total RNA was extracted from cells with RNeasy kit (Qiagen) according to the manufacturer's instruction. Complementary DNA (cDNA) was synthesized with Superscript reverse transcriptase (Invitrogen). Gene expressions were measured by 7500 real-time PCR system (Applied Biosystems) with SYBR qPCR kit (KAPA). Actinb, Gapdh or Rn18S was used as internal control. The primer sequences are available upon request.
- ELISA
- TNF-α, IL-6, IL-1β, IFN-γ, GM-CSF and IL-2 levels were assayed by Ready-SET-Go ELISA kit (eBioscience), and IL-17 level was measured by DuoSet ELISA kit (R&D Systems) according to the manufactures' instructions.
- Chromatin Immunoprecipitation Assays
- CD4+ T cells isolated from Stat5f/f or Cd4-Cre; Stat5f/f mice were activated with plate-bound anti-CD3 and anti-CD28 for 3 days. Cells were stimulated with IL-7 (20 ng/ml) or IL-2 (25 ng/ml) for 45 min. Crosslink was performed by addition of formaldehyde at final concentration of 1% for 10 min followed by quenching with Glycine. Cell lysates were fragmented by sonication and precleared with protein G Dynabeals, and subsequently precipitated with anti-STAT5 antibody (Santa Cruz) or normal rabbit IgG (Santa Cruz) overnight at 4° C. After washing and elution, crosslink reversal was clone by incubating at 65° C. for 8 hr. The eluted DNA was purified and analyzed by RT-PCR with primers specific to C42 promoter as described previously5.
- Statistics
- Statistical significance was determined by Student's t test using GraphPad Prism 6.01. The p value <0.05 was considered significant. The p values of clinical scores were determined by two-way multiple-range analysis of variance (ANOVA) for multiple comparisons. Unless otherwise specified, data were presented as mean and the standard error of the mean (mean±SEM).
- STAT5 negatively regulates
T H17 differentiation by restraining IL-17 production (Laurence et al., 2007; Yang et al., 2011). However, the function of STAT5 in TH17-mediated pathogenesis is not well understood. To explore this question, EAE was induced in Cd4-Cre; Stat5f/f (Stat5−/−) mice, where Stat5 was specifically deleted in T cell compartment, and in littermate controls by immunizing the mice with MOG35-55/CFA atday 0 andday 7. Development of paralysis was assessed by daily assignment of clinical scores. Surprisingly, diminished occurrence and severity of clinical disease in Stat5−/− mice was observed (FIGS. 1A and 1B ), a result that was opposite to expectations based on an antagonistic role for STAT5 inT H17 generation. Similar results were observed when a single MOG35-55/CFA immunization was performed or replaced CFA with LPS as the adjuvant to induce EAE (FIGS. 1C and 1D ). Consistent with reduced EAE disease in Stat5−/− mice, a remarkable reduction of immune cell infiltration in the spinal cord of Stat5−/− mice was observed (FIG. 2A ). Furthermore, the infiltration of various immune cell populations, including CD4+, CD8+. B220+ and CD11b+ cells was reduced in Stat5−/− mice (FIGS. 2B-D and data not shown). However, the frequencies of IL-17+ and IFN-γ+ cells among CD4+ T cells in the CNS were comparable between Stat5+/+ and Stat5−/− mice (FIG. 3A ), suggesting the resistance to EAE in Stat5−/− mice is independent ofT H1 andT H17 cell development. Nevertheless, decreased CD4+CD25+ Treg population in the CNS of Stat5−/− mice was detected (FIG. 3B ), indicating the resistance to EAE in Stat5−/− mice was unlikely due to altered Treg, cells. - Stat5 deletion (Cd4-cre; Stat5f/−) mice was reported to develop peripheral lymphopenia, with a reduction of both CD4+ and CD8+ T cells (Yao et al., 2006). However, another study showed that Stat5 deletion (Cd4-cre; Stat5f/f) did not affect the proportion of peripheral CD4+ T cells (Burchill et al., 2007). In the experimental setting, a change in the absolute number of peripheral CD4+ T cells was not detected by Stat5 deletion during EAE development (
FIGS. 4A and 4B ), suggesting the resistance to EAE in Stat5−/− mice was not caused by peripheral lymphopenia. Furthermore, increased frequencies of IL-17+ and IFN-γ+ cells were detected among CD4+ T cells in spleens of Stat5−/− mice (FIG. 4C ), which further support the idea that the resistance to EAE in Stat5−/− mice is likely independent ofT H1 andT H17 generation. To validate the function of STAT5 inT H1 andT H17 generation, the in vitro differentiation was performed by activating naïve CD4+ T cells under TH1- and TH17-polarizing conditions. In agreement with previous reports, that STAT5 mediated the suppressive effect of IL-2 onT H17 differentiation (data not shown). Interestingly, IL-7, which also signals through STAT5, was not observed to have a demonstrable effect onT H17 differentiation (data not shown). Nevertheless, a slight decrease of IFN-γ+ cells under TH1-polarizing condition was observed when STAT5 was deleted (data not shown). - To confirm if the resistance of EAE in Stat5+/+ mice is mediated by CD4+ T cells, Rag2−/− mice were reconstituted with Stat5+/+ or Stat5−/− CD4+ T cells followed by EAE induction. We found that Rag1−/− mice that received Stat5−/− CD4+ T cells were resistant to the disease compared with mice receiving wild-type cells (data not shown), demonstrating that Stat5−/− CD4+ T cells were impaired in their ability to promote EAE development.
- Next, whether the lack of encephalitogenicity was caused by defects in migration of Stat5−/− CD4+ T cells to the CNS was examined. It has been shown that the chemokine receptor CCR6 is essential for
T H17 cell entry into the CNS through the choroid plexus (Reboldi et al., 2009). Thus. CCR6 expression in both Stat5−/− and Stat5+/+ CD4+ T cells was examined. Increased CD4+CCR6+ cells in spleens of Stat5−/− mice compared with Stat5+/+ controls (FIG. 5A ) was observed. CXCR3 and CD69 expression was also examined, which showed increased expression of both molecules in CD4+ T cells in the absence of STAT5 (FIG. 5A ). These results indicate that Stat5−/− CD4+ T cells can infiltrate CNS. Furthermore, comparable number of CD4+ T cells present in the CNS of Stat5+/+ and Stat5−/− mice during EAE induction was observed (atday 7 and day 9) (FIG. 5B ). However, CD4+ T cells in CNS of Stat5−/− mice dropped dramatically during disease onset (Day 21) (FIGS. 5C and 5D ). Together, these results demonstrate that Stat5−/− CD4+ T cells can infiltrate CNS, but fail to induce effective inflammation in the CNS in EAE. - To further exclude the possibility that the resistance of Stat5-deficient mice to EAE was caused by any potential defect in the survival of autoreactive CD4+ T in the CNS, increased numbers of Stat5−/− CD4+ T cells than wild-type cells were transferred into Rag1−/− mice respectively to make sure comparable numbers of autoreactive CD4+ T cells were present in the CNS during EAE development. As shown in
FIGS. 6A and 6B , despite similar numbers of CD4+ T cells in the CNS between two groups of mice, reduced disease severity was nevertheless observed in mice receiving Stat5-deficient CD4+ T cells. Additionally, certain numbers of Stat5-deficient mice containing similar numbers of CD4+ T cells in the CNS as wild-type mice at peak of EAE disease were observed, yet, they were relatively resistant to EAE compared with those wild-type mice (FIG. 6C ), further suggesting that the resistance to EAE disease in Stat5-deficient mice was unlikely due to impaired CD4+ T cell survival in the CNS. - To further develop a causal link between these observations and the intrinsic impairment of Stat5−/− CD4+ T cells, MOG35-55-specific Stat5+/+ and Stat5−/− CD4+ T cells were transferred into Rag2−/− mice separately without further immunization to test if these cells were able to mediate EAE development. As shown in
FIGS. 7A and 7B , mice receiving Stat5+/+ CD4+ T cells spontaneously developedEAE disease 1 week after transfer. In contrast, mice receiving Stat5−/− CD4+ T cells had significantly reduced disease severity and incidence. The frequencies of IL-17+ and IFN-γ+ cells among CD4+ T cells in the CNS of Rag2−/− mice were comparable between two groups (FIG. 7C ), further suggesting that the intrinsic defect in encephalitogenicity of Stat5−/− CD4+ T cells is independent ofT H1 andT H17. To exclude the possible role of CD8+ T cells in the resistance to EAE observed in Stat5− mice, Rag2−/− mice were reconstituted with MOG35-55-specific Stat5+4 or Stat5−/− CD4+ T cells together with equal numbers of Stat5+/+ CD8+ T cells. The transfer of Stat5−/− CD4+ together with Stat5+/+ CD8+ T cells still failed to induce EAE (data not shown). Together, these data demonstrate that Stat5+/+ CD4+ T cells have intrinsic defect in encephalitogenicity. The relevant teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety. - To test whether GM-CSF production was impaired by Stat5 deletion, its expression was examined in MOG35-53-specific Stat5+/+ and Stat5+/+ CD4+ T cells. Splenocytes derived from MOG35-55/CFA-immunized Stat5+/+ and Stat5−/− mice were challenged with various concentrations of MOG35-55 for 24 h, to examine the secretion of GM-CSF. GM-CSF production was observed to increase in a MOG35-55 dose-dependent manner in Stat5+/+ cells (
FIG. 8A ). In contrast, GM-CSF production was severely diminished in Stat5+/− cells in all conditions. To further validate this, splenocytes derived from mice were stimulated during the development of EAE with PMA/Ionomycin in the presence of GolgiPlug for GM-CSF and IL-17 intracellular staining. Although IL-17 expression was enhanced in Stat5−/− cells, a significantly reduced proportion of GM-CSF+IL-17″ and GM-CSF+IL-17+ cells was observed among CD4+CD44hi cells in the absence of STAT5 (FIG. 8B ). Moreover, the frequency of MOG35,55-specific GM-CSF+ T cells was also significantly reduced in spleens of Stat5−/− mice (FIG. 8C ). Together, these results indicate that STAT5 is required for GM-CSF expression in autoreactive CD4+ T cells. However, STAT5, an important transcription factor inT H17 differentiation, was required for GM-CSF expression (FIG. 8D ). - Next. GM-CSF induction in the CNS during EAE development was examined. Although IL-17 and IFN-γ production by CNS-infiltrating CD4+ T cells was not impaired by Stat5 deficiency, a diminished frequency of CD4+GM-CSF+ cells in the CNS of Stat5−/− mice was detected compared with control mice (
FIG. 9A ). Further analysis showed a reduced GM-CSF+ percentage among CD4+IL-17; cells and among CD4+IFN-γ+ cells (FIG. 9A ). Similarly, Rag2−/− mice transferred with MOG35-55-specific Stat5−/− CD4+ T cells also showed a reduced frequency of CD4+GM-CSF+ T cells in the CNS compared with control mice (FIG. 9B ). GM-CSF mRNA expression in the CNS of Stat5−/− mice was markedly lower than that of Stat5+/+ mice atday 8 after EAE induction (FIG. 9C ), when comparable CD4+ T cell infiltration was detected in Stat5−/− and Stat5+/+ mice (FIGS. 5C and 5D ). Meanwhile, no significant difference of IL-17 and IFN-γ expression was detected between Stat5−/− and Stat5+/+ mice (FIG. 9C ). The impaired cytokine induction (IL-17 and IFN-γ) in the CNS of Stat5−/− mice at later stage (day 14,FIG. 9C ) could be explained by the inability of Stat5−/− CD4+ T to sustain neuroinflammation (FIGS. 5C and 5D ). Interestingly, GM-CSF induction in the CNS preceded IL-23 induction (FIG. 9C ), suggesting IL-23 might not be required for GM-CSF expression in the induction phase of EAE. In summary, the results suggest that GM-CSF expression in autoreactive CD4+ T cells is regulated by STAT5 and the impaired GM-CSF production in the absence of STAT5 caused the resistance of the mice to EAE. - Next, the mechanism by which STAT5 regulates GM-CSF expression was investigated. As the present disclosure indicates, neither IL-23 nor IL-1β seemed to be potent STAT5 stimulators (
FIG. 10A ). Furthermore, IL-1R1 expression was not changed, whereas IL-23Rα expression was increased in Stat5−/− CD4+ T cells (FIG. 10B ). These data suggest that the ability of STAT5 to induce GM-CSF expression is likely independent of IL-23 and IL-1β signaling. In contrast, both IL-2 and IL-7 potently activated STAT5 by inducing tyrosine phosphorylation (FIG. 10A ). Therefore, the effect of these two cytokines on GM-CSF induction in autoreactive T cells was further examined. Splenocytes derived from MOG35-55-immunized wild-type mice were challenged with MOG35-55 alone or plus IL-2. GM-CSF and IL-17 production by CD4+ T cells were analyzed by intracellular cytokine staining. As shown inFIG. 10C , IL-2 showed modest effects on the frequency of GM-CSF+ T cells. In contrast, IL-7 significantly promoted GM-CSF expression in both IL-1T and IL-17+ CD4+CD44hi T cells (FIG. 11A ). Furthermore, IL-7 carried out this function in a STAT5-dependent manner, as Stat5 deletion abrogated its effect on GM-CSF expression as assessed by intracellular cytokine staining and ELISA (FIG. 11A , lower panels, andFIG. 11B ). - IL-7Rα is expressed in both CD62LhiCD44loT cells and CD62loCD44hi T cells, suggesting IL-7 may directly act on CD4+ T cells to regulate GM-CSF expression. Thus, CD62LhiCD44lo and CD62LloCD44hi T cells were sorted from Stat5−/− mice and littermate controls during EAE development, and then activated cells in the presence or absence of IL-7. As shown in
FIG. 11C , CD62LloCD44hi T cells potently expressed GM-CSF, while CD62LhiCD44lo) T cells expressed 30-fold lower GM-CSF amounts. STAT5 deletion resulted in reduced basal GM-CSF production in CD62LloCD44hi T cells. As expected, IL-7 promoted GM-CSF expression in both subsets of CD4+ T cells in a STAT5-dependent manner (FIG. 11C ). - To examine the contribution of IL-7-induced GM-CSF expression in autoreactive CD4+ T cells to EAE development, mice were treated with IL-7Rα-specific antibody (clone SB/14) during EAE development. The treatment resulted in a significant reduction of disease severity, which was accompanied with reduced CNS inflammation (
FIGS. 12A and 12B ). In agreement with previous report (Lee et al., 2012), this neutralizing antibody did not have T cell depleting activity (FIG. 12C ). Notably, the blocking of IL-7 signaling resulted in decreased GM-CSF expression in CNS-infiltrating CD4+ T cells (FIGS. 120-12F ). In summary, the present findings indicate that IL-7 induces STAT5-dependent GM-CSF expression in autoreactive CD4+ T cells, which contributes to the development of neuroinflammation. - Since both
T H17 andT H1 can produce GM-CSF, it was determined if the IL-7-stimulated phenotype was related to either of these subsets. To further understand the characteristics of GM-CSF-expressing CD4+ cells, naïve CD4+ T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 under TH1- or TH17-polarizing conditions. It was observed that anti-CD3 together with anti-CD28 induced the expression of GM-CSF (FIG. 14A ). However, whileT H1 differentiation conditions promoted IFN-γ expression andT H17 conditions promoted IL-17 expression as expected, bothT H1 andT H17 differentiation conditions greatly suppressed the production of GM-CSF (FIGS. 13A and 13B ). Conversely, IL-12 and IFN-γ neutralization promoted GM-CSF-expressing cell generation (FIG. 13A ), consistent with a previous report (Codarri et al., 2011). IL-23 and IL-1β did not increase GM-CSF-expressing cell differentiation from naïve CD4+ T cells (FIG. 13A ), which was consistent with the finding that naïve CD4+ T cells did not express their receptors. TGF-β inhibits GM-CSF expression (El-Behi et al., 2011). IL-6, an essential cytokine forT H17 differentiation, had a profound inhibitory effect on GM-CSF expression (FIG. 14B ), indicating STAT3 could be a negative regulator. To address this, naïve CD4+ T cells were purified from Stat3−/− mice for cell differentiation. Strikingly, in the absence of STAT3, cells polarized underT H17 condition expressed GM-CSF (FIG. 14C ). Interestingly, even without exogenous IL-6, STAT3 still had a moderate suppressive effect on GM-CSF-expressing cell differentiation (FIG. 14C ). In addition, RORγt and T-bet have been reported unnecessary for GM-CSF expression in CD4+ T cells (El-Behi et al., 2011). Thus, the present datasupport a model wherein GM-CSF-expressing CD4+ T cells develop via a lineage distinct fromT H17 andT H1. - The present findings disclosed herein (including .g., diminished GM-CSF expression in Stat5−/− CD4+ T cells in vivo, IL-7/STAT5-mediated induction of GM-CSF expression in naïve CD4+ T cells, and the distinct features of GM-CSF-expressing TH cells versus
T H1 andT H17 cells) indicates a distinct TH cell subset that is regulated by IL-7-STAT5 signaling. This finding was further explored by examining GM-CSF-expressing TH cell differentiation in vitro by activating naïve CD4+ T cells with anti-CD3 and anti-CD28 in the presence of different concentrations of IL-7. As shown inFIGS. 15A and 15B , IL-7 strongly promoted the generation of GM-CSF-expressing cells and GM-CSF secretion. Moreover, the generation of GM-CSF-expressing TH by IL-7 was mediated by STAT5. Without STAT5, IL-7 was unable to promote the generation of GM-CSF-expressing cells (FIGS. 15C and 15D ). Further investigation showed that IL-7-induced STAT5 activation directly hound promoter regions of the Csf2 gene (FIGS. 15E and 15F ). - Small proportions of IFN-γ-expressing cells were generated during GM-CSF-expressing TH differentiation (
FIG. 1.5A ). Thus, the effect of blocking IFN-γ on GM-CSF-expressing cell generation was tested, which showed that the combination of IL-7 and IFN-γ neutralization induced the highest frequency of GM-CSF+ cells, where few IL-17+ or IFN-γ+ cells were detected (FIG. 16A ). Moreover, the expression of subset defining transcriptional factors in GM-CSF-expressing TH was examined and observed that the expression of RORγt or T-bet in GM-CSF-expressing TH was significantly lower than those in TH17 orT H1 cells, respectively (FIG. 16B ), confirming that the GM-CSF-expressing TH cells are distinct fromT H1 andT H17 cells. Together, these data suggest that IL-7-STAT5 signaling direct the differentiation of a novel GM-CSF-expressing helper T cell subset, termed TH-GM. - Next, it was determined whether IL-2 signaling could influence TH-GM differentiation from naïve CD4+ T cells. The addition of IL-2 or antibody against IL-2 only had modest effect on the frequency of GM-CSF+ cells (
FIG. 14D ), indicating a minimal effect of IL-2 on TH-GM differentiation. Unlike IL-7Rα, IL-2 high-affinity receptor IL-2Ra was not expressed in naïve CD4+ T cells, but its expression was gradually induced by TCR activation (FIGS. 17A-17C ). Thus, the minimal effect of IL-2 at least in part is due to the unresponsiveness of naïve CD4+ T cells to IL-2 stimulation. In support of this view, IL-7, but not IL-2, induced STAT5 activation and upregulated GM-CSF mRNA expression in naïve CD4+ T cells (FIGS. 17D and 17E ). To further confirm this idea, activated CD4+ T cells were stimulated with IL-2 or IL-7, which showed that both cytokines induced STAT5 activation, Csf2 promoter binding and GM-CSF mRNA upregulation (FIGS. 18A-18C ). Notably, IL-2 induced a prolonged STAT5 activation compared with IL-7 (FIG. 18A ). - To demonstrate TH-GM as distinct from known T cell subsets (e.g.,
T H1 and TH17), a whole transcriptome analysis was performed by microarray to validate its specificity compared with known T cell subsets, inparticular T H17 cells. Naïve CD4+ T cells were differentiated intoT H1,T H17 and TH-GM. Microarray analysis was performed to examine their gene expression profiles. Whole transcriptome clustering indicates TH-GM cells as representing a novel subset distinct fromT H1 orT H17 cells. T cell lineage-specific gene expression is shown in Table 1. A list of 202 genes preferentially expressed inT H1 cells were identified, compared with naïve,T H17 or TH-GM cells (fold change >1.7), among which IFN-γ and T-bet are on the top of the list (Table 1). Similarly, TH17-feature genes, such as IL-17, IL-17F, RORγt and RORα, were identified in the list including 411 genes specific toT H17 cells (Table 1). The TH-GM cell-specific gene list (“Genes preferentially upregulated in TH-GM” the TH-GM signature genes) contains 210 genes including the gene encoding GM-CSF as the top gene in the list (Table 1). A set of surface molecules which were selectively expressed at high level in TH-GM subset, and another set of surface molecules which were selectively expressed at low level in TH-GM subset compared with other subsets were identified (FIG. 19 and Table 1). These molecules (also TH-GM signature genes) can be used for further characterization by surface markers to identify the TH-GM subset of T cells. Several other genes of interest were also identified, including genes encoding cytokines and transcriptional factors, in particular IL-3. Various helper T cells were differentiated in vitro and confirmed that TH-GM cells are potent IL-3 producers as compared withT H1 andT H17 cells (FIGS. 20A, 20C and 20D ). In addition, several other cytokines, including EBI-3, PENL and RANKL were found preferentially expressed in TH-GM cells (FIG. 20B ), indicating diverse biological functions of TH-GM cells. - To test the hypothesis that GM-CSF-expressing TH subset (TH-GM) was the primary encephalitogenic effector cells, adoptive transfer of different subsets of MOG35-55-specific CD4+ T cells was performed into Rag2−/− mice for EAE induction. As shown in
FIG. 21 , GM-CSF-expressing TH cells were preferentially able to induce EAE compared withT H17 andT H1 subsets. - The effect of disrupting STAT5 activation by chemical inhibitor was examined to explore possible methods of treating autoimmune neuroinflammation. The phosphorylation on the key tyrosine residue in SH2 domain is crucial for STAT5 activation and function. A commercial STAT5 inhibitor (CAS 285986-31-4, Calbiochem) has been reported to selectively disrupt tyrosine phosphorylation and DNA binding of STAT5 (Muller et al., 2008). First, the inhibitory effect of this inhibitor on STAT5 activation upon IL-7 stimulation in CD4+ T cells was tested. At a concentration of 50 μM, the inhibitor had about 50% inhibitory effect, which was further enhanced with the increase of concentration (
FIG. 22A ). STAT5 inhibitor had low affinity and thus required a high concentration to fully block STAT5 activation, whereas JAK3 inhibitor showed potent inhibitory effect even at low concentration (FIG. 22B ). The specificity of STAT5 inhibitor was next tested by examining its effect on the activation of STAT3 and STAT1. As shown inFIGS. 22C and 22D , this STAT5 inhibitor at relatively lower concentration (50 or 100 μM) showed minimal inhibitory effect on both STAT3 and STAT1 activation. - The effect of STAT5 inhibition on TH-GM differentiation was examined. As shown, STAT5 inhibitor suppressed TH-GM differentiation in a dosage-dependent manner (
FIG. 22E ).Reduced T H1 differentiation upon STAT5 inhibitor treatment was observed (data not shown), butT H17 differentiation was not suppressed by STAT5 inhibitor (data not shown). - To explore the therapeutic effect of targeting STAT5 activation in EAE disease, the commercial STAT5 inhibitor was administered to wild-type mice intraperitoneally every other clay after disease onset. Development of paralysis was assessed by daily assignment of clinical scores. STAT5 inhibition ameliorated EAE severity, associated with reduced immune cell infiltration in the CNS (
FIGS. 23A and 23B ). In contrast, although JAK3 inhibitor can potently block STAT5 activation (FIG. 22B ), it showed detrimental effect on EAE (FIG. 23B ). Of note, STAT5 inhibitor resulted in reduced GM-CSF production in CNS-infiltrating CD4+ T cells (FIGS. 23C and 23D ). This study indicates that targeting STAT5 by chemical inhibitor is useful in therapeutic intervention in MS. - Plasma concentrations of GM-CSF and TNF-α in peripheral blood of RA patients were examined in comparison with gender/age-matched healthy control (HC), and found that both cytokines were elevated in RA (
FIG. 24A ). Ex vivo frequencies of IFN-γ-, IL-17- or GM-CSF-producing TH cells were quantified in RA and HC. High frequencies of IFN-γ- and/or GM-CSF-producing TH cells were detected in all samples, but observed low frequency (<1%) of IL-17-producing TH cells (FIG. 24B ). GM-CSF-single-producing (GM-CSF+IFN-γ−) TH cells represented a substantial population in both RA and HC (FIG. 24B ). More importantly, the frequency of this population in peripheral blood of RA was significantly higher than that of HC (FIG. 24C ). In contrast, neither GM-CSF/IFN-γ-double-producing nor IFN-γ-single-producing TH cells showed any significant difference in their frequencies between RA and HC (FIG. 24C ). Therefore, the frequency of GM-CSF-single-producing TH cells in peripheral blood is selectively elevated in RA, suggesting a functional association of TH-cell-secreted GM-CSF with RA. Moreover, a significant correlation between plasma GM-CSF concentration and GM-CSF-single-producing TH cell frequency was observed in RA (FIG. 24D ). - To further evaluate the association of GM-CSF-producing TH cells with RA, mononuclear cells were isolated from synovial fluid of RA patients and analyzed the abundance of these cells. A marked elevation of GM-CSF-producing TH cell frequency was observed in synovial fluid compared with peripheral blood, but most of these cells co-expressed IFN-γ (
FIG. 24E ). Similarly, bothT H1 andT H17 frequencies were also increased in synovial fluid, withT H17 remaining to be a minor population compared with TH1 (FIG. 24E ). - The elevation of GM-CSF and TNF-α level in plasma of RA in comparison to HC may suggest a therapeutic approach by targeting these two cytokines. The efficacy of blocking both GM-CSF and TNF-α was tested in treating arthritic mice in antigen-induced arthritis (AIA) model, which is a T-cell driven RA model and is easily inducible in C57BL/6 strain with a rapid and synchronized disease onset, facilitating the exploration of RA pathogenesis. Either GM-CSF or TNF-α individual blockade attenuated MA development (
FIG. 25A ). Interestingly, the combination of GM-CSF- and TNF-α-specific neutralizing antibodies showed better efficacy in controlling arthritis development than individual treatments (FIG. 25A ). That is, targeting GM-CSF may have beneficial efficacy in treating arthritis in a way independent of TNF-α activity. To further study the distinguishable effects of GM-CSF and TNF-α in mediating arthritis development, a mouse strain (Cd4-Cre; Stat5f/f, or Stat5−/− in short) with conditional Stat5 deletion was used in T cells for AIA induction. These conditional Stat5-knockout mice resisted arthritis development, as exemplified by milder joint selling, fewer immune cell infiltration in synovia, and reduced joint destruction (FIGS. 25B-25D ), even though they had markedly increased level of serum TNF-α as well as IFN-γ (FIG. 25E ). In contrast, serum level of GM-CSF was significantly reduced in knockout mice (FIG. 25E ), which was likely the causal factor of the resistance to arthritis development as further supported by results described below. Consistent results were also observed in collagen-induced arthritis (CIA) model (FIGS. 26A-26D ). Together, these findings suggest that GM-CSF is an important pathogenic mediator in RA and also indicate the promise of developing anti-GM-CSF drugs to treat RA patients who are anti-TNFα drugs unresponsive, marking GM-CSF-producing TH cells as a new biomarker for RA diagnosis. - On the basis of association of GM-CSF with RA, the cellular producers of GM-CSF and the regulatory mechanism underlying GM-CSF expression in arthritic mice were examined. Splenocytes were collected from wild-type AIA mice and separated cells into three fractions: splenocytes, splenocytes depleted of CD4+ T cells and CD4+ T cells; and stimulated each fraction at same cell numbers under various conditions. Splenocytes produced low but detectable level of GM-CSF without stimulation, which was markedly increased by PMA/Ionomycin or mBSA antigen stimulation (
FIG. 28A ). Under all conditions, splenocytes depleted of CD4+ T cells almost completely abrogated GM-CSF production (FIG. 28A ). In contrast, CD4+ T cells produced dramatically elevated GM-CSF in comparison to splenocytes under all conditions (FIG. 28A ). These results strongly support that CD4+ T cells are predominant producers of GM-CSF at least in spleens of arthritic mice, which is somehow consistent the observed correlation of plasma GM-CSF concentration with GM-CSF-single-producing TH cell frequency in RA (FIG. 24D ). Thus, the functional significance of TH-cell-secreted GM-CSF was examined in arthritis development. Given T-cell-specific Csf2-knockout mice is not available and STAT5 is a key regulator of GM-CSF expression in TH cells, conditional Stat5-knockout mice was used, which showed decreased GM-CSF level and resistance to arthritis development as described above. - Consistent with a previous study (Burchill et al., 2007), similar frequencies of CD4+ T cells were observed in peripheral lymphoid tissues as well as in inflamed synovial tissues of STAT5-deficient mice compared with wild-type mice at
day 7 after AIA induction (FIGS. 27A-27D ), suggesting loss of STAT5 seems to not impair CD4+ T-cell generation in periphery and infiltration in synovial tissues. To determine the requirement of STAT5 for arthritogenic potential of CD4+ T cells, ex vivo-expanded antigen-reactive CD4+ T cells, derived from Stat5+/+ and Stat5−/− ALA mice, were transferred into wild-type naïve mice separately, followed by intra-articular injection of mBSA. Mice receiving Stat5+/+ CD4+ T cells displayed an abundant immune cell infiltration in synovial tissues atday 7 after AIA induction (FIG. 27E ). In contrast, mice receiving Stat5−/− CD4+ T cells had marked reduction of synovial infiltrates (FIG. 27E ). Therefore, STAT5-deficient CD4+ T cells are defective in arthritogenic potential. - Multiple lines of evidence support a central role of T cells in RA. However, the pathogenic mechanism of T cells remains insufficiently understood. Although
T H1 is a predominant population among synovial infiltrating CD4+ T cells in human RA (Berner et al., 2000; Yamada et al., 2008), defective IFN-γ signaling results in increased disease susceptibility in animal models of arthritis (Guedez et al., 2001; Irmler et al., 2007; Manoury-Schwartz et al., 1997; Vermeire et al., 1997). In contrast,T H17 cells are proven crucial in animal models of arthritis (Pernis, 2009), but predominance ofT H17 cells is limited in both peripheral blood and synovial compartment of human RA (Yamada et al., 2008) and (FIGS. 1B and 1E ). As demonstrated herein, STAT5-regulated GM-CSF-producing TH cells potentiate arthritis pathogenesis. - To validate the regulatory role of STAT5 in GM-CSF production, splenocytes derived from AIA mice were stimulated with PMA/Ionomycin plus Golgiplug ex viva, followed by intracellular cytokine staining and flow cytometry. As expected, the frequency of GM-CSF-single-producing cells among CD4+CD44hi population was significantly decreased in Stat5−/− mice (
FIG. 28 34B). Notably, no significant differences were observed in frequencies of IL-17-single-producing (TH17) or IFN-γ-single-producing (TH1) cells between two groups (FIG. 28B ). Further study by combining mBSA restimulation and intracellular cytokine staining showed that the frequency of mBSA-specific GM-CSF-producing effector T cells was much lower in spleens of Stat5−/− mice than those in controls (FIG. 29A ). In addition, AIA mice-derived splenocytes and inguinal lymph nodes (LNs) were restimulated with mBSA ex viva to measure cytokine concentrations in culture supernatants and found a significant reduction of GM-CSF with deletion of STAT5, but comparable levels of both IL-17 and IFN-γ between two groups (FIGS. 29B and 29C ). Together, the results indicate that loss of STAT5 may specifically suppress GM-CSF-producing effector Th cells but notT H17 orT H1 cells in experimental arthritis. - To investigate the involvement of GM-CSF-producing TH cells and their regulation by STAT5 in synovial inflammation, synovial tissues were dissected from AIA mice and examined cytokine production by TH cells. In spite of multiple cellular sources of GM-CSF (Cornish et al., 2009). CD4+ TH cells were prominent producers of GM-CSF in synovial tissues of AIA mice (
FIG. 28C ), consistent with the observation in spleens (FIG. 28A ). Moreover, a significantly lower percentage of synovial GM-CSF-producing TH cells was detected in Stat5−/− mice than Stat5+/+ mice (FIG. 28D ). On the other hand, bothT H1 andT H17 cells exhibited similar percentages between two groups (FIG. 28C ). A decrease in GM-CSF level in synovial compartments of Stat5−/− mice in comparison to controls was expected. To address this, inflamed synovial tissues were harvested from AIA mice for RNA and protein extraction to examine cytokine level by qPCR and ELISA. Indeed, lower synovial GM-CSF but not IFN-γ or IL-17 was detected in Stat5−/− mice than Stat5+/+ mice atday FIGS. 28E and 30A-30C ). In addition, two important proinflammatory cytokines IL-6 and IL-1β were also found persistently and significantly reduced in STAT5-deficient mice (FIGS. 28E and 30A-30C ), indicating the attenuated synovial inflammation. Notably. TNF-α production was reduced atday 7 but not atday 5 in STAT5-deficient mice (FIGS. 28E and 30A -C). Together, these results indicate that STAT5-regulated GM-CSF expression by arthritogenic TH cells is crucial for evoking synovial inflammation. - To determine the critical role of STAT5-regulated GM-CSF production by TH cells in mediating synovitis and arthritis development, GM-CSF was administered via intra-articular injection in mixture with mBSA to the left knee joints of mBSA/CFA-immunized mice, whereas mBSA was injected alone to the right knee joints. Injection with mBSA alone was sufficient to induce abundant immune cell infiltration in the synovial compartments of Stat5+/+ mice but failed to do so in Stat5−/− mice (
FIG. 28F ). Administration of GM-CSF together with mBSA efficiently restored synovial inflammation in Stat5−/− mice (FIG. 34F ). Consistently, the Safranin-O/Fast Green staining revealed severe cartilage depletion upon GM-CSF/mBSA injection, but not mBSA alone, in Stat5−/− mice (FIG. 28G ). These results therefore provide support for the notion that STAT5-regulated GM-CSF production by arthritogenic TH cells is essential for mediating arthritis pathogenesis. - The mechanism by which GM-CSF-producing Th cells evoke synovial inflammation and drive arthritis development was examined. Myeloid lineage-derived cells, including neutrophils, DCs and macrophages, express GM-CSF receptor and are common targets of GM-CSF (Hamilton, 2008). Importantly, those cells invade synovial compartments in RA patients and mouse arthritis models, and contribute to synovitis (McInnes and Schett, 2011). The infiltration of myeloid lineage-derived cells in synovial compartments of ALA mice was examined. CD11b+ myeloid cells represented a predominant population (˜70%) among synovial infiltrating leukocytes (
FIG. 31B ). Although CD4+ TH cell infiltration was not altered by STAT5 deletion, synovial CD11b+ cell infiltration was significantly reduced in Stat5−/− mice compared with Stat5+/+ mice when examined atday 7 after arthritis induction (FIG. 31B ). This reduction is unlikely due to defective hematopoiesis, as similar frequencies of CD11b+ cells were detected in spleens of two group (FIG. 31A ). Further, CD11b+ cells continuously increased in synovial tissues of wild-type mice, but not STAT5-deficient mice, over a 7-day time course (FIG. 31C ). Notably, the selective ablation of synovial CD11b+ cell accumulation in STAT5-deficient mice can be partially restored by local administration of GM-CSF during arthritis induction (FIG. 31D ). Together, these results indicate that myeloid cell accumulation in synovial compartments may be specifically dampened by T-cell-specific STAT5 deletion and resultant GM-CSF insufficiency. - Next, different populations of CD11b+ cells, including DCs, macrophages and neutrophils were analyzed. Monocyte-derived dendritic cells (MoDCs), characterized as CD11cintCD11bhiLy6C+/hiMHCIIhi, were recently reported to be involved in the mBSA/IL-1β arthritis model (Campbell et al., 2011). In the AIA model of the present study, MoDCs were identified at low abundance in spleens and synovial tissues (data not shown). Furthermore, comparable frequencies of MoDCs were detected in both peripheral lymphoid tissues and synovial tissues between Stat5+/+ and Stat5−/− mice (data not shown). These results are in agreement with a previous study showing a dispensable role of GM-CSF in MoDC differentiation (Greter et al., 2012).
- Neutrophils have great cytotoxic potential and contribute to the RA initiation and progression in multiple ways (Wright et al., 2014). It has been suggested that RA disease activity and joint destruction directly correlates with neutrophil influx to joints (Wright et al., 2014). Based on the differential expression of Ly6C and Ly6G, CD11b+ myeloid cells can be classified into Ly6CloLy6Ghi population (neutrophils) and Ly6ChiLy6G− population (monocytes/macrophages). The present study shows that Ly6CloLy6Ghi population continued to accumulate in synovial tissues over a 7-clay time course, and represented a predominant population among synovial CD11b+ cells in wild-type mice at
day 7 after AIA induction, whereas this population was persistently and dramatically diminished in STAT5-deficient mice (FIG. 32A ). Using Giemsa stain, it was validated that synovial-infiltrating Ly6CloLy6Ghi population were neutrophils, which displayed typical polymorphonuclear characteristics with ring-shaped nuclei (FIG. 32B ). In contrast, synovial-infiltrating Ly6ChiLy6G− population had mononuclear morphology and were likely monocytes/macrophages (FIG. 32B ). Importantly, intraarticular administration of GM-CSF during arthritis induction efficiently restored neutrophil accumulation in synovial compartments of STAT5-deficient mice (FIG. 32C ), suggesting a critical role of TH-cell-derived GM-CSF in mediating neutrophil accumulation to inflamed joints. - Neutrophils are recruited during inflammation, in which complex interactions between neutrophils and vascular endothelial cells direct neutrophil adhesion and transmigration from circulation to inflamed tissues (Kolaczkowska and Kubes, 2013). In an in vitro transmigration assay, neutrophil adhesion and migration across monolayers of endothelial cells was significantly enhanced by GM-CSF as chemoattractant (
FIGS. 33A and 33B ), suggesting GM-CSF may mediate neutrophil recruitment to inflamed joints in AIA. Effective neutrophil apoptosis is crucial for the resolution of inflammation. However, in synovitis, neutrophil apoptosis is delayed with a result of extended survival and persistent inflammation (Wright et al., 2014). Thus, the effect of GM-CSF on neutrophil survival was tested and found that GM-CSF had profound efficacy in delaying neutrophil apoptosis (FIG. 33C ). Together, these results indicate that GM-CSF may mediate neutrophil recruitment and sustain neutrophil survival in synovial compartments and contribute to persistent synovitis. To determine the critical role of neutrophils in AIA, \ a neutralizing antibody (1A8) specific for Ly6G was used to deplete neutrophils in vivo. The administration of neutralizing antibody resulted in significant improvement of joint swelling in AIA (FIG. 32D ). Thus, neutrophils accumulation mediated by TH-cell-derived GM-CSF are important for AIA development. - Cytokines are important mediators in the cross-talk between innate and adaptive immunity. As shown herein, several proinflammatory cytokines (IL-6, IL-1β and TNF-α), which are in association with RA pathogenesis (Choy and Panayi, 2001), were significantly reduced in synovial tissues of STAT5-deficient AIA mice (
FIGS. 28E and 30A-30C ). To gain insights into the mechanism underlying the observed cytokine reduction, the cellular sources of these proinflammatory cytokines were examined by fractionating synovial cells into different populations based the differential expression of surface markers (FIG. 34A ). Cytokine mRNA expression level in CD45+TCRβ+ population (T cells), CD45+TCRβ−CD11c− CD11b+ population (mostly monocytes/macrophages and neutrophils) and CD45+TCRβ− CD11c+ population (dendritic cells) was assessed by RT-PCR. GM-CSF, as similar to IL-17 (as a control), was predominantly produced by synovial T cells (FIG. 34B ), further reinforcing the importance of GM-CSF-producing TH cells. In contrast, IL-6 and IL-1β were mainly produced by myeloid cells, e.g. CD11b+ population and CD11c+ population (FIG. 34B ). TNF-α was expressed by all three populations, with relatively lower abundance in T cells (FIG. 34B ). Based on the differential expression of Ly6C and Ly6G in CD11b+ population as discussed above, Ly6CloLy6Ghi population (neutrophils) and Ly6ChiLy6G− population (monocytes/macrophages) were further analyzed, which showed that monocytes/macrophages were likely the major IL-6 producers whereas neutrophils seemed to be better producers of IL-1β and TNF-α (FIG. 34C ). These results, together with the findings above (FIGS. 28E and 30A-30C ), indicate a link that TH-cell-secreted GM-CSF elicits proinflammatory cytokine expression from myeloid cells in synovitis. - To test the regulatory role of GM-CSF in the expression of IL-6 and IL-1β, bone marrow-derived macrophages (BMDMs) and bone marrow-derived dendritic cells (BMDCs) were cultured, and stimulated with GM-CSF. Indeed, GM-CSF stimulation quickly upregulated mRNA expression of both IL-6 and IL-1β within 1 hour (
FIGS. 34D and 34E ). In addition, GM-CSF markedly increased the secretion of IL-6 from BMDMs in a dosage-dependent manner (FIG. 34F ), and from BMDCs even at low dosage (FIG. 34G ). To induce mature IL-1β secretion, BMDMs were primed with LPS for 6 h during which different concentrations of GM-CSF was added, followed by ATP stimulation. The addition of GM-CSF significantly enhanced the secretion of IL-1β into culture supernatant as measured by ELISA (FIG. 34H ). Synovial fibroblasts, the active players in synovial inflammation (Muller-Ladner et al., 2007), also showed increased IL-1β mRNA expression upon GM-CSF stimulation (FIG. 34I ). An inducible effect of GM-CSF on TNF-α expression was not observed in BMDMs, BMDCs or synovial fibroblasts (data not shown). Given the functional importance of IL-6 and IL-1β in arthritis development (Choy and Panayi, 2001), TH-cell-secreted GM-CSF may mediate synovial inflammation also via eliciting the expression of IL- and IL-1β from myeloid cells and synovial fibroblasts. -
TABLE 1 Summary of genes differentially expressed in TH1, TH17, and TH-GM cells Genes differentially Genes differentially expressed in TH1 expressed in TH17 Gene Gene ID Gene Title ID Gene Title 10366586 interferon gamma 10353415 interleukin 17F 10598013 chemokine (C-C 10511779 ATPase, H+ motif) receptor 5 /// transporting, chemokine (C-C lysosomal V0 motif) receptor 2 subunit D2 10523717 secreted 10345762 interleukin 1 phosphoprotein 1 receptor, type 1 10420308 granzyme B 10359697 chemokine (C motif) ligand 1 10545135 interleukin 12 10587639 5′ nucleotidase, receptor, beta 2 ecto 10531724 placenta-specific 8 10501860 formin binding protein 1-like 10363070 glycoprotein 49 A /// 10345032 interleukin 17A leukocyte immunoglobulin- like receptor, subfamily B, member 4 10363082 leukocyte 10446965 RAS, guanyl immunoglobulin- releasing protein 3 like receptor, subfamily B, member 4 10424683 lymphocyte antigen 10565990 ADP- 6 complex, locus G ribosyltransferase 2a 10552406 natural killer cell 10465059 cathepsin W group 7 sequence 10603151 glycoprotein m6b 10358476 proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein) 10360173 SLAM family 10471953 activin receptor member 7 IIA 10455961 interferon inducible 10400006 aryl-hydrocarbon GTPase 1 receptor 10400304 EGL nine homolog 10409876 cytotoxic T 3 (C. elegans) lymphocyte- associated protein 2 alpha 10574023 metallothionein 2 10388591 carboxypeptidase D 10493108 cellular retinoic 10390640 IKAROS family acid binding protein zinc finger 3 II 10375436 family with 10590623 chemokine (C-X- sequence similarity C motif) receptor 71, member B 6 10398039 serine (or cysteine) 10367734 uronyl-2- peptidase inhibitor, sulfotransferase clade A, member 3F /// serine (or cysteine) peptidase inhibitor, clade A, member 3G 10349108 serine (or cysteine) 10500656 CD101 antigen peptidase inhibitor, clade B, member 5 10607738 carbonic anhydrase 10347895 WD repeat 5b, mitochondrial domain 69 10496539 guanylate binding 10495854 protease, serine, protein 5 12 neurotrypsin (motopsin) 10373918 leukemia inhibitory 10425049 apolipoprotein factor L9b /// apolipoprotein L9a 10455954 predicted gene 4951 10378286 integrin alpha E, epithelial- associated 10598976 tissue inhibitor of 10362896 CD24a antigen metalloproteinase 1 10492136 doublecortin-like 10409866 cytotoxic T kinase 1 lymphocyte- associated protein 2 beta 10405211 growth arrest and 10400989 potassium DNA-damage- voltage-gated inducible 45 gamma channel, subfamily H (eag- related), member 5 10503202 chromodomain 10590242 chemokine (C-C helicase DNA motif) receptor 8 binding protein 7 10542275 ets variant gene 6 10407435 aldo-keto (TEL oncogene) reductase family 1, member Cl8 10556820 transmembrane 10592023 amyloid beta protein 159 (A4) precursor- like protein 2 10444291 histocompatibility 10359480 dynamin 3 2, class II antigen A, beta 1 10439299 stefin A3 10475544 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 10547641 solute carrier family 10409767 golgi membrane 2 (facilitated glucose protein 1 transporter), member 3 10503200 chromodomain 10392464 family with helicase DNA sequence binding protein 7 similarity 20, member A 10544320 RIKEN cDNA 10504891 transmembrane 1810009J06 gene /// protein with EGF- predicted gene 2663 like and two follistatin-like domains 1 10503218 chromodomain 10504817 transforming helicase DNA growth factor, binding protein 7 beta receptor 1 10503198 chromodomain 10393559 tissue inhibitor of helicase DNA metalloproteinase binding protein 7 2 10507594 solute earner family 10474419 leucine-rich 2 (facilitated glucose repeat-containing transporter), G protein-coupled member 1 receptor 4 10438626 ets variant gene 5 10456492 DNA segment, Chr 18, ERATO Doi 653, expressed 10390328 T-box 21 10345241 dystonin 10574027 metallothionein 1 10471555 angiopoietin-like 2 10493820 S100 calcium 10494821 tetraspanin 2 binding protein A6 (calcyclin) 10376324 predicted gene 10542355 epithelial 12250 membrane protein 1 10406852 calponin 3, acidic 10500295 pleckstrin homology domain containing, family O member 1 10412076 gem (nuclear 10375402 a disintegrin and organelle) metallopeptidase associated protein 8 domain 19 (meltrin beta) 10496555 guanylate binding 10484227 SEC 14 and protein 1 /// spectrin domains guanylate binding 1 protein 5 10345074 centrin 4 10472097 formin-like 2 10503194 chromodomain 10587829 procollagen helicase DNA lysine, 2- binding protein 7 oxoglutarate 5- dioxygenase 2 10537561 RIKEN cDNA 10530536 tec protein 1810009J06 gene /// tyrosine kinase predicted gene 2663 10439895 activated leukocyte 10586700 RAR-related cell adhesion orphan receptor molecule alpha 10459772 lipase, endothelial 10354191 ring finger protein 149 10439762 S- 10438738 B-cell adenosylhomocysteine leukemia/lymphoma hydrolase 6 10482030 stomatin 10347888 chemokine (C-C motif) ligand 20 10459905 SET binding 10440131 G protein- protein 1 coupled receptor 15 10357833 ATPase, Ca++ 10453057 cytochrome P450, transporting, plasma family 1, membrane 4 subfamily b, polypeptide 1 /// RIKEN cDNA 1700038P13 gene 10475517 expressed sequence 10542140 killer cell lectin- AA467197 /// like receptor microRNA 147 subfamily B member 1F 10585778 sema domain, 10471880 microRNA 181b-2 immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A 10354529 RIKEN cDNA 10542791 PTPRF 1700019D03 gene interacting protein, binding protein 1 (liprin beta 1) 10582275 solute carrier family 10583242 sestrin 3 7 (cationic amino acid transporter, y+ system), member 5 10576034 interferon 10489569 phospholipid regulatory factor 8 transfer protein /// cathepsin A 10503222 chromodomain 10523297 cyclin G2 helicase DNA binding protein 7 10503220 chromodomain 10381187 ATPase, H+ helicase DNA transporting, binding protein 7 lysosomal V0 subunit A1 10503210 chromodomain 10346651 bone helicase DNA morphogenic binding protein 7 protein receptor, type II (serine/threonine kinase) 10476945 cystatin F 10490159 prostate (leukocystatin) transmembrane protein, androgen induced 1 10503216 chromodomain 10389581 yippee-like 2 helicase DNA (Drosophila) binding protein 7 10366983 transmembrane 10581992 avian protein 194 musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 10495675 coagulation factor 10413250 cytoplasmic III polyadenylated homeobox 10421697 RIKEN cDNA 10555063 integrator 9030625A04 gene complex subunit 4 10445112 ubiquitin D 10406982 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 6 10530627 leucine rich repeat 10596303 acid phosphatase, containing 66 prostate 10440019 transmembrane 10357472 chemokine (C-X- protein 45a C motif) receptor 4 10378783 ribosomal protein 10545130 growth arrest and L36 DNA-damage- inducible 45 alpha 10447341 ras homolog gene 10436402 claudin domain family, member Q /// containing 1 phosphatidylinositol glycan anchor biosynthesis, class F 10373452 predicted gene 129 10539135 capping protein (actin filament), gelsolin-like 10454286 microtubule- 10428534 trichorhinophalangeal associated protein, syndrome 1 RP/EB family, (human) member 2 10572497 interleukin 12 10368675 myristoylated receptor, beta 1 alanine rich protein kinase C substrate 10368060 epithelial cell 10531910 hydroxysteroid transforming (17-beta) sequence 2 dehydrogenase 13 oncogene-like 10471457 ST6 (alpha-N- 10370303 adenosine acetyl-neuraminyl- deaminase, RNA- 2,3-beta-galactosyl- specific, B1 1,3)-N- acetylgalactosaminide alpha-2,6- sialyltransferase 4 10374366 epidermal growth 10592888 chemochine (C- factor receptor X-C motif) receptor 5 10450501 tumor necrosis 10503259 transformation factor related protein 53 inducible nuclear protein 1 10347291 chemokine (C-X-C 10446771 lysocardiolipin motif) receptor 2 acyltransferase 1 10553501 solute carrier family 10428579 exostoses 17 (sodium- (multiple) 1 dependent inorganic phosphate cotransporter), member 6 10345824 interleukin 18 10476314 prion protein receptor accessory protein 10458314 transmembrane 10406598 serine protein 173 incorporator 5 10388430 serine (or cysteine) 10461765 leupaxin peptidase inhibitor, clade F, member 1 10496015 phospholipase A2, 10428536 trichorhinophalangeal group XIIA syndrome 1 (human) 10510391 spermidine synthase 10362245 erythrocyte protein band 4.1- like 2 10486396 EH-domain 10604008 predicted gene containing 4 10058 /// predicted gene 10230 /// predicted gene 10486 /// predicted gene 14632 /// predicted gene 14819 /// predicted gene 4836 /// predicted gene 2012 /// predicted gene 5169 /// predicted gene 6121 /// Sycp3 like X-linked /// predicted gene 5168 /// predicted gene 10488 /// predicted gene 14525 /// predicted gene 5935 10368054 epithelial cell 10409857 RIKEN cDNA transforming 4930486L24 gene sequence 2 oncogene-like 10608637 na 10522368 NIPA-like domain containing 1 10595718 carbohydrate 10368720 solute carrier sulfotransferase 2 family 16 (monocarboxylic acid transporters), member 10 10496580 guanylate binding 10438639 diacylglycerol protein 3 kinase, gamma 10594053 promyelocytic 10499431 synaptotagmin XI leukemia 10544829 JAZF zinc finger 1 10565840 neuraminidase 3 10601778 armadillo repeat 10494023 RAR-related containing, X-linked orphan receptor 3 gamma 10355967 adaptor-related 10391103 junction protein complex AP- plakoglobin 1, sigma 3 10592503 cytotoxic and 10417053 muscleblind-like regulatory T cell 2 molecule 10496023 caspase 6 10350341 microRNA 181b-1 10599192 LON peptidase N- 10459071 RIKEN cDNA terminal domain and 2010002N04 gene ring finger 3 10467578 phosphoinositide-3- 10463476 Kazal-type serine kinase adaptor peptidase inhibitor protein 1 domain 1 10585703 ribonuclease P 25 10348537 receptor subunit (human) (calcitonin) activity modifying protein 1 10365482 tissue inhibitor of 10348432 ArfGAP with metalloproteinase 3 GTPase domain, ankyrin repeat and PH domain 1 10469151 inter-alpha 10576332 tubulin, beta 3 /// (globulin) inhibitor melanocortin 1 H5 receptor 10503192 chromodomain 10554094 insulin-like helicase DNA growth factor 1 binding protein 7 receptor 10593050 interleukin 10 10495794 phosphodiesterase receptor, alpha 5A, cGMP- specific 10597648 myeloid 10569504 tumor necrosis differentiation factor receptor primary response superfamily, gene 88 member 23 10538290 sorting nexin 10 10452516 ankyrin repeat domain 12 10503204 chromodomain 10534596 cut-like helicase DNA homeobox 1 binding protein 7 10353707 protein tyrosine 10362073 serum/glucocorticoid phosphatase 4a1 /// regulated protein tyrosine kinase 1 phosphatase 4a1- like 10377010 SCO cytochrome 10408331 acyl-CoA oxidase deficient thioesterase 13 homolog 1 (yeast) 10440903 RIKEN cDNA 10415413 NYN domain and 4932438H23 gene retroviral integrase containing 10521205 SH3-domain 10598359 synaptophysin binding protein 2 10604587 microRNA 363 10544114 homeodomain interacting protein kinase 2 10571958 SH3 domain 10436128 myosin, heavy- containing ring chain 15 finger 1 10357553 interleukin 24 10408450 SRY-box containing gene 4 10606730 armadillo repeat 10487011 glycine containing, X-linked amidinotransferase 6 (L- arginine: glycine amidinotransferase) 10564960 furin (paired basic 10378833 slingshot amino acid cleaving homolog 2 enzyme) (Drosophila) 10402585 tryptophanyl-tRNA 10521498 collapsin synthetase response mediator protein 1 10417095 FERM, RhoGEF 10538939 eukaryotic (Arhgef) and translation pleckstrin domain initiation factor 2 protein 1 alpha kinase 3 (chondrocyte- derived) 10442435 ribonucleic acid 10585276 POU domain, binding protein S1 class 2, associating factor 1 10394990 membrane bound 10512156 aquaporin 3 O-acyltransferase domain containing 2 10538753 atonal homolog 1 10469110 USP6 N-terminal (Drosophila) like 10351667 signaling 10568392 regulator of G- lymphocytic protein signalling activation molecule 10 family member 1 10461844 guanine nucleotide 10603346 proteolipid binding protein, protein 2 alpha q polypeptide 10422057 ribosomal protein 10353947 transmembrane L7A protein 131 10572897 heme oxygenase 10452633 TGFB-induced (decycling) 1 factor homeobox 1 10507784 palmitoyl-protein 10380289 monocyte to thioesterase 1 macrophage differentiation- associated 10445702 ubiquitin specific 10521969 IMP1 inner peptidase 49 mitochondrial membrane peptidase-like (S. cerevisiae) 10569057 ribonuclease/ 10521678 CD38 antigen angiogenin inhibitor 1 10370471 1-acylglycerol-3- 10592515 ubiquitin phosphate O- associated and acyltransferase 3 SH3 domain containing, B 10586591 carbonic 10512470 CD72 antigen anyhydrase 12 10512701 translocase of outer 10587085 cDNA sequence mitochondrial BC031353 membrane 5 homolog (yeast) 10462702 HECT domain 10492689 platelet-derived containing 2 growth factor, C polypeptide 10552740 nucleoporin 62 /// 10514221 perilipin 2 Nup62-Il4i1 protein 10581996 chromodomain 10458247 leucine rich protein, Y repeat chromosome-like 2 transmembrane neuronal 2 10363901 ets variant gene 5 10468898 lymphocyte transmembrane adaptor 1 10520862 fos-like antigen 2 10555059 potassium channel tetramerisation domain containing 14 10526520 procollagen-lysine, 10408629 RIKEN cDNA 2-oxoglutarate 5- 1300014106 gene dioxygenase 3 10571274 glutathione 10546510 leucine-rich reductase repeats and immunoglobulin- like domains 1 10351206 selectin, platelet 10544596 transmembrane protein 176B 10493474 mucin 1, 10361748 F-box protein 30 transmembrane 10370000 glutathione S- 10356291 RIKEN cDNA transferase, theta 1 A530040E14 gene 10500272 predicted gene 129 10581450 DEAD (Asp-Glu- Ala-Asp) box polypeptide 28 10452815 xanthine 10414417 pellino 2 dehydrogenase 10393823 prolyl 4- 10372528 potassium large hydroxylase, beta conductance polypeptide calcium-activated channel, subfamily M, beta member 4 /// RIKEN cDNA 1700058G18 gene 10408280 leucine rich repeat 10408613 tubulin, beta 2B containing 16A 10575685 nudix (nucleoside 10411274 synaptic vesicle diphosphate linked glycoprotein 2c moiety X)-type motif 7 10599174 interleukin 13 10456357 phorbol-12- receptor, alpha 1 myristate-13- acetate-induced protein 1 10458940 zinc finger protein 10511498 pleckstrin 608 homology domain containing, family F (with FYVE domain) member 2 10476197 inosine 10402136 G protein- triphosphatase coupled receptor (nucleoside 68 triphosphate pyrophosphatase) 10419790 ajuba 10549990 vomeronasal 1 receptor, G10 /// vomernasal 1 receptor Vmn1r- ps4 /// vomeronasal 1 receptor 3 /// vomeronasal 1 receptor Vmn1r238 /// vomeronasal 1 receptor 2 10364909 ornithine 10554789 cathepsin C decarboxylase antizyme 1 /// ornithine decarboxylase antizyme 1 pseudogene 10503190 chromodomain 10427928 triple functional helicase DNA domain (PTPRF binding protein 7 interacting) 10516932 sestrin 2 10549162 ST8 alpha N acetyl- neuraminide alpha-2,8- sialyltransferase 1 10585338 KDEL (Lys-Asp- 10482109 mitochondrial Glu-Leu) containing ribosome 2 recycling factor /// RNA binding motif protein 18 10464425 G protein-coupled 10425092 cytohesin 4 receptor kinase 5 10441601 T-cell activation 10356866 programmed cell Rho GTPase- death 1 activating protein 10482059 glycoprotein 10554204 ATP/GTP galactosyltransferase binding protein- alpha 1,3 like 1 10522411 cell wall biogenesis 10403229 integrin beta 8 43 C-terminal homolog (S. cerevisiae) 10369276 coiled-coil domain 10374529 expressed containing 109A sequence AV249152 10368970 PR domain 10565434 ribosomal protein containing 1, with S13 ZNF domain 10369541 hexokinase 1 10431266 ceramide kinase 10374236 uridine 10410124 cathepsin L phosphorylase 1 10489660 engulfment and cell 10441003 runt related motility 2, ced-12 transcription homolog factor 1 (C. elegans) 10488797 peroxisomal 10555303 phosphoglucomutase membrane protein 4 2-like 1 10558090 transforming, acidic 10530215 RIKEN cDNA coiled-coil 1110003E01 gene containing protein 2 10409265 AU RNA binding 10480275 nebulette protein/enoyl- coenzyme A hydratase 10374364 thymoma viral 10434302 kelch-like 24 proto-oncogene 2 (Drosophila) 10598575 LanC (antibiotic 10565002 CREB regulated synthetase transcription component C-like 3 coactivator 3 (bacterial) 10439514 growth associated 10413338 na protein 43 10497842 Bardet-Biedl 10523670 AF4/FMR2 syndrome 7 (human) family, member 1 10462091 Kruppel-like factor 10478594 cathepsin A 9 /// predicted gene 9971 10498024 solute carrier family 10514128 tetratricopeptide 7 (cationic amino repeat domain acid transporter, y+ 39B system), member 11 10483719 chimerin 10535956 StAR-related (chimaerin) 1 lipid transfer (START) domain containing 13 10606694 Bruton 10503695 BTB and CNC agammaglobulinemia homology 2 tyrosine kinase 10443110 synaptic Ras 10584334 sialic acid GTPase activating acetylesterase protein 1 homolog (rat) 10368062 epithelial cell 10502890 ST6 (alpha-N- transforming acetyl- sequence 2 neuraminyl-2,3- oncogene-like beta-galactosyl- 1,3)-N- acetylgalactosaminide alpha-2,6- sialyltransferase 3 10575693 vesicle amine 10564467 leucine rich transport protein 1 repeat containing homolog-like 28 (T. californica) 10562897 zinc finger protein 10345715 mitogen-activated 473 /// vaccinia protein kinase related kinase 3 kinase kinase kinase 4 10373709 eukaryotic 10568668 a disintegrin and translation initiation metallopeptidase factor 4E nuclear domain 12 import factor 1 (meltrin alpha) 10487238 histidine 10462406 RIKEN cDNA decarboxylase C030046E11 gene 10594988 mitogen-activated 10472649 myosin IIIB protein kinase 6 10422436 dedicator of 10363894 inositol cytokinesis 9 polyphosphate multikinase 10459084 synaptopodin 10606058 chemokine (C-X- C motif) receptor 3 10567450 dynein, axonemal, 10439955 family with heavy chain 3 sequence similarity 55, member C 10604751 fibroblast growth 10530615 OC1A domain factor 13 containing 2 10584827 myelin protein 10528183 spermatogenesis zero-like 2 associated glutamate (E)-rich protein 4d /// spermatogenesis associated glutamate (E)-rich protein 4c /// spermatogenesis associated glutamate (E)-rich protein 4e /// predicted gene 9758 /// RIKEN cDNA 4930572O03 gene /// spermatogenesis associated glutamate (E)-rich protein 7, pseudogene 1 /// predicted gene 7361 10473356 ubiquitin- 10488507 abhydrolase conjugating enzyme domain containing E2L6 12 10498350 purinergic receptor 10420668 microRNA 15a P2Y, G-protein coupled, 14 10497862 transient receptor 10469951 ring finger potential cation protein 208 channel, subfamily C, member 3 10368056 epithelial cell 10501629 CDC14 cell transforming division cycle 14 sequence 2 homolog A oncogene-like (S. cerevisiae) 10425357 Smith-Magenis 10386789 Unc-51 like syndrome kinase 2 chromosome region, (C. elegans) candidate 7-like (human) 10498952 guanylate cyclase 1, 10401138 ATPase, H+ soluble, alpha 3 transporting, lysosomal V1 subunit D 10548905 epidermal growth 10554118 family with factor receptor sequence pathway substrate 8 similarity 169, member B 10579703 calcium 10603843 synapsin I homeostasis endoplasmic reticulum protein /// RIKEN cDNA 1700030K09 gene 10404630 RIO kinase 1 10575184 WW domain (yeast) containing E3 ubiquitin protein ligase 2 10518069 EF hand domain 10537712 glutathione S- containing 2 transferase kappa 1 10469672 glutamic acid 10511541 dpy-19-like 4 decarboxylase 2 (C. elegans) 10526941 RIKEN cDNA 10394816 predicted gene D830046C22 gene 9282 10567448 dynein, axonemal, 10587503 SH3 domain heavy chain 3 binding glutamic acid-rich protein like 2 10437885 myosin, heavy 10411359 proteolipid polypeptide 11, protein 2 smooth muscle 10600122 X-linked 10579939 ubiquitin specific lymphocyte- peptidase 38 /// regulated 3B /// X- predicted gene linked lymphocyte- 9725 regulated 3C /// X- linked lymphocyte- regulated 3A 10587665 RIKEN cDNA 10370242 poly(rC) binding 4930579C12 gene protein 3 10350753 glutamate- ammonia ligase (glutamine synthetase) 10456296 mucosa associated lymphoid tissue lymphoma translocation gene 1 10380571 guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2 /// ABI gene family, member 3 10369413 sphingosine phosphate lyase 1 10552276 ubiquitin- conjugating enzyme E2H /// predicted gene 2058 10394532 ubiquitin- conjugating enzyme E2F (putative) /// ubiquitin- conjugating enzyme E2F (putative) pseudogene 10556463 aryl hydrocarbon receptor nuclear translocator-like 10471994 kinesin family member 5C 10395328 sorting nexin 13 10599348 glutamate receptor, ionotropic, AMPA3 (alpha 3) 10601595 RIKEN cDNA 3110007F17 gene /// predicted gene 6604 /// predicted gene 5167 /// predicted gene 2411 /// predicted gene 14957 10372891 SLIT-ROBO Rho GTPase activating protein 1 10355024 islet cell autoantigen 1-like 10518147 podoplanin 10473537 olfactory receptor 1123 10424411 tumor susceptibility gene 101 10439960 centrosomal protein 97 10551852 CAP-GLY domain containing linker protein 3 10599291 reproductive homeobox 4E /// reproductive homeobox 4G /// reproductive homeobox 4F /// reproductive homeobox 4A /// reproductive homeobox 4C /// reproductive homeobox 4B /// reproductive homeobox 4D 10587315 glutathione S- transferase, alpha 4 10447167 metastasis associated 3 10480288 nebulette 10491300 SKl-like 10596637 mitogen-activated protein kinase- activated protein kinase 3 10518019 DNA-damage inducible protein 2 /// regulatory solute carrier protein, family 1, member 1 10384685 RIKEN cDNA 1700093K21 gene (0439483 Rho GTPase activating protein 31 10353844 neuralized homolog 3 homolog (Drosophila) 10459604 RIKEN cDNA 4933403F05 gene 10488892 transient receptor potential cation channel, subfamily C, member 4 associated protein 10542822 RAB15 effector protein 10553354 neuron navigator 2 10425966 ataxin 10 10360506 thymoma viral proto-oncogene 3 10531610 RasGEF domain family, member 1B 10417787 guanine nucleotide binding protein (G protein), gamma 2 10381588 granulin 10437080 tetratricopeptide repeat domain 3 10509560 ribosomal protein L38 10466886 na 10580457 NEDD4 binding protein 1 10451061 runt related transcription factor 2 10433953 yippee-like 1 (Drosophila) 10447461 stonin 1 10501909 methyltransferase like 14 /// Sec24 related gene family, member D (S. cerevisiae) 10519693 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D 10385557 CCR4-NOT transcription complex, subunit 6 10413047 plasminogen activator, urokinase 10406663 arylsulfatase B 10430113 Rho GTPase activating protein 39 10475830 mitochondrial ribosomal protein S5 10410892 RAS p21 protein activator 1 10515994 stromal membrane- associated GTPase-activating protein 2 10410099 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 10428157 ring finger protein 19A 10563643 tumor susceptibility gene 101 10412260 follistatin /// thyroid hormone receptor associated protein 3 10386539 similar to ubiquitin A-52 residue ribosomal protein fusion product 1 10415574 cyclin 1 10494978 protein tyrosine phosphatase, non- receptor type 22 (lymphoid) 10511416 thymocyte selection- associated high mobility group box 10562500 dpy-19-like 3 (C. elegans) 10568135 proline-rich transmembrane protein 2 /// RIKEN cDNA 2900092E17 gene 10514466 Jun oncogene 10500847 membrane associated guanylate kinase, WW and PDZ domain containing 3 10549760 zinc finger protein 580 10549377 RIKEN cDNA 1700034J05 gene 10430174 apolipoprotein L9a /// apolipoprotein L9b 10474333 elongation protein 4 homolog (S. cerevisiae) 10560791 predicted gene, EG381936 /// predicted gene 6176 10407159 ankyrin repeat domain 55 10603659 mediator complex subunit 14 10576854 cortexin 1 10353775 BEN domain containing 6 10573865 predicted gene 3579 10356886 solute carrier organic anion transporter family, member 4C1 10507273 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) 10424252 WDYHV motif containing 1 10518735 splA/ryanodine receptor domain and SOCS box containing 1 10562576 pleckstrin homology domain containing, family F (with FYVE domain) member 1 10375667 ring finger protein 130 10528268 protein tyrosine phosphatase, non- receptor type 12 10593205 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 10576056 microtubule- associated protein 1 light chain 3 beta 10547916 parathymosin 10377689 gamma- aminobutyric acid receptor associated protein 10602307 ovary testis transcribed /// predicted gene 15085 /// predicted gene 15127 /// predicted gene, OTTMUSG00000019001 /// leucine zipper protein 4 /// predicted gene 15097 /// predicted gene 15091 /// predicted gene 10439 /// predicted gene 15128 10426835 DIP2 disco- interacting protein 2 homolog B (Drosophila) 10439798 DAZ interacting protein 3, zinc finger 10375614 glutamine fructose-6- phosphate transaminase 2 10361882 NHS-like 1 10419274 glia maturation factor, beta 10424781 glutamate receptor, ionotropic, N- methyl D- aspartate- associated protein 1 (glutamate binding) 10546960 na 10514713 WD repeat domain 78 10394954 grainyhead-like 1 (Drosophila) 10437205 Purkinje cell protein 4 10464251 attractin like 1 10496251 3- hydroxybutyrate dehydrogenase, type 2 10396383 solute carrier family 38, member 6 10585794 cytochrome P450, family 11, subfamily a, polypeptide 1 10385719 Sec24 related gene family, member A (S. cerevisiae) 10407358 polyadenylate binding protein- interacting protein 1 10498775 golgi integral membrane protein 4 10584435 von Willebrand factor A domain containing 5A 10466304 deltex 4 homolog (Drosophila) 10598292 forkhead box P3 /// RIKEN cDNA 4930524L23 gene /// coiled-coil domain containing 22 10472440 Taxi (human T- cell leukemia virus type I) binding protein 3 10398455 protein phosphatase 2, regulatory subunit B (B56), gamma isoform 10493076 SH2 domain protein 2A 10409152 RIKEN cDNA 1110007C09 gene 10542880 RIKEN cDNA 4833442J19 gene 10378523 Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans) 10531560 anthrax toxin receptor 2 10467319 retinol binding protein 4, plasma 10395978 predicted gene 527 10471715 mitochondrial ribosome recycling factor 10511755 WW domain containing E3 ubiquitin protein ligase 1 10353754 zinc finger protein 451 10477572 chromatin modifying protein 4B 10359161 sterol O- acyltransferase 1 10462035 lactate dehydrogenase B 10543319 family with sequence similarity 3, member C 10579052 predicted gene 10033 10475532 sulfide quinone reductase-like (yeast) 10428857 metastasis suppressor 1 10475144 calpain 3 /// glucosidase, alpha; neutral C 10396645 zinc finger and BTB domain containing 1 10428302 Kruppel-like factor 10 10577882 heparan-alpha- glucosaminide N- acetyltransferase 10548069 dual-specificity tyrosine-(Y)- phosphorylation regulated kinase 4 10436053 developmental pluripotency associated 2 10401564 RIKEN cDNA 1110018G07 gene 10471535 family with sequence similarity 129, member B 10349404 mannoside acetylglucosaminyltransferase 5 10520173 amiloride- sensitive cation channel 3 10508860 solute carrier family 9 (sodium/hydrogen exchanger), member 1 10374500 vacuolar protein sorting 54 (yeast) 10387723 RIKEN cDNA 2810408A11 gene 10488020 thioredoxin- related transmembrane protein 4 10411126 junction- mediating and regulatory protein 10345706 DNA segment, Chr 1, Brigham & Womens Genetics 0212 expressed 10364375 cystatin B 10480379 mitochondrial ribosomal protein S5 10521243 G protein- coupled receptor kinase 4 10497920 ankyrin repeat domain 50 10593723 acyl-CoA synthetase bubblegum family member 1 10375634 mitogen-activated protein kinase 9 10384555 aftiphilin 10468113 Kv channel- interacting protein 2 10423363 progressive ankylosis 10538150 transmembrane protein 176A 10396485 synaptic nuclear envelope 2 10401007 protein phosphatase 2, regulatory subunit B (B56), epsilon isoform 10419151 eosinophil- associated, ribonuclease A family, member 1 10390768 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 10478145 protein phosphatase 1, regulatory (inhibitor) subunit 16B 10433057 calcium binding and coiled coil domain 1 10545921 MAX dimerization protein 1 10392449 WD repeat domain, phosphoinositide interacting 1 10545608 sema domain, immunoglobulin domain (Ig), TM domain, and short cytoplasmic domain 10567219 ADP-ribosylation factor-like 6 interacting protein 1 10471201 c-abl oncogene 1, receptor tyrosine kinase 10505841 predicted gene 13271 /// predicted gene 13290 /// predicted gene 13277 /// predicted gene 13276 10414360 lectin, galactose binding, soluble 3 10403258 guanosine diphosphate (GDP) dissociation inhibitor 2 10476759 Ras and Rab interactor 2 10430866 cytochrome P450, family 2, subfamily d, polypeptide 10 10432619 POU domain, class 6, transcription factor 1 10521972 protocadherin 7 10350646 ER degradation enhancer, mannosidase alpha-like 3 10440993 regulator of calcineurin 1 10505008 solute carrier family 44, member 1 10566670 olfactory receptor 478 10356172 phosphotyrosine interaction domain containing 1 10418506 stabilin 1 10419429 olfactory receptor 723 /// olfactory receptor 724 10581434 dipeptidase 2 10401365 zinc finger, FYVE domain containing 1 10591188 olfactory receptor 843 10565846 signal peptidase complex subunit 2 homolog (S. cerevisiae) 10467258 myoferlin 10548547 predicted gene 6600 10523012 deoxycytidine kinase 10348547 ubiquitin- conjugating enzyme E2F (putative) 10483667 corepressor interacting with RBPJ, 1 10584071 PR domain containing 10 10585249 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform 10546137 ankyrin repeat and BTB (POZ) domain containing 1 10484720 olfactory receptor 1166 10571415 vacuolar protein sorting 37 A (yeast) 10595189 solute carrier family 17 (anion/sugar transporter), member 5 10584426 olfactory receptor 910 10585986 myosin IXa 10401753 VPS33B interacting protein, apical- basolateral polarity regulator 10349793 dual serine/threonine and tyrosine protein kinase 10527528 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 10485767 olfactory receptor 1277 10557459 mitogen-activated protein kinase 3 10471486 endoglin 10420846 frizzled homolog 3 (Drosophila) 10405849 olfactory receptor 466 10568691 RIKEN cDNA A130023I24 gene 10351111 dynamin 3, opposite strand /// microRNA 214 /// microRNA 199a-2 10540785 RIKEN cDNA 6720456B07 gene 10540923 makorin, ring finger protein, 2 10413416 interleukin 17 receptor D 10386636 ubiquitin specific peptidase 22 10383799 transcobalamin 2 Genes differentially Genes upregulated Genes downregulated on upregulated in TH-GM cells on TH-GM surface TH-GM cells surface Gene Gene Gene ID Gene Title ID Gene Title Symbol Gene Title 10385918 interleukin 3 10435704 CD80 antigen Ly6a lymphocyte antigen 6 complex, locus A 10511363 preproenkephalin 10548409 killer cell lectin- Cd27 CD27 antigen like receptor subfamily C, member 1 10497878 interleukin 2 10421737 tumor necrosis Sell selectin, factor (ligand) lymphocyte superfamily, member 11 10385912 colony 10597420 chemokine (C-C Ctsw cathepsin W stimulating factor motif) receptor 4 2 (granulocyte- macrophage) 10404422 serine (or 10441633 chemokine (C-C Ltb lymphotoxin B cysteine) motif) receptor 6 peptidase inhibitor, clade B, member 6b 10408689 neuritin 1 10365933 early endosome Gngt2 guanine nucleotide antigen 1 binding protein (G protein), gamma transducing activity polypeptide 2 /// ABI gene family, member 3 10467979 stearoyl- 10404840 CD83 antigen Gpr18 G protein-coupled Coenzyme A receptor 18 desaturase 1 10469312 phosphotriesterase 10359434 Fas ligand (TNF Igfbp4 insulin-like growth related /// superfamily, factor binding Clq-like 3 member 6) protein 4 10435704 CD80 antigen 10344966 lymphocyte Il17ra interleukin 17 antigen 96 receptor A 10502655 cysteine rich 10345752 interleukin 1 Il18r1 interleukin 18 protein 61 receptor, type II receptor 1 10350159 ladinin 10439527 T cell Klrd1 killer cell lectin- immunoreceptor like receptor, with Ig and ITIM subfamily D, domains member 1 10548409 killer ceil lectin- 10494595 Notch gene Mctp2 multiple C2 like receptor homolog 2 domains, subfamily C, (Drosophila) transmembrane 2 member 1 10571399 zinc finger, 10597279 chemokine (C-C Ms4a6b membrane- DHHC domain motif) receptor- spanning 4- containing 2 like 2 domains, subfamily A, member 6B 10538791 TNFAIP3 10485405 CD44 antigen Pld3 phospholipase D interacting family, member 3 protein 3 10407126 polo-like kinase 10561104 AXL receptor Pyhin1 pyrin and HIN 2 (Drosophila) tyrosine kinase domain family, member 1 10355984 serine (or 10585048 cell adhesion S1pr1 sphingosine-1- cysteine) molecule 1 phosphate receptor peptidase 1 inhibitor, clade E, member 2 10421737 tumor necrosis Slc44a2 solute carrier factor (ligand) family 44, member superfamily, 2 member 11 10503023 cystathionase (cystathionine gamma-lyase) 10389207 chemokine (C-C motif) ligand 5 10361887 PERP, TP53 apoptosis effector 10530841 insulin-like growth factor binding protein 7 10504838 nuclear receptor subfamily 4, group A, member 3 10482762 isopentenyl- diphosphate delta isomerase 10597420 chemokine (C-C motif) receptor 4 10441633 chemokine (C-C motif) receptor 6 10595402 family with sequence similarity 46, member A 10480139 Clq-like 3 /// phosphotriesterase related 10540472 basic helix-loop- helix family, member e40 10404429 serine (or cysteine) peptidase inhibitor, clade B, member 9 10595404 family with sequence similarity 46, member A 10365933 early endosome antigen 1 10384373 fidgetin-like 1 10400072 scinderin 10377938 enolase 3, beta muscle 10589994 eomesodermin homolog (Xenopus laevis) 10404840 CD83 antigen 10485624 proline rich Gla (G- carboxyglutamic acid) 4 (transmembrane) 10369102 predicted gene 9766 10505030 fibronectin type III and SPRY domain containing 1-like 10606868 brain expressed gene 1 10501832 ATP-binding cassette, sub- family D (ALD), member 3 10457225 mitogen- activated protein kinase kinase kinase 8 10554521 phosphodiesterase 8A 10446229 tumor necrosis factor (ligand) superfamily, member 9 10593842 tetraspanin 3 10407211 phosphatidic acid phosphatase type 2A 10488655 BCL2-like 1 10470182 brain expressed myelocytomatosis oncogene 10445977 Epstein-Barr virus induced gene 3 10587495 interleukin-1 receptor- associated kinase 1 binding protein 1 10419082 RIKEN cDNA 5730469M10 gene 10472212 plakophilin 4 10487588 interleukin 1 alpha 10359434 Fas ligand (TNF superfamily, member 6) 10351015 serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 10344966 lymphocyte antigen 96 10488415 cystatin C 10598771 monoamine oxidase A 10345752 interleukin 1 receptor, type II 10588577 cytokine inducible SH2- containing protein 10439527 T cell immunoreceptor with Ig and ITIM domains 10511258 family with sequence similarity 132, member A 10403584 nidogen 1 10399973 histone deacetylase 9 10494595 Notch gene homolog 2 (Drosophila) 10346168 signal transducer and activator of transcription 4 10350630 family with sequence similarity 129, member A 10564667 neurotrophic tyrosine kinase, receptor, type 3 10419288 GTP cyclohydrolase 1 10407535 ribosomal protein L10A /// ribosomal protein L10A, pseudogene 2 10468945 acyl-Coenzyme A binding domain containing 7 10435271 HEG homolog 1 (zebrafish) 10576639 neuropilin 1 10505059 T-cell acute lymphocytic leukemia 2 10457091 neuropilin (NRP) and tolloid (TLL)- like 1 10428081 heat-responsive protein 12 10435712 CD80 antigen 10597279 chemokine (C-C motif) receptor- like 2 10485405 CD44 antigen 10436662 microRNA 155 10562044 zinc finger and BTB domain containing 32 10463599 nuclear factor of kappa light polypeptide gene enhancer in B- cells 2, p49/p100 10456005 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen- associated) 10490903 carbonic anhydrase 13 10468762 RIKEN cDNA 4930506M07 gene 10470316 na 10363195 heat shock factor 2 10596652 HemK methyltransferase family member 1 10435693 cytochrome c oxidase, subunit XVII assembly protein homolog (yeast) 10544660 oxysterol binding protein- like 3 10384725 reticuloendotheliosis oncogene 10408600 serine (or cysteine) peptidase inhibitor, clade B, member 6a 10391444 RUN domain containing 1 /// RIKEN cDNA 1700113I22 gene 10561516 nuclear factor of kappa light polypeptide gene enhancer in B- cells inhibitor, beta 10566846 DENN/MADD domain containing 5A 10435048 Tctex1 domain containing 2 10470175 lipocalin 13 10586250 DENN/MADD domain containing 4A 10512774 coronin, actin binding protein 2A 10366546 carboxypeptidase M 10354286 KDEL (Lys- Asp-Glu-Leu) containing 1 10547621 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 10440419 B-cell translocation gene 3 /// B-cell translocation gene 3 pseudogene 10407467 aldo-keto reductase family 1, member E1 10558580 undifferentiated embryonic cell transcription factor 1 10544644 na 10424543 WNT1 inducible signaling pathway protein 1 10507137 PDZK1 interacting protein 1 10384691 RIKEN cDNA 0610010F05 gene 10565315 fumarylacetoacetate hydrolase 10586248 DENN/MADD domain containing 4A 10561104 AXL receptor tyrosine kinase 10385837 interleukin 13 10440393 SAM domain, SH3 domain and nuclear localization signals, 1 10401987 potassium channel, subfamily K, member 10 10453715 RAB18, member RAS oncogene family 10496466 alcohol dehydrogenase 4 (class II), pipolypeptide 10396712 fucosyltransferase 8 10603708 calcium/calmodulin- dependent serine protein kinase (MAGUK family) 10352178 saccharopine dehydrogenase (putative) /// similar to Saccharopine dehydrogenase (putative) 10349081 PH domain and leucine rich repeat protein phosphatase 1 10364950 growth arrest and DNA- damage- inducible 45 beta 10566877 SET binding factor 2 10575160 nuclear factor of activated T-cells 5 10458090 receptor accessory protein 5 10439845 predicted gene 5486 10461558 solute carrier family 15, member 3 10586254 DENN/MADD domain containing 4A 10574166 copine II 10598467 proviral integration site 2 10447084 galactose mutarotase 10366346 pleckstrin homology-like domain, family A, member 1 10355567 transmembrane BAX inhibitor motif containing 1 10407420 neuroepithelial cell transforming gene 1 10411882 neurolysin (metallopeptidase M3 family) 10585048 cell adhesion molecule 1 10538890 hypothetical protein LOC641050 10406681 adaptor-related protein complex 3, beta 1 subunit 10455647 tumor necrosis factor, alpha- induced protein 8 10447521 transcription factor B1, mitochondrial /// T-cell lymphoma invasion and metastasis 2 10523772 leucine rich repeat containing 8D 10417759 ubiquitin- conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) 10586244 DENN/MADD domain containing 4A 10436500 glucan (1,4- alpha), branching enzyme 1 10556297 adrenomedullin 10593492 zinc finger CCCH type containing 12C 10373358 interleukin 23, alpha subunit p19 10358583 hemicentin 1 10567995 nuclear protein 1 10512030 RIKEN cDNA 3110043021 gene 10594652 lactamase, beta 10344960 transmembrane protein 70 10399908 protein kinase, cAMP dependent regulatory, type II beta 10605766 melanoma antigen, family D, 1 10474141 solute carrier family 1 (glial high affinity glutamate transporter), member 2 10461909 cDNA sequence BC016495 10548030 CD9 antigen 10525473 transmembrane protein 120B 10435266 HEG homolog 1 (zebrafish) 10593483 ferredoxin 1 10476569 RIKEN cDNA 2310003L22 gene 10526718 sperm motility kinase 3A /// sperm motility kinase 3B /// sperm motility kinase 3C 10547613 ribosomal modification protein rimK-like family member B 10511446 aspartate-beta- hydroxylase 10375137 potassium large conductance calcium-activated channel, subfamily M, beta member 1 10528154 predicted gene 6455 /// RIKEN cDNA 4933402N22 gene 10514173 ribosomal protein L34 /// predicted gene 10154 /// predicted pseudogene 10086 /// predicted gene 6404 10586227 DENN/MADD domain containing 4A 10402648 brain protein 44- like 10575745 ATM interactor 10346255 ORM1-like 1 (S. cerevisiae) 10400405 nuclear factor of kappa light polypeptide gene enhancer in B- cells inhibitor, alpha 10528527 family with sequence similarity 126, member A 10472738 DDB 1 and CUL4 associated factor 17 10368534 nuclear receptor coactivator 7 10407543 GTP binding protein 4 10376555 COP9 (constitutive photomorphogenic) homolog, subunit 3 (Arabidopsis thaliana) 10567297 inositol triphosphate receptor interacting protein-like 2 10589886 RIKEN cDNA 4930520004 gene 10423593 lysosomal- associated protein transmembrane 4B 10577954 RAB11 family interacting protein 1 (class I) 10604528 muscleblind-like 3 (Drosophila) 10432675 RIKEN cDNA I730030J21 gene 10385747 PHD finger protein 15 10398240 echinoderm microtubule associated protein like 1 10511803 RIKEN cDNA 2610029I01 gene 10466606 annexin A1 10520304 ARP3 actin- related protein 3homolog B (yeast) 10425903 na 10488709 RIKEN cDNA 8430427H17 gene 10376096 acyl-CoA synthetase long- chain family member 6 10429491 activity regulated cytoskeletal- associated protein 10439710 pleckstrin homology-like domain, family B, member 210467110 expressed sequence AI747699 10536898 interferon regulatory factor 5 10505044 fukutin 10605370 membrane protein, palmitoylated 10363669 DnaJ (Hsp40) homolog, subfamily C, member 1210496727 dimethylarginine dimethylaminohydrolase 1 10587683 B-cell leukemia/ lymphoma 2 related protein A1a /// B-cell leukemia/ lymphoma 2 related protein A1d /// B-cell leukemia/ lymphoma 2 related protein A1b /// B-cell leukemia/ lymphoma 2 related protein A1e 10458816 toll like receptor adaptor molecule 2 10513008 Kruppel-like factor 4 (gut) 10550906 plasminogen activator, urokinase receptor 10362674 U3A small nuclear RNA 10473190 DnaJ (Hsp40) homolog, subfamily C, member 1010477581 ribosomal protein L5 10571774 aspartylglucosaminidase 10395356 anterior gradient homolog 3 (Xenopus laevis) 10392440 solute carrier family 16 (monocarboxylic acid transporters), member 610352815 interferon regulatory factor 6 -
- Afkarian, M., Sedy, J. R., Yang, J., Jacobson, N. G., Cereb, N., Yang, S. Y., Murphy. T. L., and Murphy, K. M. (2002). T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nature
immunology 3, 549-557. - Ansel, K. M., Djuretic, I., Tanasa, B., and Rao. A, (2006). Regulation of Th2 differentiation and 114 locus accessibility. Annual review of
immunology 24, 607-656. - Baron. J. L., Madri, J. A., Ruddle, N. H., Hashim, G., and Janeway, C. A., Jr. (1993). Surface expression of
alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177, 57-68. - Bell, A. L., Magill. M. K., McKane, W. R., Kirk, F., and Irvine, A. E. (1995). Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 14, 177-182.
- Berner, B., Akca, D., Jung, T., Muller, G. A., and Reuss-Borst, M. A. (2000). Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27, 1128-1135.
- Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., and Kuchroo, V. K. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238.
- Brustic, A., Heink, S., Huber, M., Rosenplanter, C., Stadelmann, C., Yu. P., Arpaia, E., Mak, T. W., Kamradt, T., and Lohoff, M. (2007). The development of inflammatory T(H)-17 cells requires interferon-
regulatory factor 4. Natureimmunology 8, 958-966. - Burchill, M. A., Yang, J., Vogtenhuber, C., Blazar, B. R., and Farmr, M. A. (2007). IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178, 280-290.
- Campbell. I. K., Rich, M. J., Bischof, R. J., Dunn. A. R., Grail. D., and Hamilton, J. A. (1998). Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 161, 3639-3644.
- Campbell, I. K., van Nieuwenhuijze, A., Segura, E., O'Donnell, K., Coghill, E., Hommel, M., Gerondakis, S., Villadangos. J. A., and Wicks, I. P. (2011). Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells. J Immunol 186, 5468-5477.
- Choy, E H., and Panayi, G. S. (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344, 907-916.
- Codarri, L., Gyulveszi, G., Tosevski, V., Hesske, L., Fontana. A., Magnenat, L., Suter, T., and Becher. B. (2011). RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12, 560-567.
- Cook, A. D., Braine, E. L., Campbell, I. K., Rich, M. J., and Hamilton, J. A. (2001). Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 3, 293-298.
- Cope, A. P., Schulze-Koops, H., and Aringer, M. (2007). The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 25, S4-11.
- Cornish, A. L., Campbell, I. K., McKenzie, B. S., Chatfield, S., and Wicks, I. P. (2009). G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 5, 554-559.
- Croxford, A. L., Mair, F., and Becher, B. (2012). IL-23: one cytokine in control of autoimmunity. European journal of
immunology 42, 2263-2273. - Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan. S., Churakova, T., et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748.
- El-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G. X., Dittel, B. N., and Rostami, A. (2011). The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.
Nat Immunol 12, 568-575. - Gran. B., Zhang, G. X., Yu, S., Li. J., Chen, X. H., Ventura, E. S., Kamoun, M., and Rostami, A. (2002). IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 69, 7104-7110.
- Gregory, S. G., Schmidt, S., Seth. P., Oksenberg, J. R., Hart, J., Prokop, A., Caillier, S. J., Ban, M., Goris, A., Barcellos, L. F., et al. (2007).
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.Nature genetics 39, 1083-1091. - Greter, M., Helft, J., Chow, A., Hashimoto, D., Mortha, A., Agudo-Cantcro, J., Bogunovic, M., Gautier, E. L., Miller, J., Leboeuf, M., et al., (2012). GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells.
Immunity 36, 1031-1046. - Guedez, Y. B., Whittington, K. B., Clayton, J. L., Joosten, L. A., van de Loo, F. A., van den Berg, W. B., and Rosloniec, E. F. (2001). Genetic ablation of interferon-gamma upregulates interleukin-1 beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain.
Arthritis Rheum 44, 2413-2424. - Gutcher, I., and Becher, B. (2007). APC-derived cytokines and T cell polarization in autoimmune inflammation.
J Clin Invest 117, 1119-1127. - Haak, S., Croxford, A. L., Kreymborg, K., Heppner, F. L., Pouly, S., Becher, B., and Waisman, A. (2009). IL-17A and IL-17F do not contribute vitally to autoimmune neuroinflammation in mice. J Clin Invest 119, 61-69.
- Hamilton, J. A. (2008). Colony-stimulating factors in inflammation and autoimmunity.
Nat Rev Immunol 8, 533-544. - Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy,
- K. M., and Weaver, C. T. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the
T helper type Nat Immunol 6, 1123-1132. - Hofstetter, 1-1.1-1., Ibrahim, S. M., Koczan, D., Kruse, N., Weishaupt, A., Toyka, K. V., and Gold, R. (2005). Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237, 123-130.
- Irmler, I. M., Gajda, M., and Brauer. R. (2007). Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179, 6228-6236.
- Ivanov, I I. McKenzie, B. S., Zhou. L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., and Littman, D. R. (2006). The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells. Cell 126, 1121-1133.
- Kaplan, M. N., Schindler, U., Smiley, S. T., and Grusby, M. J. (1996a). Stat6 is required for mediating responses to IL-4 and for development of Th2 cells.
Immunity 4, 313-319. - Kaplan, M. H., Sun, Y. L., Hoey, T., and Grusby, M. J. (1996b). Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382, 174-177.
- Kolaczkowska, E., and Kubes, P. (2013). Neutrophil recruitment and function in health and inflammation.
Nat Rev Immunol 13, 159-175. - Komatsu, N., and Takayanagi, H. (2012). Autoimmune arthritis: the interface between the immune system and joints. Adv Immunol 115, 45-71.
- Korn. T., Bettelli, E., Gao, W., Awasihi, A., Jager. A., Strom, T. B., Oukka, M., and Kuchroo, V. K. (2007). IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448, 484-487.
- Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., and Cua, D. J. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 233-240.
- Laurence, A., Tato. C. M., Davidson, T. S., Kanno, Y., Chen. Z., Yao, Z., Blank, R. B., Meylan, F., Siegel. R., Hennighausen, L., et al. (2007). Interleukin-2 signaling via STAT5 constrains
T helper 17 cell generation.Immunity 26, 371-381. - Lawlor, K. E., Wong, P. K., Campbell, P. K., van Rooijen, N., and Wicks, I. P. (2005). Acute CD4+T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor. Arthritis Rheum 52, 3749-3754.
- Lee, L. F., Logronio, K., Tu, G. H., Zhai, W., Ni, I., Mei, L., Dilley, J., Yu, J., Rajpal, A., Brown, C., et al. (2012). Anti-IL-7 receptor-alpha reverses established
type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc NatlAcad Sci USA 109, 12674-12679. - Leonard, J. P., Waldburger, K. E., and Goldman, S. J. (1995). Prevention of experimental autoimmune encephalomyelitis by antibodies against
interleukin 12. J Exp Med 181.381-386. - Lighvani, A. A., Frucht, D. M., Jankovic, D., Yamanc, H., Aliberti, J., Hissong, B. D., Nguyen, B. V., Gadina, M., Sher. A., Paul, W. E., and O'Shea. J. J. (2001). T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 98, 15137-15142.
- Liu, X., Lee, Y. S., Yu, C. R., and Egwuagu, C. E. (2008). Loss of STAT5 in CD4+ T cells prevents development of experimental autoimmune diseases.
J Immunol 180, 6070-6076. - Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Stroher, S., Cannella, B., Allard, J., et al. (2002). Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.
Nat Med 8, 500-508. - Lundmark, F., Duvefelt. K., Iacobaeus, E., Kockum, I., Wallstrom, E., Khademi, M., Oturai, A., Ryder, L. P., Saatchi, J., Harbo, H. F., et al. (2007). Variation in
interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis:Nature genetics 39, 1108-1113. - Manoury-Schwartz, B., Chiocchia, G., Bcssis, N., Ahchsira-Amar, O., Batteux, F., Muller, S., Huang, S., Boissier, M. C., and Fournier, C. (1997). High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 158, 5501-5506.
- MeGeachy, M. J., Chen, Y., Tato, C. M., Laurence, A., Joyce-Shaikh, B., Blumenschein, W. M., McClanahan, T. K., O'Shea, J. J., and Cua, D. J. (2009). The
interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo.Nat Immunol 10, 314-324. - McInnes, I. B., and Schen, G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis.
Nat Rev Immunol 7, 429-442. - McInnes, I. B., and Schen, G. (2011). The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205-2219.
- Muller-Ladner, U., Ospelt, C., Gay, S., Distler, O., and Pap, T. (2007). Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts.
Arthritis Res Ther 9, 223. - Muller, J., Sperl, B., Reindl, W., Kiessling, A., and Berg, T. (2008). Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem: a European journal of
chemical biology 9, 723-727. - Nurieva, R., Yang, X. O., Martinez, G., Zhang, Y., Panopoulos, A. D., Ma, L., Schluns, K., Tian, Q., Watowich, Jetten. A. M., and Dong, C. (2007). Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480-483.
- Okada. Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., Suzuki, A., Yoshida, S., et al. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376-381.
- Pernis, A. B. (2009). Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med 265, 644-652.
- Plater-Zyberk. C., Joosten, L. A., Helsen, M. M., Hepp, J., Baeuerle, P. A., and van den Berg, W. B. (2007). GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 66, 452-457.
- Ponomarev, E. D., Shriver, L. P., Maresz, K., Pedras-Vasconcelos, J., Verthelyi, D., and Dittel, B. N. (2007). GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 178, 39-48.
- Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccclli, A., Lanzavecchia, A., Engelhardt. B., and Sallusto, F. (2009). C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.
Nat Immunol 10, 514-523. - Segal, B. M., and Shevach, E. M. (1996). IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 184, 771-775.
- Shimoda, K., van Deursen, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A., et al. (1996). Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene.
Nature 380, 630-633. - Sonderegger, I., Iezzi, G., Maier, R., Schmitz, N., Kurrer, M., and Kopf, M. (2008). GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 205, 2281-2294.
- Steinman, L. (2007). A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.
Nat Med 13, 139-145. - Stritesky, G. L., Ych, N., and Kaplan. M. H. (2008). IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 181, 5948-5955.
- Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., and Glimcher, L. H. (2002). Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 295, 338-342.
- Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., Nakanishi, K., Yoshida. N., Kishimoto, T., and Akira. S. (1996). Essential role of Stat6 in IL-4 signalling.
Nature 380, 627-630. - Thierfelder. W. E., van Deursen. J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A., Doherty, P. C., Grosveld, G. C., and Elle, J. N. (1996). Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382, 171-174.
- Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J. C., and Stockinger. B. (2008). The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453, 106-109.
- Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., and Stockinger, B. (2006). TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
Immunity 24, 179-189. - Vermeire, K., Heremans, H., Vandeputte, M., Huang, S., Billiau, A., and Matthys, P. (1997). Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 158, 5507-5513.
- Willenborg, D. O., Fordham, S., Bernard, C. C., Cowden, W. B., and Ramshaw, I. A. (1996). IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157, 3223-3227.
- Wright, H. L., Moots, R. J., and Edwards, S. W. (2014). The multifactoral role of neutrophils in rheumatoid arthritis.
Nat Rev Rheumatol 10, 593-601. - Yamada, H., Nakashima, Y., Okazaki, K., Mawatari, T., Fukushi, J. I., Kaibara, N., Hori, A., Iwamoto, Y., and Yoshikai, Y. (2008). Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 67, 1299-1304.
- Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, S. S., and Dong, C. (2007a). STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. The Journal of
biological chemistry 282, 9358-9363. - Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang. H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., et al. (2008).
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma.Immunity 28, 29-39. - Yang, X. P., Ghoreschi, K., Steward-Tharp, S. M., Rodriguez-Canales, J., Zhu, J., Grainger, J. R., Hirahara, K., Sun, H. W., Wei, L., Vahedi. G., et al. (2011). Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.
Nat Immunol 12, 247-254. - Yang, Y., Ochando, J. C., Bromberg, J. S., and Ding, Y. (2007b). Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNgamma/Stat1 signals. Blood 110, 2494-2500.
- Yang, Y. H., and Hamilton. J. A. (2001). Dependence of interleukin-1-induced arthritis on granulocyte-macrophage colony-stimulating factor.
Arthritis Rheum 44, 111-119. - Yao, Z., Cui, Y., Watford, W. T., Bream, J. H., Yamaoka, K., Hissong, B. D., Li, D., Durum, S. K., Jiang, Q., Bhandoola, A., et al. (2006). Stat5a/h are essential for normal lymphoid development and differentiation. Proc Natl
Acad Sci USA 103, 1000-1005. - Zhang, G. X., Gran, B., Yu, S., Li. J., Siglienti, L., Chen, X., Kamoun, M., and Rostami, A. (2003). Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 170, 2153-2160.
- Zhou, L., Ivanov, I I, Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E., Leonard. W. J., and Littman. D. R. (2007). IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.
Nature immunology 8, 967-974. - Zhu, J., and Paul, W. E. (2010). Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunological reviews 238, 247-262.
- While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (20)
1.-33. (canceled)
34. A method of treating an inflammatory disease associated with a TNF-α-independent inflammatory pathway, comprising administering to a subject in need thereof an effective amount of a signal transducer and activator of transcription 5 (STAT5) inhibitor, wherein the inflammatory disease is mediated by granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting T-helper (Th-GM) cells, wherein the STAT5 inhibitor reduces serum level of GM-CSF in the subject and thereby providing a therapeutic benefit to the subject in a TNF-α-independent manner.
35. The method of claim 34 , wherein the inflammatory disease is rheumatoid arthritis.
36. The method of claim 34 , wherein the inflammatory disease is multiple sclerosis.
37. The method of claim 34 , wherein the TH-GM cells are differentiated from precursor CD4+ cells in the presence of activated STAT5 and IL-7.
38. The method of claim 34 , wherein the STAT5 inhibitor is pimozide.
39. The method of claim 34 , wherein the STAT5 inhibitor is CAS 285986-31-4.
40. The method of claim 34 , wherein the STAT5 inhibitor is an antibody that specifically binds to STAT5.
41. The method of claim 34 , wherein the STAT5 inhibitor is an antisense nucleic acid, small interfering RNA, short hairpin RNA, or microRNA.
42. A method of treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of (A) a STAT5 inhibitor and (B) a therapeutic agent that inhibits the TNF-α inflammatory pathway.
43. The method of claim 42 , wherein the STAT5 inhibitor is pimozide.
44. The method of claim 42 , wherein the STAT5 inhibitor is CAS 285986-31-4.
45. The method of claim 42 , wherein the STAT5 inhibitor is an antibody that specifically binds to STAT5.
46. The method of claim 42 , wherein the STAT5 inhibitor is an antisense nucleic acid, small interfering RNA, short hairpin RNA, or microRNA.
47. The method of claim 42 , wherein the therapeutic agent that inhibits the TNF-α inflammatory pathway is an etanercept, adalimumab, infliximab, golimumab, or certolizumab pegol.
48. The method of claim 42 , wherein the therapeutic agent that inhibits the TNF-α inflammatory pathway is prednisone, methotrexate, or tofacitinib.
49. The method of claim 42 , Wherein the therapeutic agent that inhibits the TNF-α inflammatory pathway is anakinra, abatacept, rituximab, or tocilizumab.
50. The method of claim 42 , wherein (A) and (B) are administered sequentially.
51. The method of claim 42 , wherein (A) and (B) are administered simultaneously.
52. The method of claim 42 , wherein (A) and (B) are administered in a single dose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/902,189 US20200408757A1 (en) | 2014-09-26 | 2020-06-15 | Methods and Compositions for Modulating TH-GM Cell Function |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201406130P | 2014-09-26 | ||
SG10201406130P | 2014-09-26 | ||
PCT/SG2015/050344 WO2016048247A1 (en) | 2014-09-26 | 2015-09-25 | Methods and compositions for modulating th-gm cell function |
US201715514644A | 2017-03-27 | 2017-03-27 | |
US16/902,189 US20200408757A1 (en) | 2014-09-26 | 2020-06-15 | Methods and Compositions for Modulating TH-GM Cell Function |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2015/050344 Continuation WO2016048247A1 (en) | 2014-09-26 | 2015-09-25 | Methods and compositions for modulating th-gm cell function |
US15/514,644 Continuation US10690666B2 (en) | 2014-09-26 | 2015-09-25 | Methods and compositions for modulating TH-GM cell function |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200408757A1 true US20200408757A1 (en) | 2020-12-31 |
Family
ID=55581587
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/514,644 Active 2036-03-31 US10690666B2 (en) | 2014-09-26 | 2015-09-25 | Methods and compositions for modulating TH-GM cell function |
US16/902,189 Pending US20200408757A1 (en) | 2014-09-26 | 2020-06-15 | Methods and Compositions for Modulating TH-GM Cell Function |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/514,644 Active 2036-03-31 US10690666B2 (en) | 2014-09-26 | 2015-09-25 | Methods and compositions for modulating TH-GM cell function |
Country Status (9)
Country | Link |
---|---|
US (2) | US10690666B2 (en) |
EP (2) | EP3739039A1 (en) |
JP (3) | JP6729911B2 (en) |
KR (3) | KR102507694B1 (en) |
CN (1) | CN107002037A (en) |
AU (3) | AU2015322125B2 (en) |
CA (2) | CA2962757C (en) |
SG (1) | SG11201702475VA (en) |
WO (1) | WO2016048247A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11612595B2 (en) | 2017-05-16 | 2023-03-28 | Generos Biopharma Ltd. | Compositions and methods for treating rheumatoid arthritis |
JP2022528481A (en) * | 2019-04-09 | 2022-06-10 | ジェネラス バイオファーマ リミテッド | Pharmaceutical compositions of pimozide and methotrexate, and their use |
WO2020216335A1 (en) * | 2019-04-26 | 2020-10-29 | 健艾仕生物医药有限公司 | Use of compound in preparation of drug for treating atherosclerosis |
WO2020216378A1 (en) | 2019-04-26 | 2020-10-29 | 健艾仕生物医药有限公司 | Heterocyclic compound, application thereof, and composition containing same |
CN116369249B (en) * | 2023-01-13 | 2024-05-17 | 四川轻化工大学 | Construction method of zebra fish enteritis model |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012164398A2 (en) * | 2011-06-01 | 2012-12-06 | Netherlands Cancer Institute | Modulation of the ubiquitin-proteasome system (ups) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002241303A (en) * | 2001-02-13 | 2002-08-28 | Hisamitsu Pharmaceut Co Inc | Gm-csf of epithelial cell comprising ets transcription factor or gene coding for the same and/or defensin protein manifestation-controlling agent |
WO2003038072A1 (en) * | 2001-10-31 | 2003-05-08 | Universite Libre De Bruxelles | Generation and use of new types of dendritic cells |
JP4711963B2 (en) | 2003-09-15 | 2011-06-29 | オクラホマ メディカル リサーチ ファウンデーション | Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases |
US7776313B2 (en) | 2006-05-25 | 2010-08-17 | University Health Network | Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis |
US20080286234A1 (en) * | 2007-05-15 | 2008-11-20 | Eyink Daniel A | Method for treating demyelinating diseases |
WO2009039199A2 (en) * | 2007-09-17 | 2009-03-26 | Intradigm Corporation | Compositions comprising stat5 sirna and methods of use thereof |
TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
EA020766B1 (en) * | 2008-07-08 | 2015-01-30 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
EP2193790A1 (en) | 2008-12-04 | 2010-06-09 | Klinikum der Universität Regensburg | IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage |
JP2013520208A (en) * | 2010-02-24 | 2013-06-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | Diagnosis, prognosis and treatment of autoimmune diseases |
KR20120128492A (en) * | 2011-05-17 | 2012-11-27 | 연세대학교 산학협력단 | Pharmaceutical Compositions for Preventing or Treating Bone Disorders |
KR20140103122A (en) * | 2011-11-17 | 2014-08-25 | 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 | Compositions and methods for treating glioma |
EP2669295A1 (en) * | 2012-05-29 | 2013-12-04 | Universitätsklinikum Regensburg | Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel IL-3 antibodies |
-
2015
- 2015-09-25 EP EP20184784.5A patent/EP3739039A1/en active Pending
- 2015-09-25 CA CA2962757A patent/CA2962757C/en active Active
- 2015-09-25 US US15/514,644 patent/US10690666B2/en active Active
- 2015-09-25 KR KR1020227003921A patent/KR102507694B1/en active IP Right Grant
- 2015-09-25 CA CA3147152A patent/CA3147152A1/en active Pending
- 2015-09-25 KR KR1020177010959A patent/KR102221013B1/en active IP Right Grant
- 2015-09-25 EP EP15843971.1A patent/EP3198007B1/en active Active
- 2015-09-25 AU AU2015322125A patent/AU2015322125B2/en active Active
- 2015-09-25 CN CN201580064433.6A patent/CN107002037A/en active Pending
- 2015-09-25 KR KR1020217005240A patent/KR102360824B1/en active IP Right Grant
- 2015-09-25 SG SG11201702475VA patent/SG11201702475VA/en unknown
- 2015-09-25 JP JP2017516733A patent/JP6729911B2/en active Active
- 2015-09-25 WO PCT/SG2015/050344 patent/WO2016048247A1/en active Application Filing
-
2020
- 2020-06-15 US US16/902,189 patent/US20200408757A1/en active Pending
- 2020-06-26 JP JP2020110115A patent/JP7106604B2/en active Active
-
2021
- 2021-02-25 AU AU2021201241A patent/AU2021201241B2/en active Active
-
2022
- 2022-07-13 JP JP2022112150A patent/JP2022140482A/en active Pending
- 2022-10-24 AU AU2022256995A patent/AU2022256995A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012164398A2 (en) * | 2011-06-01 | 2012-12-06 | Netherlands Cancer Institute | Modulation of the ubiquitin-proteasome system (ups) |
Non-Patent Citations (3)
Title |
---|
Dougan et al (Immunity, 2019; 50:796-811) (Year: 2019) * |
Freire et al (Periodontol 2000, 2013; 63(1):149-164) (Year: 2000) * |
Tabas et al (Science, 2013; 339(6116):166-172) (Year: 2013) * |
Also Published As
Publication number | Publication date |
---|---|
AU2021201241B2 (en) | 2022-08-04 |
AU2022256995A1 (en) | 2022-11-24 |
KR20220025115A (en) | 2022-03-03 |
JP7106604B2 (en) | 2022-07-26 |
CA2962757C (en) | 2022-03-22 |
CA2962757A1 (en) | 2016-03-31 |
AU2015322125B2 (en) | 2021-01-07 |
KR102360824B1 (en) | 2022-02-09 |
US20170219581A1 (en) | 2017-08-03 |
KR20210033037A (en) | 2021-03-25 |
JP2022140482A (en) | 2022-09-26 |
AU2015322125A1 (en) | 2017-04-20 |
AU2021201241A1 (en) | 2021-03-11 |
KR102507694B1 (en) | 2023-03-08 |
CN107002037A (en) | 2017-08-01 |
EP3198007A4 (en) | 2018-08-08 |
JP2020165991A (en) | 2020-10-08 |
KR20170066451A (en) | 2017-06-14 |
WO2016048247A1 (en) | 2016-03-31 |
EP3198007B1 (en) | 2023-11-01 |
EP3198007A1 (en) | 2017-08-02 |
KR102221013B1 (en) | 2021-03-02 |
SG11201702475VA (en) | 2017-04-27 |
CA3147152A1 (en) | 2016-03-31 |
EP3739039A1 (en) | 2020-11-18 |
JP6729911B2 (en) | 2020-07-29 |
JP2017531792A (en) | 2017-10-26 |
US10690666B2 (en) | 2020-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200408757A1 (en) | Methods and Compositions for Modulating TH-GM Cell Function | |
Garo et al. | Smad7 controls immunoregulatory PDL2/1-PD1 signaling in intestinal inflammation and autoimmunity | |
Medina et al. | Ebi3 prevents Trypanosoma cruzi-induced myocarditis by dampening IFN-γ-driven inflammation | |
US20170233816A1 (en) | Markers of immune response | |
Julián et al. | CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice | |
US20140234843A1 (en) | Methods and compositions for expanding cells and improving engraftment | |
정다운 | E prostanoid receptor 4 expressing macrophages mediate mucosal repair by production of Cxcl1 during colitis | |
Marciniak | Involvement of Notch pathway in synovial fibroblasts and hematopoietic cells in experimental models of arthritis | |
Fu | The Transcriptional Regulation and Function of IL-9 in Allergic Lung Inflammation and Tumor Growth | |
US20220018853A1 (en) | Use of gilz as a biomarker in sepsis | |
Lin et al. | Increased Expression of TLR8 in Peripheral Blood CD16+ Monocytes Positively Correlates with Disease Activity in Anti-CCP+ Rheumatoid Arthritis Patients | |
Vázquez | Targeting the IL-23/Th17 pathway to treat Myasthenia Gravis | |
Clark | Studies on Myeloid Cell Functions in Periodontitis | |
Jaufmann | Regulation of innate and adaptive B-cell responses by the proteins SLy2 and CXCR1 | |
CA3180476A1 (en) | Markers and cellular antecedents of rheumatoid arthritis flares | |
Waddell | Role of macrophages and eosinophils in inflammatory bowel diseases | |
Ridgley | Cytokine mediated CD4+ T-cell dysregulation in early rheumatoid arthritis | |
Mohamad | Disease mechanism in two novel primary immunodeficiencies characterized by increased viral susceptibility and immune dysregulation | |
Polletti | Reorganization of the macrophage epigenome during sustained stimulation | |
Malmhäll | T cell subsets in asthma and allergy-role of glucocorticoids, plasticity and microRNA-155 | |
Verjans et al. | The cAMP response element modulator (CREM) regulates T | |
Campbell Harding | Regulation of IL-4 mediated signalling in primary human bronchial fibroblasts by IL-13Rα2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL UNIVERSITY OF SINGAPORE, SINGAPORE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FU, XIN-YUAN;SHENG, WANQIANG;ZHANG, YONGLIANG;AND OTHERS;REEL/FRAME:052944/0582 Effective date: 20151009 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |